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Ac acetyl e.e. 
 
enantiomeric excess 
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-amino                                                                       
cyclopropanecarboxylic acid                                             Fmoc
 
 
9-fluorenylmethyl 
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aminoisobutyric acid                            HATU 
 
 
2-(7-aza-benzotriazole-1-l)- 
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benzyl                                     
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MeOH 
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MS 
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I. Introduction 
 
I. 0. Preface 
“When we look at a cell through a microscope or analyze its electrical or biochemical activity, we 
are, in essence, observing proteins”.1  
Proteins are biochemical compounds produced by a process called “protein synthesis” in all living 
cells and constitute most of a cell’s dry mass. Proteins and peptides are present in all living 
organism and appear as hormones, receptors, enzymes, etc. (Table 1) 
 
Peptide Name Species Peptide Sequence 
Thyrotropin-releasing hormone Human pGlu-His-Pro-NH2 
Gonadotropin-releasing hormone Human pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-
NH2 
Gastrin I Human pGlu-Gly-Pro-Trp-Leu-(Glu)5-Ala-Try-Gly-
Trp-Met-Asp-Phe-NH2 
Fertilization promoting peptide Human pGlu-Glu-Pro-NH2 
Growth-inhibition pentapeptide Mouse pGlu-Glu-Asp-Ser-Gly-OH 
Caerulin-like peptide Amphibian pGlu-Asp-Tyr-(HSO3)-Lys-Gly-Trp-Met-
Asp-Phe-NH2 
Adipokinetic hormone Insect pGlu-Lys-Thr-Phe-Ser-Pro-Asp-Trp-NH2 
Leucosulfakinin-II Insect pGlu-Ser-Asp-Asp-Tyr-(SO3H)-Gly-His-Met-
Arg-Phe-NH2 
Corazonin Insect pGlu-Thr-Phe-Gly-Tyr-Ser-Arg-Gly-Trp-Thr-
Asn-NH2 
Chitinase Plant pGlu-Cys-Glu-Thr-Thr-Ile-Tyr-Cys-Cys-Ser-
Gly-His-NH2 
 
Table 1. Some examples of peptides. 
 
An interesting property of proteins and peptides is the ability to fold into specific spatial 
conformations.
2
 These structures are stabilized by weak bonds such as hydrogen bonding, Van Der 
Waals forces, and ionic interactions.
1,3
 Their biological functions are associated with their final 
structure, therefore in order to understand the functions of proteins and peptides, it is necessary to 
know their three-dimensional structure.
4 
The scientific field of medicinal chemistry and 
biochemistry utilizes different techniques such as X-ray crystallography, CD and two dimensional 
NMR spectroscopy to determine the structure of proteins and peptides (Figure 1).
5  
 
 
 2 
 
When a protein performs a biological activity, its conformation is called active conformation. 
Different factors such as pH,
 
phosphorylation, ionic concentration, and the binding of a ligand, can 
favor several conformational changes.
6
 There are different techniques to detect transitions between 
different conformations. Recently, an optical technique called second-harmonic generation (SHG) 
has been applied to probe structural dynamics as described by Salafsky et al.
7
  
 
 
 
 
 
 
 
Figure 1. Three-dimensional structure of porcine pepsin. Pepsin was the first globular protein crystal successfully 
applied in X-ray diffraction.
8
 
“The discovery of peptide hormones, growth factors and neuropeptides implicated in vital 
biological functions of our organism has increased interest in therapeutic use of short peptides”.9 
Table 2 shows some examples of active endogenous peptides. Therefore, peptide analogues and 
peptide mimetics have been widely investigated in order to obtain new useful ligands for SAR 
studies.
10 
Name Biological function 
Insulin 
Decreases glucose level in 
blood. 
Somatostatin 
Inhibits the secretation of 
growth hormon, insulin and 
glucagon. 
Oxytocin 
Induces contraction of smooth 
muscles, especially uterine 
muscle. 
Neurotensin 
Causes constrictions of blood 
vessels. 
Met-enkephalin 
Morphine-like properties, 
analgesic 
Table 2. Some examples of active endogenous peptides.11 
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Unnatural amino acids, because of their ability to induce folding, have been extensively used as 
building blocks for the design of new peptide analogues.
12
 The synthesis of conformationally 
constrained -amino acids and their use as building blocks in foldamers will be the objective of this 
thesis. 
 
I. 1. General information on peptides 
Peptides are defined as “amides derived from two or more amino carboxylic acid molecules (the 
same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen 
atom of another with formal loss of water”.13 Because of the delocalization of the electrons, as 
shown by formula of resonance, the amide bond or peptide bond tends to be planar (Figure 2).  
 
                                                         
 
 
 
                                               a)                                                          b) 
 
 
 
 
                                                                                  c) 
Figure 2. a) General formula of a -amino acid; b) Sequence of a -peptide and a peptide bond,14                                 
c) Formula of resonance of peptide bond.
 
The carbon atoms from the first one directly connected to the carboxyl group, are named using the 
greek letters: α, β, γ, δ, є. In natural amino acids, the amino group is connected to the alpha carbon. 
If the amino group is connected to different carbon atoms along the chain, then this is usually an 
example of an unnatural amino acid.  
 4 
 
Thus, it is called -amino acid, when the amino group is on the beta carbon and so on. The spatial 
arrangement of the peptide depends on the orientation of the groups connected by three repeating 
bonds, which can be described by dihedral (or torsion) angles. These values describe the rotation 
about each of the three bonds and thus are the internal degrees of freedom of a protein or peptide.
15
 
The peptide dihedral angles are ω, φ and ψ. The first angle corresponds to the peptide bond and thus 
has a value close to 180 degrees. The dihedral angle φ describes the bond between the nitrogen and 
alpha carbon, and ψ describes the bond between alpha carbon and the carbon of the carboxylic 
group. The angles φ and ψ can have different values according to the final conformation.               
(Figure 3).
15 
 
 
                                                          Figure 3. Dihedral angles. 
All peptides have an amino end terminus called N-terminus and a carboxyl end terminus called             
C-Terminus. Peptides and proteins have four levels of organization that together give rise to their 
specific three-dimensional conformation. These levels of organization are classified as follows: 
primary structure, secondary structure, tertiary structure and quaternary structure. 
 
I. 1. 1. Primary structure                                                                                                                                    
The primary structure is a complete description of all peptide bonds which hold together the amino 
acids, and also it provides the location of any disulfide bonds, specifying the cysteines involved in 
these bonds. The primary structure is always denoted by writing the amino acid sequence, using the 
standard three-letter abbreviations in order, from the N-terminus to the C-terminus.
1 
 
 
I. 1. 2. Secondary structure                                                                                                                          
 
The secondary structure was proposed in 1951 by Linus Pauling
 
and coworkers,
16,17
 suggesting that  
a polypeptide chain does not remain in an elongated form in liquid phase, but it folds in a regular 
repetitive arrangement, stabilized by hydrogen bonds. The polypeptide chain folds up according to 
specific values of the dihedral angles ψ and φ, and to the steric hindrance of side groups.15  
 5 
 
A method to predict the secondary structure of a polypeptide chain is the Ramachandran plot, that 
shows the possible values of the ψ and φ for each amino acid residue.18 However, there are many 
proteins that have some domains with a defined structure and others which are not organized at all. 
A non-organized conformation is called a random coil. Three kinds of secondary structure can be 
observed: helices, sheets and turns. 
 
 
 
I. 1. 2. 1. Helices  
 
Helices are one of the most common secondary structures utilized by peptides and proteins. They 
consist of a helical structure, which is generally stabilized by hydrogen bonds. The helices are 
usually in the right-handed form, but in some cases the left-handed form has been observed.
19
 There 
are different kinds of helices that can be classified according to the periodicity of the helix, where 
the most common one adopted by proteins is the -helix. This structure is very compact, stabilized 
by the hydrogen bond between the carbonyl group of an i residue with the nitrogen of the residue 
i+4, forming a 13-membered ring (Figure 4).
20
 
 
 
 
Figure 4. General representation of a -helix. Hydrogen bonds are indicated with yellow color.21 
 
The ability to form an -helix depends on several factors, one of the most representative is the 
steric effect of side chains. Other helices are the 310 helix and the -helix. The first one is stabilized 
by a hydrogen bond between the carbonyl group of an i residue with the nitrogen of the residue i+3, 
forming a 10-membered ring.  
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The -helix represents a rare class of helices. They have been found in 15% of known proteins, and 
present a hydrogen bond between an i residue and an residue i+5.
22
 However, the -helix does not 
seem to always adopt a regular repetition like the - and 310-helices.
23,20
 
 
 
 
I. 1. 2. 2.-Sheet  

-Sheet consist of beta strands where hydrogen bonds are arranged parallel to each other, and the 
two fragments are far away from each other. This is a planar conformation, and the R groups are 
placed perpendicular to the plane of the peptide bonds. There are two types of -sheet, the parallel 
type, where both fragments are oriented in the same direction and the anti-parallel, where they are 
oriented in opposite directions (Figure 5).
20 
 
Figure 5. The parallel and anti-parallel -sheet. Hydrogen bonds are indicated with red and green color
 24
 
 
 
 
I. 1. 2. 3. Turns  
 
Turns are another kind of secondary structure that are formed at some points of a peptide sequence 
driven by a few hydrogen bonds.
25
 There are different kinds of turns and they are classified on the 
base of the ring size of the hydrogen bond forming the turn.

 7 
 
-Turns are most common and involve hydrogen bonding between the i residue and the i+3 residue. 
On the basis of their backbone dihedral angles, three types of -turn are known and are named type 
I, II and III (Figure 6). Moreover, there are also -turns (hydrogen bonding between the i residue 
and the i+4 residue), -turns (between the i residue and the i+2 residue),26 -turns (between the i 
residue and the i+1 residue) and -turns (between the i residue and the i+5 residue).27,20  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.  From left to right (-turn-type I, -turn-type II, -turn type III).24 
 
 
 
 
I. 1. 3. Tertiary structure  
 
“The tertiary structure of a protein is the spatial organization (including conformation) of an entire 
protein molecule consisting of a single chain”.28 They derive from combinations of all regions with 
specific secondary structures. The tertiary structure is stabilized by secondary bonding,  established 
between the side chains of amino acids such as the disulfide bond between cysteines.
29
 The three-
dimensional tertiary structure of proteins is very important for its function.
4
 
 
 
I. 1. 4. Quaternary structure  
 
“Many protein molecules are composed of more than one subunit, where each subunit is a separate 
polypeptide chain and can form a stable folded structure by itself”.20 The spatial organization of 
these polypeptide chains into more complex multi-subunits is called quaternary structure. The 
proteins can be defined globulars, if they fold in a spherical shape, and fibrous, if they maintain an 
elongated shape.
30,1
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I. 2. Synthesis of peptides 
 
Peptide synthesis consists of coupling of a carboxyl group and an amino group between two amino 
acids. The mixture of two amino acids in solution at room temperature leads to the formation of a 
salt by a simple acid-base reaction. Therefore, it is necessary to convert the carboxylic acid to an 
activated form, favoring a nucleophilic attack by the amino group. In a typical peptide coupling 
reaction, a peptide coupling reagent
  
(PCR)
31
 reacts with the carboxylic group, generating a reactive 
intermediate, which will react with the amino group of a second amino acid, leading to the 
formation of a peptide bond as illustrated in Scheme 1.32  
 
 
Scheme 1. Typical peptide coupling reaction. PCR (Peptide coupling reagent). 
 
Activated forms of carboxylic acids for peptide coupling reactions are acid halides,
33
 anhydrides,
34
 
activated amides,
35
 and esters.
36
 The carbodiimides 1 have especially attracted attention as peptide 
coupling reagents.
37
 They have been widely used in peptide synthesis because of their moderate 
activity, which is important in peptide coupling to avoid secondary reactions (Figure 7). In 1955, 
Sheehan et al. suggested dicyclohexylcarbodiimide (DCC) 2 as peptide coupling reagent.
38
 A great 
advantage is that the by-product N,N'-dicyclohexylurea is insoluble in most organic solvents and 
thus it is possible to separate it from the dissolved product by filtration.  
 
 
Figure 7. General formula of a carbodiimide 1;  Dicyclohexylcarbodiimide  (DCC) 2;                                                        
N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC) 3. 
 9 
 
The general mechanism is shown in scheme 2. The carboxyl group of the N-protected amino acid 4 
attacks the C=N bond of the general carbodiimide 1 leading to the O-acylisourea intermediate 5. 
This highly reactive compound 5 reacts with a free amino group of a C-protected amino acid 6, 
being a good nucleophile, determining the formation of peptide 7 and the dialkylurea by-product 
8.
39
 
 
 
Scheme 2. Activation of a -amino acid using a carbodiimide reagent. 
Side reactions are a problem during peptide coupling. One of the most common side reactions 
during the coupling promoted by the carbodiimides is the racemization of a peptide sequence, 
because of their high reactivity. Racemization can occur in the course of a coupling reaction 
because of the formation of an oxazolone intermediate 10 from the O-acylisourea intermediate 9 
(Scheme 3).
31
 In the presence of a base, which is an important component in peptide couplings, 
compound 10 could be deprotonated in -position giving the anion 11, that is stabilized by 
resonance. Compound 11 could be reprotonated again, providing racemization of a peptide 
sequence 13. 
 10 
 
 
 
Scheme 3. Racemization of a peptide sequence by formation of oxazolone intermediate 10. 
Many of the side reactions can be avoided by using some additives or racemization 
suppressants.
40,31
 The racemization suppressants intercept the O-acylisourea intermediate 9, 
generating a reactive ester which reacts quickly with the amino group before racemization occurs. 
The most widely used are HOBt 14 and HOAt 15 (Figure 8).
41
 
 
 
Figure 8. Structure of HOBt 14, and HOAt 15.  
  
To avoid racemization many reagents similar to HOBt 14 have been developed.
42 
Examples are 
phosphonium-based reagents such as BOP 16 and PyBOP 17 (Figure 9).
43
 With the phosphonium-
based reagents the racemization is minimal, and combining activation and coupling reagent, they 
can be used without prior activation by carbondiimides.  
.  
 11 
 
Compound 16 is also useful to prepare esters in mild conditions.
44
 
 
 
 
Figure 9. Phosphonium-based reagents BOP 16 and PyBOP 17. 
 
Other very popular coupling reagents are uronium salts, such as HBTU 18 and HATU 19.
45
 Both 
compounds crystallize as guanidinium N-oxide, as demonstrated by Carpino et al., using X-ray 
crystallography studies (Figure 10).
46
 
 
 
 
Figure 10. Guanidinium N-oxide structures of compounds 18 and 19. 
Peptides can either be synthesized in liquid-phase or in solid-phase. In liquid-phase peptide 
synthesis, it is possible to isolate and analyze the intermediate products after each amino acid 
addition.
47
 Furthermore, the liquid-phase synthesis allows the development and application of new 
strategies such as the design of new protecting groups for the side chains and the use of new 
coupling reagents.
48 
The synthesis of peptides in liquid phase is mainly used to synthesize small 
peptides,
 
while for long sequence of peptides, the solid phase synthesis is mostly utilized.
47 
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I. 2. 1. Solid phase peptide synthesis(SPPS) 
 
“Solid-phase peptide synthesis (SPPS) consists in the elongation of a peptidic chain anchored to a 
solid matrix by successive additions of amino acids which are linked by amide (peptide) bond 
formation between the carboxyl group of the incoming amino acid and the amino group of the 
amino acid previously bound to the matrix, until the peptide of the desired sequence and length has 
been synthesized”.47 This procedure was introduced in 1963 by Merrifield, who showed the 
synthesis of a tripeptide on a solid phase.
49  
Solid phase synthesis has many advantages, such as use 
of large excess of reagents, which leads to faster reaction (2-3 hours) and removal of                        
by-products and excess of reagents by washing of the solid support since the peptide is anchored to 
it, leading to a more facile purification. Scheme 4 shows the general scheme of SPPS using Fmoc 
as a N-protecting group, which is a base labile. The cleavage of the Fmoc group by an appropriate 
base (piperidine), leads to the free amine of a attached peptide or amino acid that will be coupled to 
a single activated N-protected amino acid. Then, the new N-protected peptide will be deprotected 
again, generating a new free N-terminal amine, which can be attacked by another activated amino 
acid.
50
 For the cleavage of the peptide from the resin and deprotection of the side chain protection 
groups, a so called “cleavage cocktail” (1 mL per 30 mg resin) is used, which usually consists of 
TFA and different scavengers. The choice of the cleavage cocktail depends on the nature of the 
support and the nature of the protecting groups.
51 After that, the crude peptides are usually purified 
by preparative HPLC.
52 
Development in SPPS has led to two main schemes of protection, the 
Boc/Bzl and Fmoc/t-Bu strategies, where Fmoc (base labile) and Boc (acid labile) are the protecting 
groups for the amino group, and t-Bu and Bzl groups are used to protect the side chains of several 
amino acids.
47 
Furthermore, it is sometimes necessary to use different protecting groups for the side 
chains, depending on their nature, such as TBS and trityl group for alcohols, and Pbf or Pmc for 
guanidine groups.
53
 Recently, microwave irradiation has been used for SPPS, especially for 
coupling of  sterically hindered amino acids.
54
 The microwave energy can prevent aggregation of 
preformed chains leading to faster reactions (reaction time 1.5–20 min), low degrees of 
racemization, and high yields of the final peptide product.
55
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Scheme 4. General scheme of SPPS. 
 
Solid supports for solid phase have to meet several requirements, such as uniform size of the 
particles, easily filterable, and moreover they have to be chemically inert and stable under the 
conditions of synthesis.
47
 The supports for solid phase can be of three types: gel-type supports, 
surface-type supports and composites.
56
 The gel-type supports are the most common, and consist of 
solvated polymers with different functional groups. 
 14 
 
These includes polystyrene, polyacrylamide and polyethylene glycol (PEG).
57,56
 For the Fmoc 
strategy, a common resin is Rink amide MBHA resin 20, which is already derivatized with a    
Fmoc-amine.
58 
Thus, the synthesis can be started before any prior preparation. There are some cases 
such as the Wang Type resin 21, which need to be preloaded with the first amino acid (Figure 11).  
 
 
 
Figure 11. Structure of Rink amide MBHA resin 20 already Fmoc derivatized and Wang Type resin 21. 
Modern automated SPPS instrumentations are often used for the synthesis of short and long peptide 
sequences. It permits coupling with a yield of 99.99%, which leads to an overall yield of 99% for a 
50 amino acid peptide.
59
 
 
 
I. 3. Application of Peptides                                                                                           
Peptide research is a continuously growing field of medicinal chemistry and biochemistry. Peptides 
have intensively been used to prepare antibodies in animals, and inhibitors for protein tyrosine 
kinases against cancer and other diseases.
60
 Furthermore, structure-activity-relationship (SAR) 
studies about different peptidic ligands, have increased the interest in the preparation of new 
synthetic peptides.
61
 They have been used, for example, as probes for studies of protein-peptide 
interactions, and as peptidomimetics.
62,63  
“
Peptidomimetics are compounds whose essential elements (pharmacophore) mimic a natural 
peptide or protein in 3D space and which retain the ability to interact with the biological target and 
produce the same biological effect”.63 They can be new compounds prepared by chemical synthesis, 
such as -peptides,64,65 or they can be designed by modification of an existing peptide such as 
incorporation of new compounds, in order to modify some molecular properties.
66
  
 15 
 
Unnatural amino acids have been intensively studied in the area of peptide research, and have been 
used as pharmaceuticals. For example
 
well-known are L-Dopa, which is used to alleviate the 
symptoms of Parkinson's disease, and D-Penicillamine for the treatment of arthritis.
67
 Moreover, 
unnatural amino acids have become a very important class of building blocks to prepare foldamers 
and, in the design of new potent ligands for biological receptors by incorporation into biologically 
active peptides.
68,69
 “Foldamers are sequence-specific oligomers akin to peptides, proteins and 
oligonucleotides that fold into well-defined three-dimensional structures. They offer to the chemical 
biologist a broad pallet of building blocks for the construction of molecules that test and extend our 
understanding of protein folding and function”.70 Foldamers have been intensively studied and have 
shown to have interesting properties.
71
 The first application of unnatural amino acids into foldamers 
were reported by the groups of Gellman and Seebach.
72,64
 Conformationally constrained  trans-
ACHC 22 was used by Gellman et al. to prepare different homooligomers, which showed a strong 
tendency to fold into a helical structure.
73
 Moreover, even heterooligomers showed the ability to 
adopt well-defined conformations. Recently, Gellman also showed that -hybrid peptides 23, 
which are composed of two different unnatural amino acids in alternate order, give stable secondary 
structure (Figure 12).
74
 
 
 
 
Figure 12. Examples of homooligomeric and heterooligomeric foldamers which give stable secondary structures. 
 
Cyclic and bicyclic -amino acids have been used to prepare potent analogues of natural peptides, 
and have shown interesting properties. For example, cispentacin derivative 24 has been 
incorporated into 6 positions of the gonadotropin releasing hormone as reported by Mulzer et al.,
75
 
and the bicyclic amino acid 25, which was incorporated into different bioactive peptides such as 
enkephalin, somatostatin and growth hormone releasing factor (GRF) by Nagai et al.
76
 (Figure 13).  
 
 16 
 
 
Figure 13. Unnatural amino acids incorporated in peptide analogues. 
 
In both cases, different analogues showed some activity against the own receptor. -ACCs 26 has 
been incorporated into different analogues such as neuropeptide Y (NPY),
77
 calcitonin gene related 
peptide
78
 and orexin peptide,
79 
as reported by Reiser et al. Truncated NPY analogues 27 (residues 
25-36) containing -ACCs 26 in different positions in the C-terminus, showed good affinity and 
selectivity for the Y1 receptor (Figure 14).
77
 
 
 
 
 
 
                 
 
                                                                 
 
 
 
Figure 14. -ACCs 26 as constrained -amino acid analogues. Truncated NPY analogues 27 (residues 25-36) 
containing -ACCs. 
 
Cispentacin derivaties 28 were also incorporated in NPY analogues 29 in the group of Reiser               
(Figure 15), but unfortunately in this case, they showed affinities only in a high micromolar 
range.
80
 
 
 
 
                  
                                                                                                 
Figure 15. Cispentacin derivaties 28; Truncated NPY analogues 29 containing compound 28. 
 17 
 
After several applications of -amino acids in -peptides in our research group, we focused on new 
conformationally constrained -amino acids as building blocks in the design of NPY analogues. On 
the basis, that differences in ring size can produce significant differences in the conformation of the 
resultant peptides and in the biological activity, as described by Thompson
 
et al.,
81
 -amino acids in 
which the backbone is constrained by a five-membered ring have been investigated. In this work 
cis-(30), trans-(31) and trans-(32) 2-(2-aminocyclopentyl) acetic acids were prepared in 
enatiomerically pure form (Figure 16).  
 
                    
 
 
 
 
 
 
Figure 16. Different isomers of 2-(2-aminocyclopentyl) acetic acid and structure of trans-pentacin 33 
 
Furthermore, trans-pentacin 33 has also been introduced into NPY analogues in this work                
(Figure 16). Gellman et al. showed that -peptides containing trans-pentacin 33 adopt a well-
defined helical secondary structure.
82
 In conclusion, the synthesis of NPY analogues containing 
different isomers of 2-(2-aminocyclopentyl) acetic acid and the trans-pentacin 33, with their 
conformational investigations, and the testing of their biological activity against the different NPY 
receptors, is the aim of this work.  
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Chapter 1 
 
1.1 Application and synthesis of -amino acids 
 
1. 1. 1. -Amino acids in foldamers 
 
After several years of extensive studies on -amino acids in foldamers and peptide analogues,                   
-amino acids have been investigated and have shown interesting properties. In the -peptide family, 
helices have been observed in oligomers with only four residues. It was also shown that going from 
-peptides to - and -peptides, more stable helices are obtained. Because of their high stability and 
diversity, -amino acids are a interesting class of unnatural amino acids in the field of foldamers.1,2 
Many foldamers containing -amino acids have been reported so far.3,4 Interesting linear -peptides 
that form discrete secondary structures have been described by Seebach et al.
5
 A series of (R,R,R)--
amino acids with side chains in the 2-, 3-, and 4-positions (Figure 17), were prepared and 
investigated. -Tetrapeptide 34, and -hexapeptides 35 showed a (M)-2.614 helix in the solid state 
and in MeOH solution (Figure 18). 
 
 
 
 
Figure 17. -2,3,4-Tetra- and hexapeptide derivatives 34 and 35 used for structure investigations. 
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Figure 18. “(M)-2.614 Helical structures of -peptides 33 and 34.  a) Structure of -tetrapeptide 33 in the crystal state 
determined by X-ray structure analysis.  b) Bundle of  20 conformers of  hexapeptide 34 in MeOH obtained by 
simulated annealing calculations using restraints from NMR data. c) Superposition of the peptide backbones from the 
X-ray diffraction structure (blue) and NMR structure (red)”.6 
 
Foldamers containing cyclic -amino acids, being more conformationally restricted, have attracted 
more attention and have been intensively studied. Homo- and heterochiral tetrameric -peptides 
derivatives, in which the backbone is constrained by a five-membered ring, were prepared and 
investigated by Smith et al.
7
 (Figure 19). 
  
                                                                      
 
 
 
 
 
 
 
 
 
 
Figure 19. Homochiral -peptide 36 and alternating heterochiral -peptide 37. 
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These peptides showed a bend-ribbon conformation in solution stabilized by intramolecular 
hydrogen bonds forming a 7-membered ring (Figure 20). 
 
 
 
Figure 20. Observed bend-ribbon solution conformation of -peptide 36. 
 
Other -peptides using conformationally constrained -amino acids were prepared by Gellman et 
al.
8
 A series of -peptides 40-44 were prepared by liquid phase method using a (Boc)-protected 
gabapentin 38 at the N-terminus and conformationally constrained -amino acid 39 (Scheme 5).  
 
 
 
Scheme 5. Structure of gabapentin 38 and aunnatural-amino acid 39. Structure of -peptides 40-44 (arrows 
indicate H-bonds in the crystal structure.
8
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The crystal structures of peptides 40-44 showed that segments derived from gabapantin 38 display 
the 14-helical conformation (Figure 21, the peptides 40-44 are numberd from 3 to 7, from the 
original document).  
 
 
 
Figure 21. “a) Crystal structures of  40-44 (3-7 from the original document); b) Stereoview of the 14-helical segment 
of 40 (N-terminal gabapentin residue not shown; c) View along the helix axis of the 14-helical segment of 44.             
Orange: Boc-protected gabapentin residue;  green: residues derived from 44;  red: O, blue: N”.9 
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1. 1. 2. Application of -amino acids  

“-Amino acids have attracted considerable attention as biologically active compounds in the 
central nervous system (CNS) of mammals”.10 The most known examples for natural-amino acids 
are GABA 45 (-aminobutyric acid), which is an inhibitory neurotransmitter in the central nervous 
system
11
 and the -amino--hydroxybutyric acid (GABOB) 46, which possess antitumor and 
antifungal activity.
12,13
 Concerning the application of -amino acids as therapeutics, there are, for 
example the vigabatrin 47 and the baclofen 48. The first one is an important anticonvulsant, while 
the baclofen is used in the treatment of spasticity and alcoholism, being a GABAB receptor agonist 
(Figure 22).
14
 
 
       
Figure 22. Some examples of -amino acids. 
 
Foldamers derived from -peptides seem to have several promising applications. They display 
higher stability toward proteolytic enzymes than -peptides, as shown by Seebach et al.15 A group 
of -peptides were tested against 15 proteolytic enzymes and no degradation was observed after 48 
h, while -peptides usually degrade after 15 min.  Furthermore,-amino acids have been used to 
design analogues of biological compounds. An interesting class of -amino acids, in which the 
backbone is constrained by a five-membered ring, as GABA analogues have been reported by Allan 
et al. (Figure 23).
16 
 
 
Figure 23. Cyclopentane GABA analogues. 
 
All these analogues were tested at 100 M against a GABA EC50 dose (50 M), showing that  
cyclopentane GABA analogues TACP, CACP and 4-ACP-1-CA are potent GABAA agonists.  
 27 
 
Additionally, cis- and trans-2-aminocyclopropyl, -cyclobutyl, -cyclopentyl, and -cyclohexylacetic 
acids as GABAanalogues of restricted conformation were described by Kennewell et al., but only 
the cyclopropyl and cyclobutyl series showed any significant biological activity (Figure 24).
17 
 
 
 
Figure 24. cis- and  trans-2-aminocyclopropyl, -cyclobutyl, -cyclopentyl, and -cyclohexylacetic acids as GABA 
analogues. 
 
Moreover, -peptides are able to mimic the -turn of biologically active peptides as described by 
Seebach et al., showing different N-acyl -dipeptides with a good affinity for human somatostatin 
receptors.
18 
Therefore, -amino acids could be a interesting class of building blocks in the design of 
new peptide analogues. 
 
 
 
 
1. 1. 3.  Synthesis of conformationally constrained -amino acids 
Conformationally constrained -amino acids are a very important class of unnatural amino acids, 
which have been intensively investigated in order to generate new analogues, building blocks for 
peptidomimetics, as well as to study their properties in foldamers.
19 
Therefore, over the last few 
years the stereoselective synthesis of new cyclic -amino acids has attracted interest.10 An 
interesting synthetic route to prepare trans-cyclobutane and cyclopropane amino acids has been 
reported by Kennewell et al.
17
 and is shown in scheme 6. Trans-cyclobutane 1,2-diethylester 52 was 
used as starting material for the cyclobutane series, while the synthesis of the cyclopropane series 
started with the trans-dimethylester 53.  
 28 
 
Partial hydrolysis of 52 and 53 yielded the mono-acids 54 and 55, which were reduced by borane 
tetrahydrofurane complex, giving the trans isomers alcohols 56 and 57. 
20
  
Tosylation of both alcohols has been carried out using p-toluenesulfonyl chloride and pyridine, 
obtaining the tosylates 58 and 59. The treatment with potassium cyanide afforded the nitriles 60 and 
61, which have been converted first into the acid hydrazides 62 and 63, then by Curtius 
rearrangement to the carbamates 64 and 65, according to the methods of Witiak et al.
21
 and Hart et 
al.
22
 Compound 64 and 65 were hydrolized in sodium hydroxied solution, affording the amino acids 
66 and 67.  
 
 
 
 
 
Scheme 6. Synthetic routes for trans-cyclobutane and cyclopropane -amino acids.  
Reagents and conditions:  a) NaOH-aq., EtOH, reflux, 2 h, 55%; b) BH3THF-Et2O, 0 °C, 1h, 95%; c) p-MeC6H4SO2Cl-
pyridine, 88%; d) KCN-DMSO, heat, 3 h, 75%; e) NH2NH2 H2O, EtOH, heat, 1 h, 58%; f) 1. NaNO2,HCl, 0 °C, 1 h;               
2. MeOH, reflux, 16 h, 78%; g) NaOH-aq., EtOH, reflux, 16 h, 60%. 
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An interesting synthetic rout toward the enantioselective synthesis of cyclic -amino acids has been 
shown by Kessler et al.
23 
In this method, a sugar derived -amino acid was prepared from diacetone 
glucose 68 (Scheme 7).                  
This synthesis starts with the activation of an alcohol group in compound 68, generating the triflyl 
activated diacetone glucose 69, which will be converted into the azide 70, followed by inversion of 
the configuration. After that, the exocyclic hydroxyl group was deprotected by acetic acid affording 
diol 71. Then, the azide was reduced by hydrogenation and Fmoc protected producing compound 
72. Concluding, oxidation of the primary alcohol by TEMPO, sodium hypochlorite and KBr yielded 
-amino acid 73. 
 
 
Scheme 7. Enantioselective synthesis of cyclic -amino acids from carbohydrates. Reagents and conditions: a) Tf2O, 
pyridine, -10 °C, DCM, 1.5 h, 98%; b) NaN3, Bu4NCl (cat), 50 °C, DMF, 5 h, 70%;  c) HOAc, 3 h, 65 °C, 77%;               
d) H2, Pd/C, MeOH, FmocCl, NaHCO3, THF, MeOH, r.t., 24 h, 90%;  e) NaOCl, TEMPO (cat), KBr, DCM, sat. aq. 
NaHCO3, Bu4NCl, overnight, 62%. 
 
Furthermore, the synthesis of different enantiomerically pure cyclopentane -amino acids has been 
reported. Figure 25 presents different compounds prepared by Ordònez et al.
 
in order to test them 
as GABA analogues.
10
 
 30 
 
 
Figure 25. Cyclopentane -amino acids. 
In most of the cases, the products in enantiomerically pure form were obtained starting from 
commercially available enantiopure starting materials, as in the case of compound 51           
(Scheme 8),
24,25
 or by enzymatic resolution as in the case of compound 50 (Scheme 9). Hydrolysis 
of enantiopure lactam (1S,4R)-77 gave (1R,4S)-ACPECA 78 in quantitative yield, which was 
protected by Boc-anhydride and esterificated giving methyl ester (1R,4S)-79 in 98% yield. 
Isomerization of the double bond in the presence of DBU provided the corresponding derivative 
(4R)-80 in 95% yield, which was hydrolyzed in acidic conditions, yielding the (4R)-4-ACPCA 51.
10  
 
Scheme 8. Synthesis of (4R)-4-ACPCA 51 from commercially available enantiopure starting material 77.              
Reagents and conditions:  a) 6 M HCl, 12 h, quant. ; b) 1. (Boc)2O, Et3N, MeOH, r.t., 3 h; 2. CH2N2, DCM, 1h, 98%;                 
c) DBU, THF, reflux, 10 h, 95%; d) 1. AcOH, HCl 1 M, 100 °C, 1 h, 77%. 
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The preparation of enantiomerically pure (1R,3S)-CACP 50 by enzymatic desymmetrization has 
been described by Chenevert et al.
26
 The synthetic route starts with ozonolysis and simultaneously 
esterification of norbornene 81, affording the diester 82 in 93% yield. Cholesterol esterase (CE) has 
been used to catalyze the partial hydrolysis of diester 82, producing (1R,3S)-83 in 95% yield and 
90% ee. Ammonolysis of 83 using NH3 in MeOH yielded amide 84 in 82% yield, which was 
converted into the amine under Hoffmann rearrangement conditions, affording (1S,3R)CACP-50 in 
92% yield.
27
 
 
 
Scheme 9. Synthesis of (1S,3R)-CACP 50 by enzymatic resolution. Reagents and conditions: a) 1. O3 , MeOH;                  
2. H2O2, HCO2H; 3. MeOH/H
+
, 93%; b) CE, phosphate buffer pH 7, 37 °C, MeOH, 95% c) NH3, MeOH, 82%;                      
d) (CF3CO2)2IC6H6, MeCN, H2O, 92%. 
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1. 2.  Synthesis of the 2-(2-amino cyclopentyl) acetic acid derivative 
 
At the beginning of this project, the focus was on the application of foldamers and NPY analogues 
containing the 2-(2-amino cyclopentyl) acetic acid derivative, precisely the 2-((1S,2R,3R,5R)-2-
amino-3-(hydroxymethyl)-5-methoxycyclopentyl)acetic acid 85, which has been described by 
Florian Sahr in his PhD thesis.
28 
The -amino acid 85 has been synthesized by modifications of 
intramolecular 1,3-dipolar cycloaddition product 86, which was obtained through several steps from 
cyclopropanation’s product of 2-furoic methyl ester 87 (Scheme 10). 
 
 
 
Scheme 10. -Amino acid 85 obtained from intramolecular 1,3-dipolar cycloaddition product 86, which is an  
important intermediate synthesized in several step from the compound 87. 
 
The entire synthesis consists first in the preparation of anti-4,5-disubstituted -butyrolactone 
aldehyde 88 (Scheme 11), which will then yield to the intramolecular 1,3-dipolar cycloaddition 
product 86. The first step is the copper(I)-catalysed cyclopropanation of 2-furoic methyl ester 89 in 
presence of ethyl diazoacetate (EDA) and bis(oxazoline) ligand 90, yielding cyclopropane 
derivaties 87 in 36% yield and 99% ee. Ozonolysis of compound 87 leads to the cleavage of the 
double bond, giving cyclopropane carbaldehyde 91 in 92% yield. Sakurai allylation of compound 
91, using trimethylallylsilane in the presence of boron trifluoride etherate, produced compound 92, 
which in basic condition was converted into the free cyclopropane alcohol intermediate 93.  
Compound 93, being highly unstable, evolves to the trans-substituted lactone 88 in 41% yield, by a 
retro-aldol-lactonisation-cascade reaction. 
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Scheme 11. Synthesis of anti-4,5-disubstituted -butyrolactone aldehyde 88.29 Reagents and conditions:  a) Cu(OTf)2, 
PhNHNH2, compound 86, ethyl diazoacetate (10% – 15% solution in DCM), 0 °C, 45%, after recrystallization 36% 
(99% ee). b) O3, DCM, DMS, -78 °C → r.t., 24 h, 92%. c) Allyl trimethylsilane, BF3·OEt2, DCM, -78 °C, 18 h;                               
d) Ba(OH)2·8H2O, MeOH, 0 °C, 24 h (41 %) over two steps. 
 
The second part is the synthesis of compound 86 by an intramolecular 1,3-dipolar cycloaddition 
reaction (Scheme 12). -Butyrolactone 88 was treated with N-benzylhydroxylamine hydrochloride 
giving the nitrone 94, which was not possible to purify because of its instability on silica gel and its 
poor crystallisation properties. Thus, crude 94 was dissolved in anhydrous benzene and refluxed for 
24 hours, yielding a diastereomeric mixture of fused cycloadducts 86 and 95 in a 3:1 ratio. 
 
 
 
Scheme 12. Cycloaddition of nitrone 94.29 Reagents and conditions: a) N-benzylhydroxylamine hydrochloride, 
NaOAc
.
3H2O, ethanol/water (4:1), r.t., 2h; b) Benzene, reflux, 24 h, 55%. 
 
The major diastereomer 86 was converted to a broad variety of protected unnatural-amino acids. 
Cispentacin derivatives with an annelated lactone 96, as well as open chain products modified with 
protected alcohol groups 97 and protected guanidinium group 98, were obtained (Figure 26). 
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Figure 26. Different protected unnatural amino acids prepared from compound 86. 
 
Moreover, the 2-((1S,2R,3R,5R)-2-Fmoc-amino-3-(hydroxymethyl)-5-methoxycyclopentyl) acetic 
acid 99 with a cyclopentane backbone and a free alcohol group was also obtained from compound 
86. The synthetic route to obtain -amino acid 99 is shown in Scheme 13. The first step is the 
reduction of the lactone 86 using lithium aluminiumhydride, affording the diol 100 in quantitative 
yield. Then, a selective protection of the primary alcohol took place by TBSCl in the presence of 
triethylamine and a catalytic amount of DMAP, obtaining compound 101 in 92% yield. The 
secondary alcohol was protected as a methoxy group using iodomethane in the presence of sodium 
hydride as a base, yielding compound 102. Protected diol intermediate 102 was oxidized under 
Jones oxidation conditions affording compound 103. During this reaction, the acidic conditions will 
cleavage the silyl ether, realizing the primary alcohol, which is then oxidized to carboxylic acid. 
Subsequently, the isoxazoline moiety was opened by hydrogenation at atmospheric pressure 
catalysed by Pd(OH)2-C, which allowed the removing of the benzyl group as well, affording a free 
hydroxyl group and free amine. Free -amino acid 85 was simultaneously protected with FmocOSu, 
yielding compound99. 
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Scheme 13. Synthesis of Fmoc-2-((1S,2R,3R,5R)-2-amino-3-(hydroxymethyl)-5-methoxycyclopentyl)acetic acid 99. 
Reagents and conditions:  a) LAH, THF, 0 °C, 1 h, 98%; b) TBSCl, NEt3, DMAP, DCM, 18 h, 92%; 
c) MeI, NaH, THF, 0 °C for 1 h, r.t. for 18h, 80%; d) Jones oxidation, acetone, 0°C – r.t., 6 h, 86%;  e) 1. Pd(OH)2-C, 
H2, MeOH, overnight, 95%; 2. FmocOSu, NaHCO3, acetone/water, r.t., 24 h, 58%. 
 
As previously mentioned, the focus was on the synthesis of foldamers and NPY analogues 
containing -amino acid 85. Fmoc protected -amino acid 99 was used to prepare different peptides 
by solid phase synthesis. Therefore, it was necessary to protect the primary alcohol group to avoid 
undesidered coupling to that position during the synthesis. The Fmoc/tBu strategy has been chosen 
for this approach. The problem of this step was the difficulty to protect selectively the alcohol as a 
t-butyl ether in the presence of a free carboxylic acid. It was planned to protect simultaneously the 
primary alcohol and the carboxylic acid giving compound 104. After that, a selective cleavage of              
t-butyl ester group would take place, giving compound 105, as shown in Scheme 14. 
 
 
Scheme 14. Retrosynthetic scheme for t-butyl protected amino acid 105. 
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The general reaction proceeds in the presence of trimethylsilyl triflate and a base, as described by 
Bannwarth et al.
29
  The t-butyl ester 106 is converted into the trimethylsilyl ester 107, which after 
aqueous workup yields the corresponding free carboxylic acid 108 (Scheme 15). The t-butyl ether 
is stable in the presence of trimethylsilyl triflate. 
 
 
 
 
Scheme 15. General selective cleavage of t-butyl ester 106. Reagents and condition: a) Trimethylsilyl triflate, NEt3; 
b) H2O. 
 
Unfortunately, the protection reaction did not give any good yield. Two different methods were 
tried: isobutylene in the presence of BF3
.
OEt2 and H3PO4,
30
 and t-BuOH in the presence of H2SO4 
and MgSO4 as drying agent.
31
 In both methods the protection gave yields minor than 40%                  
(Scheme 16).
 
 
 
 
                                                                                                         
 
 
Scheme 16. Methods for t-butyl protection. Reagents and conditions: a) Isobutylene, BF3·OEt2, H3PO4, DCM/THF,    
-78 °C, 5 days, 22%;  b) H2SO4 (conc.), MgSO4, t-BuOH, DCM, r.t., 36 h, 36%. 
 
Therefore, it was decided to use another protecting group for the primary alcohol. Finally, -amino 
acid 99 was protected with TBSCl, providing the O-TBS group as described by Koksch et al.
32 
The 
reaction was run in dry DMF, in the presence of imidazole and a catalytic amount of DMAP for     
32 h at room temperature, affording the protected -amino acid 109 in   80% yield (Scheme 17). 
 
 
 
Scheme 17. Protection of primary alcohol 99. Reagents and conditions:  a) TBSCl, imidazole, DMAP, DMF, r.t.,             
32 h, 78.8%. 
 
 37 
 
1. 2. 1. NPY analogues containing 2-(2-amino cyclopentyl) acetic acid derivaties 
 
Compound 109 was used to synthesize alternated - peptides and different NPY analogues 110 
and 111 by SPPS (Figure 27). The synthesis was performed using Rink amide MBHA resin 20 
(loading 0.6 mmol/g), HBTU in combination with HOBt and DIPEA as coupling reagents.  
 
 
 
 
 
 
                                         
 
 
                         
                                                                                                          
                                                                                   
 
 
Figure 27. Structure of NPY analogues containing -amino acid 85. 
 
Unfortunately, the yields for each coupling were quite low, leading after 5-6 couplings to a final 
yield <10%. Other coupling reagents were tried, such as EDC in combination with HOBt, but also 
in this case the final yield was not good enough to obtain an analyzable amount of pure peptide. 
Therefore, the coupling of -amino acid 109 was investigated by synthesis in solution. A dipeptide 
112 was prepared by coupling compound 109 and free O-benzyl ester alanine 113 in DMF/DCM 
1:1, using different coupling reagents (Scheme 18). 
 
 
 
Scheme 18. Coupling in solution of the amino acid 109. Reagents and conditions: a) HBTU/ HOBt, DIPEA, 
DMF/DCM (1:1), 0 °C for 1 h, overnight at r.t., 48%; b) EDC/HOBt, DIPEA, DMF/DCM (1:1), 0 °C, 1 h, overnight at 
r.t., 68%; 
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The couplings in solution showed that using EDC/HOBt, the yield (68%) was higher than using the 
HBTU/HOBt approach (48%). Therefore, it was planned to synthesize a --alternated peptide 114 
by liquid phase synthesis, using EDC/HOBt as coupling reagent (Figure 28).  
 
 
 
                                                                    
 
 
 
Figure 28. --Alternated peptide containing -amino acid 85. 
 
The synthesis of compound 114 has been carried out by coupling of two tripeptides 115 and 116, 
which consist of Pbf-arginine, -amino acid 109 and alanine in a specific order (Figure 29). The 
tripeptides were prepared by a repeated cycle of coupling-deprotection steps in solution. The 
cleavage of Fmoc group was performed by stirring in 10% piperidine in DCM for 20 min, while 
hydrogenation in presence of Pd/C as catalyst was used to cleave the benzyl group. 
 
 
 
 
 
 
 
 
Figure 29. --Alternated tripeptides 115 and 116 prepared by liquid phase synthesis. 
 
The final coupling produced a protected --hexapeptide in 60% yield, which was purified by 
preparative reversed HPLC. Furthermore, during the HPLC purification the TBS groups have been 
cleaved, due to the presence of TFA, affording compound 117 as confirmed by HPLC/MASS 
(Figure 30). 
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Figure 30. Structure of --hexapeptide 117, after HPLC purification. 
 
Unfortunately, the whole synthesis carried out only a small amount of pure peptide 117, from 
which, after the cleavage of the protecting groups, it was not possible to isolate and analyze the free 
peptide. In conclusion, it was decided to cut off the research in this direction because of the difficult 
coupling, as well as the long and challenging synthesis of the -amino acid 109. The research focus 
moved to the synthesis and application of the 2-(2-amino cyclopentyl) acetic acid without any side 
chains, which will be presented in the next paragraph.  
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1. 3. Synthesis of isomers of the 2-(2-amino cyclopentyl) acetic acid 
 
As previously mentioned, during this project we focused on the synthesis of enantiomerically pure 
isomers of the 2-(2-amino cyclopentyl) acetic acid (Figure 31). 
 
                      
 
 
Figure 31. Isomers of the 2-(2-amino cyclopentyl) acetic acid. 
A simple way to synthesize the cis-30 and trans-31 isomers has previously been described by 
Kennewell et al.,
17
 with a slight modification to the method of Booth et al.
33
 (Scheme 19).
 
The 
oxime
34
 118 was hydrogenated over platinum oxide in ethanolic HCl
35
, providing a mixture of 
isomers which were separated by distillation affording the cis-lactam 119 and the trans-amino-ester 
120. Then, hydrolysis of 119 and 120 yielded the cis-30 and trans-31 amino acids which were 
isolated by ion-exchange chromatography. 
 
 
Scheme 19. General synthesis of isomers 30 and 31. Reagents and conditions: a) 1. H2-PtO2-HCl-EtOH, 2. heat;                                  
b) NaOH-aq.-EtOH, heat, 24 h, 56%; c) NaOH-aq.-EtOH, heat, 1h, 80%. 
 
The synthesis of compound 32 has been shown by Page et al.
36
 (Scheme 20). Cyclopentene oxide
37 
121 was opened by sodium azide in ammonium chloride and aqueous ethanol, affording the azido 
cyclopentanol, which was reduced using triphenyl phosphine and simultaneously Boc-protected in 
situ, producing compound 122 in 22% yield over three steps. After that, compound 122 was 
ringclosed to the protected aziridine 123 in 75% yield, using Mitsunobu conditions.  
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Dimethyl malonate was used to open the aziridine system, by enolate generation, in a regioselective 
fashion yielding compound 124 as trans-isomer. Diester 124 was hydrolyzed in aqueous potassium 
hydroxide in order to convert first one of the methyl esters into the corresponding acid, and then 
into compound 125 as result of decarboxylation in xylene. Additionally, compound 125 was 
hydrolyzed in hydrochloric acid, affording the trans-2-(2-amino cyclopentyl) acetic acid 32 in 80% 
yield as HCl-salt. 
 
 
 
 
 
Scheme 20.  Synthesis of isomer 32, as described by Page et al. Reagents and conditions: a) NH4Cl, NaN3,                 
EtOH–H2O (1:1), reflux, overnight; b) PPh3, toluene, reflux, 1.5 h; c) aq NaHCO3, EtOAc, Boc2O, 0 °C → r.t., 
overnight, 22% over three steps; d) PPh3, DIAD, THF, –78 °C → r.t., 75%; e) NaH, dimethyl malonate, DME, reflux, 
24 h, 95%; f) 1 M KOH, MeOH, KHSO4; g) xylenes, reflux, 4 h 68%; h) 4 M HCl, r.t., 14 h, 80%. 
 
In both described methods, the amino acids were obtained in good yield and with regioselective 
fashion, but not enantioselective. Thus, the products were obtained as racemic mixtures. 
In this work the preparation of enantiomerically pure trans -amino acid 32 has been carried out by 
a synthetic route described by Gellman et al., using  a common way to synthesize -amino acids 
from -amino acids by an Arndt-Eistert homologation (Scheme 21).38 After formation of                      
α-diazoketone 127 from Boc-protected -amino acid 126 by reaction with diazomethane, the                   
-amino acid can be obtained as methyl ester 128 and as free carboxylic acid 129, using different 
catalysts and conditions. 
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Scheme 21. Arndt-Eistert homologation of -amino acid 126. 
Reagents and conditions: a) 1. Et3N/ClCO2Et, -15 °C; 2. CH2N2, -5 °C; b) Cat. PhCO2Ag in Et3N/MeOH;                      
c) Cat. CF3CO2Ag in THF/H2O 9:1. 
 
In our case, compound 32 is obtained as Fmoc-protected -amino acid 130 by a homologation of 
enantiomerically pure trans-Fmoc-pentacin 132 (Scheme 22).
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Scheme 22. Retrosynthetic scheme for trans-Fmoc--amino acid 130. 
 
The synthetic route starts with the preparation of enantiomerically pure trans-Fmoc-pentacin 132, 
which has also been described by Gellman et al. (Scheme 23).
40
 In the first step, -ketoester 133 
was allowed to react with (S)-(-)--methylbenzylamine 134 to form enamine 135. After that, 
NaBH3CN was added at 0 °C, giving, after formation of hydrochloric salt and recrystallization, the 
ethyl (1S,2S)-2-[(S)-phenylethyl]-aminocyclopentane carboxylate hydrochloride 136 in 29% yield 
and with a d.e. of 99%.
41,42
 Then, compound 136 was hydrolyzed by stirring over LiOH, affording 
the (1S,2S)-2-[(S)-phenylethyl]-aminocyclopentanecarboxylic acid 137. Removal of the chiral 
auxiliary has been performed by hydrogenation in autoclave (50 bar) and 10% Pd/C as catalyst. The 
resulting salt (1S,2S)-aminocyclopentanecarboxylic acid 33 was protected with Fmoc-OSu, 
affording the (1S,2S)-Fmoc-pentacin 132 in 85% yield. 
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Scheme 23. Synthesis of trans-Fmoc-pentacin 132. Reagents and conditions: a) AcOH, EtOH, reflux, 8 h;                        
b) 1. NaBH3CN; 2. HCl, recrystallization, 29%; c) LiOH, THF/MEOH/H2O, 9 h, 0 °C, quant.; d) H2 (50 bar) 10% Pd/C, 
EtOH, 48 h, quant.; e) Fmoc-OSu, NaHCO3, Acetone/H2O 1:1, overnight, 85% . 
 
After that, Arndt-Eistert homologation
43
 of compound 132 was carried out (Scheme 24). The trans-
Fmoc-pentacin 132 was activated by isobutylchloroformate in the presence of N-methylmorpholine 
at -15 °C in THF. The mixture was allowed to warm to 0 °C, and freshly ethereal diazomethane 
solution,
44,45
 prepared from N-methyl-nitroso-urea in 50% KOH, was added dropwise, affording the 
α-diazoketone 131 in 72% yield.46 Subsequently, Wolff-rearrangement47,48 of the -diazoketone 131 
in the presence of water and silver benzoate as catalyst, produced 2-((1R,2S)-2-Fmoc-
aminocyclopentyl) acetic acid 130 in 35% yield. 
 
 
 
 
Scheme 24. Synthesis of 2-((1R,2S)-2-Fmoc-aminocyclopentyl) acetic acid 130.                                                                           
Reagents and conditions: a) 1. IBCF/N-methylmorpholine, THF, -15 °C; 2. CH2N2, 0 °C, 4 h, 72%; b) cat. PhCO2Ag, 
ultrasounds, dioxane/H2O, 1 h, 35%. 
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The Cis--amino acid 30 and trans-isomer 31 have also been successfully prepared. The synthesis 
of cis-hydrochloride salt compound 30 has previously been described by Omar et al.
49
 In this work, 
the Fmoc-amino acid was prepared by a slight modification of the reported protocol (Scheme 25). 
 
 
 
 
Scheme 25.  Synthesis of  2-((1S,2S)-2-Fmoc-aminocyclopentyl) acetic acid 143. Reagents and conditions:                        
a) Benzene (abs.), reflux, 6 h, 78% ; b) 1. NaBH4, 1 h, 0 °C ; 2. HCl, 0 °C, recrystallization, 55% ; 3. LiOH, 
THF/MeOH/H2O, 0 °C, 9 h, quant.; c)  Li/NH3, -78 °C, THF/tBuOH, overnight, 77% ; d) 1 N HCl, 80 °C, 8 h, 55%;              
e) Fmoc-OSu, NaHCO3, Acetone/H2O 1:1, 18 h, 85%. 
 
 
Racemic ethyl 2-(2-oxocyclopentyl)acetate
50
 138 was allowed to react with R-(+)--
methylbenzylamine 139 using a Dean-Stark-trap, affording the imine mixture 140. In this step 
theoretically four diastereoisomers are obtained as shown in Figure 32. 
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Figure 32. The imine mixture 140 consists of four diastereoisomers. 
 
In the reported protocol, the imine mixture 140 was reduced by hydrogenation in autoclave in the 
presence of Raney-Nickel, yielding only the cis-phenylethylamino-cyclopentyl acetate in 
enantiomerically pure form. Unfortunately, we could not reproduce this step. Therefore, in this 
work it was planned to reduce the imine mixture 140 by another common way to synthesize                    
-amino acids from imines, by using NaBH4 at 0 °C.
51
 In these conditions, only two different 
isomers 148 and 149 were obtained in an 2:1 diastereomeric ratio, determined by 
1
H-NMR 
(Scheme 26). 
 
 
 
 
 
Scheme 26. Reduction of imine mixture 140 gave only two isomers 148 and 149.                                                            
Reagents and conditions: a) NaBH4, EtOH, 0 °C, 1 h, 55%. 
 
 
NOESY analysis confirmed that the major isomer has the trans-configuration and the minor one has 
the cis-configuration (Figure 33 and Figure 34). 
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Figure 33. NOESY spectrum of compound 149 shows interaction between hydrogen 1 and 2. (cis-isomer). 
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Figure 34. NOESY spectrum of compound 148 shows no interaction between hydrogen 1 and 2. (trans-isomer). 
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A freshly solution of HCl in ethyl acetate was added dropwise separately to solution of each 
phenylethylamino-cyclopentyl acetate 148 and 149 in diethyl ether cooled at 0 °C, affording after 
recrystallization the hydrochloride salts 150 and 151. X-ray structure of these salts proved the 
corrected stereochemistry (Figure 35). The stereochemistry of compound 150 was exactly the 
opposite of trans--amino acid 130. Thus, the final Fmoc-amino acid synthesized by modifications 
of compound 150 will be the enantiomer of trans--amino acid 130. 
 
 
              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35. The hydrochloride salts of trans- and cis-ethyl 2-((R)-1-phenylethylamino)cyclopentyl)acetate (150, 151);  
X-ray structures of compound 150 and 151. 
 
 
After that, the synthesis of Fmoc--amino acids has been carried out by modifications of  the 
hydrochloride salts 150 and 151. Scheme 27 shows the synthesis of trans-Fmoc--amino acid 153. 
The hydrochloride salts 150 was hydrolyzed in presence of LiOH, giving 2-((1S,2R)-2-((R)-1-
phenylethylamino)cyclopentyl)acetic acid 152 in quantitative yield. Compound 152 was dissolved 
in ethanol, Pd/C (10 %) was added and the resulting mixture was shaken under H2 (50 bar) at 50 °C 
for 48 h, affording 2-((1S,2R)-2-aminocyclopentyl)acetic acid 31, which was protected with    
Fmoc-OSu, yielding the 2-((1S,2R)-2-Fmoc-aminocyclopentyl) acetic acid 153.  
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Scheme 27. Synthesis of 2-((1S,2R)-2-Fmoc-aminocyclopentyl) acetic acid 153. Reagents and conditions: a) LiOH, 
THF/MEOH/H2O, 9 h, 0 °C, quant.; b) H2 (50 bar), 10 % Pd/C, 50 °C, EtOH, 48 h, 85%; c) Fmoc-OSu, NaHCO3, 
Acetone/H2O 1:1, 18 h, 85%. . 
 
The isomer 151 was used to prepare cis-Fmoc-amino acid 143. The same route was tried, but 
because of cis-stereochemistry, lactamization took place during hydrolysis using LiOH, and the 
compound 151 was converted into lactam 141 in quantitative yield (Scheme 28). 
 
 
 
Scheme 28. Lactamization of compound 151. 
 
Therefore, a new synthetic route was planned to obtain Fmoc-protected cis--amino acid 143 from 
lactam 141, and it is shown in Scheme 29. 
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Scheme 29. New synthetic route to prepare 2-((1R,2R)-2-Fmoc-aminocyclopentyl) acetic acid 143.                                                           
Reagents and conditions: a) Li/NH3, -78 °C, THF/t-BuOH, overnight, 77%; b) 1 N HCl, 80 °C, 8 h, 55% ;                             
c) Fmoc-OSu, NaHCO3, Acetone/H2O 1:1, 18 h, 85%. 
 
Debenzylation of compound 141 was carried out by Birch reaction.
52
 The reaction was run at -78 °C 
in liquid ammonia and lithium, then t-BuOH was added together with compound 141 in THF. 
Lactam 142 was obtained in 77% yield.
53,54
 Compound 142 was hydrolysed
54
 in 1 N HCl, giving 
the 2-((1R,2R)-2-aminocyclopentyl) acetic acid 30, which was protected with Fmoc-OSu, affording 
the 2-((1R,2R)-2-Fmoc-aminocyclopentyl) acetic acid 143 in 85% yield. In conclusion, in this work 
three isomers of 2-(2-Fmoc-aminocyclopentyl) acetic acid were prepared in enantioselective form, 
and were used to synthesize different NPY analogues by solid phase synthesis. Furthermore, trans-
pentacin 33 was an important intermediate compound for the synthesis of -amino acid 130 and thus 
it has also been prepared in good amount in this work. As mentioned in the introduction, on the 
base of its good result in foldamers as shown by Gellman et al.,
55
 NPY analogues containing 
compound 33, and in different combination with the -amino acids 30, 31 and 32 have also been 
prepared. The synthesis and conformational analysis of NPY analogues containing  and -amino 
acid will be presented in the next chapter. 
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Chapter 2 
 
2. 1. Synthesis and conformational investigation of NPY analogues 
 
2. 1. 1.  Structure inducing moieties in NPY analogues 
 
“Neuropeptide Y (NPY) is one of the most abundant neuropeptides in the central nervous system”.56 
NPY was isolated in 1982 from a porcine brain by Tatemoto et al.,
57
 and it is a important member 
of a peptide family, together with peptide YY (PYY) and pancreatic polypeptide (PP). The  peptides 
in this family consist of 36 amino acids, have a high content of tyrosine, and an amide group at the 
C-terminus.
58
 The three peptides show a high homology in their peptide sequence, especially 
between NPY and PYY, and a bit less with pancreatic polypeptide (PP).
59
 NPY has been found in 
nonsympathetic neurons in several organs such as the gastrointestinal tract, salivary glands, the 
urinogenital system, and the heart.
60
 In the periphery, it has been found in the sympathetic nervous 
system, co-stored with norepinephrine.
61
 NMR studies on NPY have shown that it consists of a              
C-terminal part folded into an -helical conformation and a N-terminal part which is unfolded.62 
Contrary to the structure of avian PP, which consists of a -turn type II that connects a type II 
polyproline helix to an amphiphilic -helix, as confirmed by X-ray crystallography.63 The activities 
of NPY are mediated through G-protein-coupled receptors of class A (rhodopsin-like) (Figure 
36).
64
 These receptors are metabotropic, and can thus open and close ion channels.  
 
Figure 36. Structure of receptors rhodopsin-like GPCR family.67 
 
Contrary to ionotropic receptors which open the channels directly, in this case after binding of the 
ligand, a series of reactions mediated by a intracellular second messenger lead to a channel-opening 
or other cellular effects.
65
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In this class of receptor, the intracellular second messenger is usually the cyclic adenosine 
monophosphate (cAMP), but some studies showed NPY receptors can also couple with 
phospholipase C, releasing the Ca
2+
 from intracellular stores.
66
  
“Five receptor subtypes have been cloned in mammals (Y1, Y2, Y4, Y5, and y6)”.
68
 NPY and PYY 
show a high affinity for Y1, Y2 and Y5 receptor subtypes, while the PP prefers the Y4 receptor.
69 
On 
the base of the degree of amino acid sequence identity, the receptors can be organized into three 
subfamilies, which are called subfamilies Y1, Y2 and Y5.
70 
These subtypes of NPY receptors have 
an important role in many different processes such as stimulation of feeding, regulation of blood 
pressure, anxiety, stress, depression, memory and learning processes 
71
 (Table 3). Furthermore, they 
perform other biological functions such as vasoconstriction in periphery, modulation of pain and 
epileptic seizures.
72
 
 
Receptors Physiological implications 
 Y1 
Regulation of blood pressure, food intake, seizure regulation, 
anxiety, pain sensitivity, depression. 
 Y2 
 
Regulation of blood pressure, food intake, seizure regulation, 
anxiety, hypothalamic regulation of bone formation, pain 
sensitivity, depression, regulation of the motility of the 
gastrointestinal tract. 
 
 Y4 
 
 
Food intake, regulation of the motility of the gastrointestinal 
tract. 
                          Y5 
 
Food intake, seizure regulation, anxiety. 
 
Table 3. Physiological effects mediated by different NPY receptors.73 
 
The development of subtype-selective ligands for each receptor could help shed light on the 
working of each receptor, since NPY shows a different affinity towards each of them.
74 
Subtype 
selective agonists and antagonists have been synthesized and tested.
75
 Several non peptidic as well 
as peptidic, selective ligands are shown in table 4. 
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Compounds Properties  
1. NPY(18–36) 
Antagonized NPY effects on rat cardiac 
ventricular membranes
76 
and myocytes, 
canine purkinje fibers, and NMDA response 
in rat hippocampus. Partial agonist at Y1 
receptors and full agonist at Y2 receptors.
77,78
 
2. N--Ac-[3-(2,6-dichlorobenzyl-Tyr27,         
D-Thr32] NPY(27–36), PYX1 
 
N--Ac-[3-(2,6-dichlorobenzyl)-Tyr27,36,              
D-Thr32] NPY(27–36), PYX2 
Bound to rat brain bearing predominantly Y2 
receptors and antagonized NPY effects on 
HEL cells. PYX2 also antagonized NPY-
induced feeding. Demonstrated for the time 
that decapeptide based compounds can also 
interact with NPY receptors. Found to be 
weak or inactive antagonist by other 
investigators.
79
 
3. [D-Trp32] NPY. 
Antagonized NPY-induced feeding in rats and 
mice.
80,81
 Reported to be a weak
82
 and 
potent
83
 Y5 selective ligand. Also reported to 
be weak agonist on feeding.
82
 
4. Antagonists based on centrally truncated 
NPY analogs: 
e.g. 1. Des-AA7–24[D-Ala5, Aoc6, D-
Trp32]NPY; 
2. Des-AA6–24[Aca5, Ala28] NPY. 
  Antagonized NPY effects on HEL cells, and 
NPY-induced hypertension in rats.
84
 Only 
moderately potent and nonselective. 
5. [D-Tyr27,36, D-Thr32]NPY(27–36). 
Antagonized rat food intake induced by both 
food deprivation and exogeneous NPY. 
Receptor affinities or selectivity not 
reported.
85
 
6. Nonapeptide antagonists: 
e.g. 1. Des-Asn29[Trp28, 32, Nva] NPY(27–
36); 
         2. [Pro30, Tyr32, Leu34] NPY(28–36). 
 
Moderately potent Y1 receptor antagonist, 
Y1>Y2 ;
86
 
Potent Y1 receptor antagonist, Y1>Y2.
87
 
 
Table 4. List of some peptide and non peptide antagonists.88 
 
Some studies have established that specific positions on the NPY sequence, such as the two 
arginines in positions 33 and 35 and the tyrosine amide in position 36, are fundamental to the 
recognition process by the respective receptor. Therefore, removing these amino acids, the 
corresponding analogue loses its selectivity and thus its activity.
89 
It has also been shown that 
substitutions close to these positions allows to obtain analogues which fold in a different 
conformation and have different selectivity for some receptor subtypes. For example, the 
introduction of a proline residue in position 34 reduced the Y2 receptor affinity, but maintains the 
affinity toward the Y1 and Y5 receptors.
90,81
 Moreover, the introduction of the turn-inducing Ala-
Aib sequence in positions 31 and 32, led to a Y5-selective analogue as reported by Cabrele et al.
91
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In order to rigidify the peptide backbone and to stabilize any distinct secondary structure in NPY 
analogues, new conformationally constrained amino acids as building blocks have been 
investigated. As previously mentioned in the introduction, the two enantiomers of -ACC 26 were 
introduced in the C-terminus (residues 25-36) of the NPY in position 32 and 34.
92
 These analogues 
showed a good affinity and selectivity to the Y1 receptor subtype. Furthermore, depending on the 
position of the substitution and the absolute configuration of -ACC 26, different affinity and 
selectivity have been observed. (Table 5).  
 
Peptide Sequence Y1 Y2 Y5 
 
154 
 
Ac-RHYINLITRQRY-NH2 
 
>1000 
 
21 
 
>1000 
 
155 
 
Ac-RHYINL-IT-R-(+)-RY-NH2 
 
37(±20) 
 
>1000 
 
724 
 
156 
 
Ac-RHYINL-IT-R(–)RY-NH2 
 
>1000 
 
>1000 
 
>1000 
 
157 
 
Ac-RHYINLI(+)RQRY-NH2 
 
>1000 
 
>1000 
 
>1000 
 
158 
 
Ac-RHYINLI(–)RQRY-NH2 
 
>1000 
 
>1000 
 
>1000 
 
159 
 
Ac-RHYINL-I(+)-R(–)RY-NH2 
 
50(±10) 
 
>1000 
 
617 
 
160 
 
Ac-RHYINL-R(+)-R(–)RY-NH2 
 
29(±13) 
 
>1000 
 
118 
 
Table 5. Sequence and affinities of NPY analogues containing -ACC (where (+) = (+)-ACC and (–) = (–)-ACC). 
The affinities are expressed as Ki values [nM].
93
 
 
On the base of these results with -ACC, different NPY analogues containing isomers of                     
2-(2-aminocyclopentyl) acetic acid and trans-pentacin 33 in position 32 and 34 were prepared. 
Their synthesis will be presented in the next paragraph.  
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2. 1. 2. NPY analogues containing isomers of the 2-(2-amino cyclopentyl) acetic acid 
 
Different NPY analogues containing isomers of the 2-(2-amino cyclopentyl) acetic acid have been 
prepared in collaboration with the group of Prof. Dr. Chiara Cabrele at University of Bochum. 
Fmoc-protected unnatural -amino acids 130, 153, 143 and 132 have been used to synthesize 
truncated NPY analogues (residues 25-36) by solid phase synthesis using Fmoc chemistry. 
Recently, the synthesis and conformational analysis on -- foldamer containing trans-pentacin 33 
and a -amino acid in which the backbone is constrained by a six-membered ring has been reported 
by Gellman et al., and these peptides showed to adopt an a-helix like conformation in water.
94
 On 
the base of these results, NPY analogues containing trans-pentacin 33 in combination with the               
-amino acids 30, 31 and 32 as --foldamers were prepared and investigated. Figure 37 shows 
two NPY analogues containing compounds 30 and 33. 
 
 
 
 
 
 
 
 
 
 
 
                                                
 
 
 
 
 
 
Figure 37. Structure of the NPY analogues containing unnatural amino acids 30 and 33 as --foldamers. 
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In peptide 161, the original structure of NPY has been modified in three positions. Tyrosine in 
position 28 was replaced with a threonine. The cis--amino acid 30 has been introduced in position 
31, and trans-pentacin 33 in position 34. In peptide 162, cis--amino acid 30 was introduced in 
position 31, and trans-pentacin 33 in position 34 and 28. 
Moreover, NPY analogues containing only a unnatural amino acid have been prepared and are 
shown in Figure 38.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
.  
 
 
 
Figure 38. Structure of the NPY analogues containing unnatural amino acids 33 and 30 in position 34. 
 
In this case, only a unnatural amino acid has been introduced in position 34. trans-pentacin 33 in 
peptide 163, and cis--amino acid 30 in peptide 164.  
All crude peptides have been characterized by MS and analytical HPLC, confirming that the main 
peaks correspond to the desired peptides (Figure 39 and Figure 40). 
 
 
 
 
 
 
 
 
 57 
 
Ac-Arg
1
-His
2
-Thr
3
-Ile
4
-Asn
5
-(1S,2S-ACPA)
6
-Thr
7
-Arg
8
-(1S,2S-ACPC)
9
-Arg
10
-Tyr
11
-NH2      161 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ac-Arg
1
-His
2
-(1S,2S-ACPC)
3
-Ile
4
-Asn
5
-(1S,2S-ACPA)
6
-Thr
7
-Arg
8
-(1S,2S-ACPC)
9
-Arg
10
-Tyr
11
-NH2     162 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39. Characterization of the crude peptides 161 and 162 by HPLC-MS. 
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Figure 40. Characterization of the crude peptides 163 and 164 by HPLC-MS. 
 
NPY analogues containing the trans-isomers 31 and 32 were also prepared. Peptides 165 and 166 
contain two substitutions. Trans-pentacin 33 in position 34, and the trans--amino acids in position 
31. Trans-isomer 31 was introduced in peptide 165, while its enantiomer trans-isomer 32 in peptide 
166. Therefore, these peptides are diastereoisomers (Figure 41). 
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Figure 41.  Structure of the NPY analogues containing unnatural amino acids 31, 32 and 33. 
 
 
Analytical HPLC of crudes NPY analogues 165 and 166 displayed very good chromatogramms, 
showing a main peak which corresponds to the product and only few impurities (Figure 42 and 43). 
 
Ac-Arg
1
-His
2
-Tyr
3
-Ile
4
-Asn
5
-(1S,2R-ACPA)
6
-Thr
7
-Arg
8
-(1S,2S-ACPC)
9
-Arg
10
-Tyr
11
-NH2   165 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42. Analytical HPLC of crude NPY analogue 165. 
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Figure 43. Analytical HPLC of crude NPY analogue 166. 
 
Concluding, in the last part of this work trans--amino acid 31 and 32 have also been introduced in 
position 34 into the structure of NPY segment, generating the analogues 167 and 168 as shown in 
figure 44.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44. Structure of the NPY analogues containing unnatural amino acids 31 and 32 in position 34. 
 
0 10 20 30 40 50
0
500
1000
1500
2000
A
b
s
. 
2
2
0
 n
m
 (
a
u
)
Time (min)
 61 
 
Analytical HPLC of crude NPY analogues 167 and 168 are shown in figure 45.  
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Figure 45. Analytical HPLC of the crudes NPY analogues 167 and 168. 
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The synthesis of all peptides was performed using Fmoc-Rink-amide MBHA resin (loading: 0.45 
mmol/g), HBTU in combination with HOBt and DIPEA as coupling reagents. Peptide cleavage 
from the resin and simultaneous side-chain deprotection has been performed by mixture 
TFA/water/TIS/thioanisole. All peptide crudes were purified by preparative reversed phase HPLC, 
affording the pure peptides with a high degree of purity (86-98%). After purification, NPY 
analogues were subjected to conformational investigation, which will be introduced in the next 
paragraph.  
 
 
 
 
2. 2. Conformational Investigations 
 
Peptides and proteins fold into a defined conformation which depends in principal on the kind of 
amino acids in their sequence.
95
 Conformational analysis of the three dimensional structure of a 
peptide allows the understanding of its physical, chemical and biological properties.
96
 This 
investigation consists of the characterization of the secondary structure and structural investigations 
at atomic resolution. The last one is obtained by X-ray crystallography, which allows a direct way 
to observe the structure of the peptide. Actually, the analysis of the secondary structure is the most 
common for the characterization of peptides. The techniques used to investigate the three 
dimensional structure are circular dichroism, 1D and 2D NMR spectroscopy.
96
 
 
 
2. 2. 1. Circular dichroism 
 
Circular dichroism is an important spectroscopic technique to investigate the secondary structure of 
peptides, proteins and nucleic acids. The principle of CD spectroscopy is based on the different 
absorption of the left and right circularly polarized components of light by an optically active 
substance such as a peptide. When these components are recombined, a projection of the resulting 
amplitude yields an ellipse. The extent of this ellipticity is then measured, giving a CD spectrum.
97 
Concerning a peptide, the UV-CD spectropolarimeter measures the ellipticity in the absorption band 
of amide bonds (180-250 nm). The absorption →* of amides can change according to the 
presence of hydrogen bond, and thus on the presence of any secondary structure.
98
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The CD spectrum shows some curves that are the results of the combination of absorbance of the 
orientated chromophores in the three dimensional arrangement, therefore each peptide secondary 
structure will give a specific curve. Figure 46 shows the typical CD spectra for some secondary 
structures of -peptides. The analysis are performed in solvents which do not absorb in amide band, 
such as methanol, trifluoroethanol, water and acetonitrile.  
 
Figure 46. CD spectra of the common secondary structures seen for -peptides.99 
 
The ellipticity can be calculated by the Beer-Lambert law: = CDmeasured/(C
.
l
.
n), whereis the 
ellipticity in deg cm
2.
dmol
-1
, C is the concentration in mol
.
L
-1
, l is the length of the cell in cm and n 
is the number of amino acids.
 
Circular dichroism can suggest if and which secondary structure the peptide adopts, but it does not 
give any information about which amides are involved in hydrogen bonding.
100 
NMR analysis can 
give a lot of information concerning this last point. 
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2. 2. 2. NMR investigations 
 
Nuclear Magnetic Resonance (NMR) spectroscopy is a useful technique to investigate the 
secondary structure of peptides and proteins in solution. It allows the analysis on an atomic level, 
especially concerning the presence and location of hydrogen bonding. Important information are 
obtained from 1D and 2D NMR spectra.
101
 
 
 
 
2. 2. 2. 1. 1D-proton NMR spectra 
 
1D-proton NMR spectra are used to identify the protons that are involved in an intramolecular 
hydrogen bonding. The NMR analysis can be influenced by different factors: the choice of solvent, 
hydrogen deuterium exchange and the variation of temperature. The solvent can influence the 
ability of a peptide to adopt a secondary structure, thus peptides often show different conformations 
in different solvents.
102
  
Hydrogen deuterium exchange studies give information on the presence and on which part of the 
peptide is stabilized by hydrogen bonding. A secondary structure in solution can modify the proton 
exchange, producing a slower exchange rate of labile protons, which can be measured by time 
dependent NMR-spectroscopy.
 
This measurement is not possible in small molecules where proton 
exchange is too fast. The experiments are conducted in the presence of deuterated solvents, 
encouraging the exchange between the deuterium with amide protons of the peptide. In this moment 
the exchange rates are measured. Longer exchange time with deuterium indicates that the protons 
are blocked and stabilized by hydrogen bonding. Contrary to protons which are not involved in 
hydrogen bonding, where the exchange time is much shorter.
103,101 NMR analysis can also be 
influenced by variation of temperature, which can modify the hydrogen-bonded state of amide 
protons.
104 
This information is obtained from the temperature coefficient (/T). For these studies, 
it is fundamental that no aggregation occurs and thus they are conducted in a specific concentration 
to avoid it.
 
Generally, if amide protons exchange slowly with the deuterium and have a temperature 
coefficient  more positive than -4.5 ppb/K, then they are involved in a hydrogen bonding. Contrary 
to protons not involved in a hydrogen bonding that exchange rapidly and have a temperature 
coefficient more negative than -4.5 ppb/K.
105,106
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2. 2. 2. 2.  Information from 2D-proton NMR spectra 
2D NMR investigation allows to obtain structural information on peptides and proteins.
107 
A typical 
2D spectrum displays the diagonal peaks, which are peaks in a 1D-NMR, and the cross peaks which 
indicate couplings between the protons.
108
 The COSY (correlation spectroscopy), TOCSY (total 
correlation spectroscopy), ROESY(rotating-frame overhauser spectroscopy) and NOESY (nuclear 
overhauser effect spectroscopy) experiments are very useful in peptide analysis. “The COSY 
displays [
1
H,
1
H]-correlations due to scalar (through-bond) coupling”.101 Therefore, it allows to 
identify vicinal protons. “A TOCSY experiment contains all cross peaks due to protons of the same 
spin system”.101 In this case, it is not necessary that the two nuclei are directly coupled, but the 
cross peaks are observed also between nuclei which are connected by a chain of couplings. This is 
very useful to identify large interconnected networks of spin couplings such as the side chains of 
amino acids.
109 
Coupling by spatial interaction are shown by NOESY and ROESY. “Cross peaks in 
the NOESY are due to dipolar couplings resulting from interactions of spins via space and hence 
only depend on the distance but not on the number of intervening bonds”.101 Therefore, hydrogen 
atoms of different amino acids which are far away in the primary structure, can be very close in a 
three dimensional structure and give spatial interactions. A NOE peak usually is displayed when 
two protons are within 5 Å, but it depends also on other factors such as molecular weight. 
Sometimes, the protons are within 5 Å, but the NOE is close to zero. This is due to the cross-
relaxation rate constant which becomes negative as the correlation time increases. For peptides with 
high molecular weight, it is better to use ROESY, which is very similar to NOESY, but in this case 
the cross-relaxation rate constant is always positive.
108 
The presence of NOE or ROE peaks between 
protons which are far away in the sequence, indicates that the peptide or protein folds in a specific 
conformation stabilized by hydrogen bonding. Furthermore, NMR analysis can suggest which kind 
of secondary structure is adopted by the peptide. Concerning to this, interatomic distances, the 
three-bond coupling constants 
3
JHN, intensity and kind of contacts in NOESY or ROESY spectrum 
are a very useful tool to predict a kind of secondary structure.
110  
Table 6 shows sequential (between 
the i residue and the i+1 residue) and medium (between the i residue and  i+2, i+3, and i+4) range 
1
H-
1
H distances for identification of secondary structure. 
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Contacs -Helix 310 Helix Antiparallel  Parallel Type I Turn Type II Turn 
dN 3.5 3.4 2.2 2.2 3.4/3.2 2.2/3.2 
dN (i, i+2) 4.4 3.8   3.6 3.3 
dN (i, i+3) 3.4 3.3   3.1-4.2 3.8/4.7 
dN (i, i+4) 4.2      
dNN 2.8 2.6 3.3 4.0 2.6/2.4 4.5/2.4 
dNN (i, i+2) 4.2 4.1   3.8 4.3 
d (i, i+3) 2.5-4.4 3.1-5.1     
 
Table 6. Useful sequential and medium range 1H-1H distances (in Å) for identification of 
secondary structure in polypeptide chains. For the helices,  sheets, and turns, no number is given for 
distances >4.5 Å.
111
 
 
 
Some more information about the secondary structure are given from spin-spin coupling constants 
3
JHN, which isdirectly related to the backbon dhiedral angle , and from the intensity of NOE 
peaks. Generally, values of coupling constant minor than 5 Hz indicates a turn or helical structure, 
while values higher than 6 Hz are characteristic of extended or unordered conformation.
110 
 Table 7 
summarizes the sequential and medium range proton-proton NOEs and the spin-spin coupling 
constants 
3
JHN in some common secondary structures. 
 
Distances ap -Helix 310 Helix Turn I Turn II Turn I’ Turn II’ 
Half-
Turn 
dN (i, i+4) 
  
 
      
d (i, i+3) 
  
 
      
dN (i, i+3) 
  
 
      
dNN (i,i+2) 
 
 
 
 
      
dN (i, i+2) 
  
 
      
dNN 
        
 
dN 
        
 
3
JHN 9 9 9 9 9  
1 2 3 4 5  
4 4 4 4 4 4 4 
1 2 3 4 5 6 7 
4 4 4 4 4 4 
1 2 3 4 5 6 
4 9 
1 2 3 4 
4 5 
1 2 3 4 
7 5 
1 2 3 4 
7 9 
1 2 3 4 
4 9 
1 2 3 4 
 
Table 7. The sequential and medium range proton-proton NOE's and the spin-spin coupling constants 3JHN in some 
common secondary structures. The numbers at the bottom represent the amino acid residues in the given secondary 
structure. The thickness of the line is proportional to the intensity of the NOE.
110
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2. 3. Conformation analysis of NPY segment and analogues 
 
Conformational investigation of Neuropeptide Y has allowed to know its structure.
 
COSY and 
TOCSY studies allowed to assign all chemical shift for each protons and to confirm the -helical 
folding by NOESY and ROESY analysis.
112
 Gurrath et al. showed the conformational analysis of 
two C-terminal segments, NPY (13-36) and NPY (18-36), by CD measurement, 2D NMR and 
conformational refinement of NMR-derived structure by molecular mechanism simulations.
113 
Table 8 shows all chemical shift for NPY segment (18-36). 
 
Residue NH H

 H

 H
1
 H

 H
1
 H

 H
1
 
 
Ala
18
 
 
- 
 
4.17 
 
1.57  CH3

 
 
- 
 
- 
 
- 
 
- 
 
- 
Arg
19
 8.48 4.36 1.83  1.68  3.25  
Tyr
20
 7.75 4.50 3.15/3.10  - - - - 
Tyr
21
 7.53 4.40 3.15  - - - - 
Ser
22
 7.86 4.28 4.08 4.03 - - - - 
Ala
23
 7.94 4.26 1.61  CH3

 - - - - - 
Leu
24
 7.99 4.31 1.88 1.76 1.78 - 1.11 CH3

 105 CH3

 
Arg
25
 8.17 4.04 1.94  1.75 1.66 3.22  
His
26
 8.11 4.46 3.47  - - - - 
Tyr
27
 8.36 4.35 3.35  - - - - 
Ile
28
 8.71 3.78 2.03 1.02 CH3

 1.92 1.42 0.95 CH3

 - 
Asn
29
 8.21 4.42 3.12 2.88 - - - - 
Leu
30
 8.00 4.15 1.85  1.70 - 0.94 CH3
2
  
Ile
31
 8.41 3.91 1.92 0.89 CH3

 1.47 1.24 0.78 CH2

 - 
Thr
32
 8.11 4.10 4.46 - 1.42  CH3

 - - - 
Arg
33
 7.95 4.23 2.08  1.89 1.84 3.26  
Gln
34
 8.13 4.18 2.25  2.57 2.47 - - 
Arg
35
 7.95 4.21 1.80 1.72 1.48  3.12  
Tyr
36
 7.81 4.68 3.32 2.98 - -  - 
 
Table 8. 1H Assignment of NPY (18-36) in TFE-d2/H2O 9:1 at T = 308 K.
114
 
 
Furthermore, the group of Gurrath reported some more structural information on the NPY segment 
derived from CD spectroscopy studies. The CD spectrum in aqueous solution showed a typical 
unfolded conformation, but the presence of TFE induced helix formation with a maximum helix 
content of 80%, in the presence of 30% of TFE, as revealed by typical CD spectrum with two 
negative minima at 222 and 208 nm (Figure 47). 
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Figure 47. CD spectra of NPY(18-36) segment in water/TFE 
mixtures. TFE percentages are indicated on the spectra.
115
 
 
In the last 20 years, the synthesis of NPY segments as well as analogues and its conformational 
analysis has attracted interest. Aguilar et al. reported the conformation analysis on NPY (18-36) 
analogues, containing a single D-amino acid substitution, in hydrophobic environments by CD 
spectroscopy.
116
 The CD spectra were recorded in phosphate buffer, and in mixture with organic 
solvent (Figure 46). 
 
Figure 48. CD spectra of NPY (18-36) measured in 15 mM organophpsphate buffer, 40% acetonitrile in buffer, and 
90% TFE in buffer.
117
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The results showed that NPY (18-36) does not adopt any helical structure in buffer, but the                    
-helical content was increased in presence of organic solvents. This result confirms that the 
conformation adopted by NPY segment in solution is influenced by the solvent conditions. CD 
spectra were recorded for each analogues using the same buffer condition, indicating the importance 
of central region of NPY segment for the maintenance of the -helical conformation, while the                     
D-amino acid substitutions within N- and C-terminal regions do not influence the secondary 
structure. Concluding, CD spectra measured in the same condition detect several information about 
the conformation changing as a result of introduction of new building blocks on the NPY sequence. 
Therefore, CD as well as NMR studies are an important tool for the conformational analysis of 
NPY analogues.
118,113 
 
 
 
 
2. 4. Conformation analysis of NPY analogues containing the 2-(2-amino 
cyclopentyl) acetic acid 
 
NPY analogues have been investigated by CD- as well as NMR spectroscopy. All CD spectra were 
recorded in water, and in 20% of methanol and TFE in water. Being very soluble in water, no much 
organic solvent was used for the analysis, but only the necessary amount to stabilize any 
conformation (20-30%). Furthermore, the CD were measured in phosphate buffer 50-100 mM at pH 
7.4, and in 20% of methanol and TFE in buffer. The peptide concentration for each analysis was  
0.3 mM. NMR spectra were recorded in water, with 10% of D2O. 1D NMR experiments were 
acquired at five different temperatures (283, 288, 293, 303 and 313 K), in order to have a good 
dispersion of signals. This temperature was used to record the 2D experiments. The complete 
sequence-specific resonance assignment has been done by using COSY, TOCSY and ROESY 
spectra. Furthermore, the NOE peaks intensities were converted into distance, and were classified as 
strong (1.8-2.7 Å), medium (1.8-3.3 Å) and weak (1.8-5 Å).
111 
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2. 4. 1 Results on NPY analogues 161 and 162 
 
2. 4. 1. 1. CD studies 
As already mentioned, NPY analogues 161 and 162 contain two different unnatural amino acids, the 
trans-pentacin 33 and the cis--amino acid 30. Thus, these analogues can be considered as                         
--foldamers. The CD spectra of compound 161 are shown in figure 49. 
 
 
 
 
 
 
 
 
 
                                           a)                                                                        b)                      
Figure 49. CD spectra of compound 161. a) CD spectrum in water, and in 20% of methanol and TFE in water; b) CD 
spectrum in phosphate buffer and in 20% of methanol or TFE in buffer. 
 
All CD spectra showed only negative bands. The peptide 161 in water displays a broad band with a  
minimum at 197 nm and a shoulder at about 205 nm (panel a of Figure 49). 
The CD curve obtained in the presence of 20% methanol is very similar to that in water, however 
with reduced intensity. This suggests that methanol does not significantly change the conformation 
adopted in water. In presence of 20% TFE, the CD curve shows a minimum at about 205 nm, as 
already detected in water and water/methanol, whereas the minimum at 197 nm disappears almost 
completely. These results suggest that the two CD signals at 205 nm and 197 nm are probably 
related to two different conformations, which are both present in water and water/methanol, 
whereas TFE seems to stabilize the conformation related with the CD contribution as 205 nm. By 
using phosphate buffer at pH 7.4 in place of water, there is a blue-shift of the CD bands (from 205 
nm to 200 nm, and from 197 nm to 195 nm). Interestingly, the band at shorter wavelength, which 
disappears in water/TFE, is still present in buffer/TFE, whereas it disappears in buffer/methanol. 
Apparently, the effect of the two organic solvents on the conformation is different at acidic (water) 
and slightly basic pH (buffer).  
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                                         a)                                                                             b) 
Figure 50. CD spectra of compound 162. a) CD spectrum in water and in 20% of methanol and TFE in water; b) CD 
spectrum in phosphate buffer and in 20% of methanol and TFE in buffer. 
 
Peptide 162 is expected to be more structured than peptide 161, having one more unnatural amino 
acid unit in its structure. Comparison of the CD spectra of 162 (Figure 50) and 161 (Figure 49) in 
water and in the presence of organic solvent reveals that the band at 197 nm in water and 
water/methanol is less pronounced for the peptide 162 than for the peptide 161. Moreover, the CD 
spectrum of 162 in water/TFE shows a more positive contribution below 200 nm than peptide 161, 
leading to a crossover at 194 nm (panel a of Figure 50). As already observed for peptide 161, the 
effect of TFE on the conformation of peptide 162 is different in buffer and in water. Indeed, in 
water/TFE the band at 197 nm is not present but it reappears in butter/TFE (panel b of Figure 50).  
Instead, the CD shape in water/methanol is similar to that in buffer/methanol, with the only 
difference found in the relative intensity between the two bands. The CD spectra of compounds 161 
and 162 are reminiscent of the disordered state of -peptides, being characterized by a broad 
negative band centered below 200 nm. However, the comparison of the CD spectra of -peptides 
with those of peptides containing unnatural building blocks is critical. As already mentioned, 
Gellman et al. reported a conformational analysis on a --foldamer with the alternated sequence 
 by CD and NMR spectroscopy, showing that this peptide (numbered with 1 in Figure 51) 
adopts an  -helix-like conformation in aqueous solution.94  
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                                                                                                      
 
Figure 51. CD spectrum for -- peptide 1 and -peptide 2 reported by Gellman et al.119 
 
The CD spectrum of this foldamer displays a negative band at about 205 nm and a positive band 
below 190 nm with a crossover at 196 nm (Figure 51).For our peptides 161 and 162, this CD curve 
should be a better reference than those of -peptides, especially for the peptide 162 that also 
contains a similar alternated sequence (). Indeed, the CD spectrum with most 
similarity to that of the peptide 1 of Gellman at al. is that of peptide 162 in water/TFE, being the 
only one with a crossover. This could suggest that the two foldamers may adopt a similar 
conformation. 
 
 
 
2. 4. 1. 2.  NMR studies 
Peptide 161 and 162 have been investigated by NMR spectroscopy. The best dispersion of signals 
was obtained at 283 K for both peptides, thus this temperature was used to record 2D experiments. 
Under these conditions all amide protons and side chains could be identified, confirming the right 
sequence. Moreover, the temperature dependency and hydrogen/deuterium exchange were analyzed  
by 1D NMR. Table 9 shows the temperature coefficients (/T) found in the NPY analogue 161, 
for the amide protons of two threonines in position 28 and 32, asparagine in position 30,                     
cis--amino acid 30 in position 31, arginine in position 33 and trans-pentacin 33 in position 34. No 
temperature coefficients could be determined for the other amide protons due to signal overlap. 
Moreover, it should be noted that the amide protons of the two threonines were also overlapped. 
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Temperature 
 
NH-
Thr
28/32
 
NH-
Asn
30
 
NH- 
30
31
 
NH-
Arg
33
 
NH- 
33
34
 
 
283.0   K 
 
8.0237 8.3232 7.7731 8.1924 7.8147 
 
288.0   K 
 
8.0359 8.3374 7.7835 8.2041 7.8344 
 
293.0   K 
 
8.0495 8.3537 7.7965 8.2181 7.8571 
 
298.0   K 
 
8.0631 8.3689 7.8082 8.2298 7.8799 
 
303.0   K 
 
8.0756 8.3829 7.8193 8.2420 7.9002 
 
313.0   K 
 
8.1012 8.4140 7.8419 8.2687 7.9423 
/T 
(ppb/K) 
2.58 3.02 2.29 2.54 4.25 
 
Table 9. Temperature coefficients (/T) for the NPY analogue 161. 
 
The temperature coefficients for peptide 161 show all positive values with a maximum of 4.2 ppb/K 
for the amide proton of trans-pentacin 33 and a minimum of 2.29 ppb/K for the amide proton of                  
-amino acid 30 in position 31 (Table 9). Usually, the temperature coefficients are negative for 
protons involved in hydrogen bonding, as the formation of a H-bond leads to a downfield shift. 
Indeed, for structured proteins the temperature coefficients of H-bonded amide protons are between 
-4.6 and -1 ppb/K.
104
 However, temperature coefficients between -28 and 12 ppb/K have been 
observed for partially folded peptides, which have been attributed to a conformational change 
during the warming.
120 
Obviously, this makes the use of these temperature coefficients as indicators 
of H-bonds for partially folded peptides very difficult, although some studies showed that amide 
protons involved in a strong intramolecular hydrogen bond display temperature coefficients < 3 
ppb/K, while for a weak intramolecular hydrogen bond the values are > 8 ppb/K.
121
 
In contrast, Andersen and coworkers proposed the use of a different parameter that relates the 
chemical shift deviation of the amide protons (CSD-NH) from the random coil value with the 
temperature coefficients: if the correlation (R
2
) between these two values is > 75%, it can be 
assumed that the peptide adopts a single ordered conformation in the cooled state, which unfolds 
upon warming.
120
 R
2
 values > 95% are characteristic for helices and -hairpins. The slope of the 
linear fit reflects the unfolding facility (steeper means easier to unfold).  
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To evaluate the correlation between the CSD-NH values and the temperature coefficients for 
peptide 161, the CSD-NH values for the natural residues were first calculated by using the random 
coil values reported by Wright et al.
122
 The chemical shift deviations are derived from the lowest 
temperature included in the experiment and are reported in Table 10. The linear regression of the 
three experimental CSD-NH values and of the corresponding temperature coefficients is shown in 
Figure 52.  
 
 NH-Thr
28/32
 NH-Asn
30
 NH-Arg
33
 
/T (ppb/K) 2.58 3.02 2.54 
CSD-NH (ppm) -0.4963 -0.4368 -0.4976 
 
Table 10. Temperature coefficients (/T) and chemical shift deviation of the amide protons (CSD-NH) for the 
NPY analogue 161. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 52. Correlation between temperature coefficients (/T)  and the NH shift deviation from the random coil 
expectation value (CSD-NH). 
 
The correlation was found to be > 99%, which would indicate that the NPY analogue 161 adopts an 
ordered conformation at 283 K, which however easily unfolds to a random coil state upon heating 
up to 313 K. Deuterium/proton exchange experiment have been performed in pure deuterium oxide, 
and as a result, all amide protons, were already exchanged after 12 min at 283 K (Figure 53).  
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However, a broad peak is present at 8.21 ppm, which could be the amide proton of arginine in 
position 33, although slightly shifted. Furthermore, other two broad peaks are present at 7.43 ppm 
and 6.69 ppm, which would be close to the signals of side-chain amide of asparagine at position 30. 
It was noted that the phenyl ring signals of tyrosine in position 36 are downfield shifted. This might 
suggest a conformational change of the peptide upon lyophilization: in fact, the NMR probe in 
H2O/D2O (9:1) used for the 2D experiments needed to be lyophilized before dissolving it in D2O. 
To prove this hypothesis, the NMR probe in D2O was lyophilized again and then dissolved in 
D2O/H2O (8:2). A new 1D NMR was recorded, which showed a very different signal dispersion 
when compared to the first NMR sample. As shown in Figure 53, not only most signals are shifted, 
but also broad signals are present, which might be an indication of peptide aggregation. The latter 
hypothesis would explain, why some amide protons did not fully exchanged in D2O: indeed, it is 
expected that aggregation protects polar groups from contacts with the solvent.  
 
 
 
                            
                               Arg
33
                                                    Asn
30
                                     Asn
30 
 
a) 
 
 
 
 
 
b) 
 
 
 
 
c) 
 
 
Figure 53. Deuterium/proton exchange studies. a) NMR sample in H2O/D2O 9:1 prepared with the peptide obtained 
after HPLC purification and lyophilization; b) NMR sample in 100% D2O, obtained after lyophilization from the first 
NMR sample; c) NMR sample in H2O/D2O 8:2, obtained after lyophilization from the NMR sample in 100% D2O. 
(Vertical lines show the shifted signals). 
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Further information on the conformation of the peptide is given from the spin-spin coupling 
constants 
3
JNH Table 11 shows all spin-spin coupling constants for peptide 161. 
Protons 3JHN(Hz) 
 
HN-Thr28/32 
 
6.6 
 
HN-Asn30 
 
6.9 
 
HN-3031 
 
8.5 
 
HN-Arg33 
 
6.8 
 
HN-3334 
 
7.0 
 
Table 11. Vicinal coupling constants for HN, H of peptide 161 in H2O/D2O (90:10). 
 
All coupling constants show values higher than 6 Hz, excluding the presence of a typical -helix. 
Furthermore, the coupling constant for HN in cis--amino acid 30 shows a value of 8.5 Hz, which 
is typical for antiparallel -sheet. This might indicate that the -amino acid adopts a straight,                   
-strand-like conformation, alternatively it might be involved in a turn motif. 2D NMR experiments 
allowed to assign all resonances and also to detect all contacts. Moreover, the intensities of all NOE 
peaks were converted into distances. Sequential and medium range proton-proton distances in 
peptide 161 are summarized in tables 12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 77 
 
Contacts 
Distances 
(Å) 
dN 
(i,i+1) 
dN 
(i,i+1) 
dN 
(i,i+1) 
dNN 
(i,i+1) 
d 
(i,i+1) 
d 
(i,i+2) 
d 
(i,i+1) 
H Ile29-HN Asn30 3.2 Medium       
HN 33
34
-H Arg35 2.8 Medium       
H 3031-HN Thr32 3.4 Weak       
HArg33-HN 3334 3.1 Medium       
H Asn30-HN 3031 2.9 Medium       
H Thr32-HN Arg33 2.9 Medium       
H Thr28-HN Ile29 3.2 Medium       
H Ile29-HN Asn30 4.4  Weak      
H Asn30-HN 3031 4.3  Weak      
H Ile29-HN Asn30 4.4   Weak     
H Thr32-HN Arg33 4.5   Weak     
H Thr28-HN Ile29 4.6   Weak     
HN Asn
30
-HN 30
31
 4.7    Weak    
HN Arg
33
-HN 33
34
  4.3    Weak    
HN Ile
29
-HN Asn
30
 4.8    Weak    
HN Thr
32
-HN Arg
33
 4.7    Weak    
H Ile29-H Asn30 4.3     Weak   
H Thr32-H 3334 4.5      Weak  
H Arg35-H Tyr36  4.7       Weak 
 
 
 
 
Table 12. All sequential and medium range proton-proton NOEs in peptide 161 (the different line thickness reflects 
the weak and medium NOE intensity) 
 
ROESY analysis of peptide 161 showed many contacts (i,i+1) of medium and weak intensity, and 
only one contact d (i,i+2) of weak intensity between the side chain of Thr
32
 and the H of 3334.  
Distances Ac-Arg
26
-His
27
-Thr
28
-Ile
29
-Asn
30
-30
31
-Thr
32
-Arg
33
-33
34
-Arg
35
-Tyr
36
-NH2 
dN (i, i+1) 
 
dN (i, i+1) 
 
dN (i, i+1) 
 
dNN (i, i+1) 
 
d (i, i+1) 
 
d (i, i+2) 
d(i, i+1) 
 
 78 
 
No contacts (i,i+3), and (i,i+4) were observed, suggesting an extended conformation, at least for 
the N-terminal region of the peptide. Instead, the detection of the indicated NH-NH backbone-to-
side-chain and side-chain-to-side-chain contacts within the segment 29-34, suggests the presence of 
a folded structure at the C-terminus of the peptide. These results would fit with the interpretation of 
the CD data, based on the presence of a structural motif and a flexible backbone related to the CD 
bands at 205 nm and 197 nm, respectively (Figure 49).                                                                 
CD studies of peptide 162 suggested that this peptide could adopt a conformation similar to that              
of the -- peptide reported by Gellman et al., displaying a similar CD signature in water/TFE                
(Figure 50 and Figure 51). As for peptide 161, the best dispersion of signals in 1D NMR was 
obtained at 283 K. Temperature coefficients and chemical shift deviations have been determined 
and are shown in table 13. 
Temperature 
 
NH-
Asn
30
 
    NH- 
    30
31
 
NH-
Thr
32
 
NH- 
Tyr
36
 
 
283.0   K 
 
8.2948 7.5917 8.1907 8.0933 
 
288.0   K 
 
8.3189 7.6144 8.2079 8.1179 
 
293.0   K 
 
8.3388 7.6342 8.2208 8.1359 
 
303.0   K 
 
n.d 7.6723 n.d. n.d 
 
313.0   K 
 
n.d. 7.7085 n.d n.d. 
/T (ppb/K) 4.00 6.88 3.01 4.26 
 
CSD-NH (ppm)
 
-0.4652 
 
- 
 
-0.3293 
 
-0.4967 
 
Table 13. Temperature coefficients (/T) and chemical shift deviation (CSD-NH) for the NPY analogue 162. 
 
The NMR spectrum of peptide 162 displayed signals overlap, making the peak assignment difficult. 
Temperature coefficients have been determined for the amide protons of asparagine in position 30, 
threonine in position 32, tyrosine in position 36 and cis--amino acid 30 in position 31. They show 
positive values between 3.00 and 6.88 ppb/K, suggesting an equilibrium between hydrogen bonded 
(folded) and non-hydrogen bonded state (unfolded).
123
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The values are higher than in peptide 161. In particular, the value for the amide proton of cis--
amino acid 30 in position 31 is almost 7 ppb/K, while it was 2.29 ppb/K in peptide 161.  
The correlation between CSD-NH values and the corresponding temperature coefficients was found 
to be > 99%. Thus likely to peptide 161, peptide 162 could adopt an ordered conformation in the 
cooled state which unfolds upon warming (Figure 54). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 54. Correlation between temperature coefficients (/T)  and the NH shift deviation from the random coil 
expectation value (CSD-NH). 
 
 
Deuterium/proton exchange experiment performed in pure deuterium oxide showed results very 
similar to those of peptide 161, with the presence of the broad peaks around 8.21, 7.69 and 6.75 
ppm (Figure 55).  
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Figure 55. Deuterium proton exchange studies. a) NMR sample in H2O/D2O 9:1 prepared with the peptide obtained 
after HPLC purification and lyophilization; b) NMR sample in 100% D2O, obtained after lyophilization from the first 
NMR sample; c) NMR sample in H2O/D2O 8:2, obtained after lyophilization from the NMR sample in 100% D2O. 
(Vertical lines show the shifted signals). 
 
Moreover, the spectrum obtained after repeated lyophilization is much less dispersed, suggesting 
also in this case aggregation of the peptide after freeze-drying. Further, coupling constants were 
calculated and showed values higher than 6 Hz, thus excluding a typical -helix conformation 
(Table 14). 
 
Protons 3JHN(Hz) 
HN-Asn30 7.0 
 
HN-3031 
 
8.4 
 
HN-Arg33 
 
6.9 
 
HN-Tyr36 
 
8.1 
 
Table 14. Vicinal coupling constants for HN, H of peptide 162 in H2O/D2O (90:10). 
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It is interesting to note that the values of the coupling constants are very close to those of the same 
amino acids in peptide 161, which could suggest a similar conformation in this region. For peptide 
162 also the coupling constant of the C-terminal tyrosine could be determined, which is 8.1 Hz, thus 
indicating a -strand- or turn-like conformation, as for the -amino acid 30 at position 31. 
Sequential and medium range proton-proton distances in peptide 162 are summarized in tables 15. 
 
Contacts 
Distances 
(Å) 
dN 
(i,i+1) 
dN 
(i,i+1) 
dN 
(i,i+1) 
dNN 
(i,i+1) 
dNN 
(i,i+5) 
d 
(i,i+1) 
H Ile29-HN Asn30 3.0 Medium      
HN 33
34
-H Arg35 3.0 Medium      
H 3328-HN Ile29 3.3 Medium      
HHis27-HN 3328 4.4 Weak      
H Asn30-HN 3031 3.1 Medium      
H 3031-HN Thr32 3.4 Weak      
H Arg35-HN Tyr36 3.1 Medium      
H Arg33-HN 3334 3.2 Medium      
HIle29-HN Asn30 4.4  Weak     
HAsn30-HN 3031 4.4  Weak     
H Ile29-HN Ans30 4.2   Weak    
H Thr32-HN Arg33 4.7   Weak    
HN Asn
30
-HN 30
31
 4.5    Weak   
HN Ile
29
-HN Asn
30
 4.0    Weak   
HN 30
31
-HN Thr
32
 3.8    Weak   
HN Arg
33
-HN 33
34
 3.9    Weak   
HN Asn
30
-HN Arg
35
 4.7     Weak  
H Ile29-H Asn30 4.3      Weak 
 
 
Table 15. All sequential and medium range proton-proton NOEs in peptide 162 (the different line thickness reflects 
the weak and medium NOE intensity). 
 
Distances Ac-Arg
26
-His
27
-33
28
-Ile
29
-Asn
30
-30
31
-Thr
32
-Arg
33
-33
34
-Arg
35
-Tyr
36
-NH2 
dN (i, i+1) 
 
dN (i, i+1) 
 
dN (i, i+1) 
 
dNN (i, i+1) 
 
dNN (i, i+5) 
 
d (i, i+1) 
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ROESY analysis showed contacts (i,i+1) of medium and weak intensity, but also one contact 
(i,i+5) of weak intensity between Asn
30 
and Arg
35
. By comparing the NOE contacts of the peptides 
161 and 162, it was noted that seven and five side-chain-to-backbone NOEs were found for peptides 
161 and 162, respectively. The NOEs 29-N30, 30-N31, 32-N33 were common to both peptides, 
whereas the NOEs of peptide 161 involving 29-30 and the residue pairs 32-34 and 35-36 were not 
found in peptide 162.  In contrast, in the latter peptide the NOEs 29-N30 and 29-30 were detected. 
Apparently, a slightly different spatial distribution of the side chains around positions 29 and 30 is 
present in the two peptides, which is attributed to the presence of the additional unnatural amino 
acid at position 28 in peptide 162. However, it is interesting to note that there are also some 
differences in the C-terminal region, although the sequence is identical: indeed, the NOEs between 
the residue pairs 32-34 and 35-36 are present only in peptide 161, while the long-range (i,i+5)            
NH-NH connectivity is present only in  peptide 162.  
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2. 4. 2. Results on NPY analogues 163 and 164 
 
2. 4. 2. 1.  CD studies 
In NPY analogues 163 and 164, only one unnatural amino acid has been introduced in position 34, 
which is the trans-pentacin 33 in peptide 163, and cis--amino acid 30 in peptide 164. These 
compounds are more similar to NPY (25-36), and thus CD spectra of the NPY segment in different 
solvents can be used as reference. The CD spectra of compound 163 are shown in figure 56. 
 
 
 
 
 
 
 
 
 
 
         a)                                                                          b) 
Figure 56. CD spectra of compound 163. a) CD spectrum in water and in 20% of methanol and TFE in water; b) CD 
spectrum in phosphate buffer and in 20% of methanol and TFE in buffer. 
 
The CD spectrum of peptide 163 in water displays two negative bands at 197 and 204 nm (panel a 
of Figure 56). In presence of organic solvents, the curves change significantly. In particular, in 
presence of methanol, the relative intensity of the two bands (which are slightly red-shifted) is 
modified from about 1:1 to >1 at the expenses of the band at 197 nm. In presence of TFE, the curve 
assumes a shape similar to that of a 310 helical conformation, displaying a minimum at 206 nm with 
a negative shoulder at 220 nm, and a maximum at 195 nm. The curve of peptide 163 in buffer is  
similar to the curve shown in water, but it displays reduced intensity and blue-shift (panel b of 
Figure 56). The CD spectrum in buffer /methanol displays the same shape but minor intensity 
compared with that in water/methanol. This holds also for the buffer/TFE mixture.  
Therefore, these results suggest that the conformation of peptide 163 is not affected by the pH; in 
water or buffer the peptide chain is highly flexible, however, upon addition of methanol or TFE, a 
helical structure is stabilized.  
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CD spectra of compound 163 have been compared with CD signature of NPY segment (25-36) as 
shown in Figure 56. 
 
 
 
 
 
 
 
 
 
                                        a)                                                                              b) 
Figure 57. CD spectra of peptide 163 in comparison with NPY segment (25-36). 
It is interesting to see that the presence of the unnatural amino acid induces a different conformation 
to the NPY sequence: indeed, in the presence of TFE the native sequence is -helical prone, 
whereas the peptide 163 is 310-helix-like. The CD spectra of compound 164 are shown in figure 58. 
 
 
                            
 
 
 
 
 
             a)                                                                             b) 
Figure 58. CD spectra of compound 164. a) CD spectrum in water and in 20% of methanol and TFE in water; b) CD 
spectrum in phosphate buffer and in 20% of methanol and TFE in buffer. 
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The conformational properties of peptide 164 are very different from those of the peptide 163. 
Indeed, the minimum at 196 nm and a weak shoulder at 215 nm observed in water and 
water/methanol suggest a highly flexible structure. Also the weak CD intensity of the spectra in 
buffer and buffer/methanol are indicative of lack of ordered structure. In contrast, both in 
water/TFE and buffer/TFE mixtures the peptide is more ordered, as suggested by the negative CD 
bands at 218 nm and 205 nm. In water/TFE the minima are slightly blue-shifted and an additional 
minimum at 197 nm is detectable, probably reflecting the presence of a disordered fraction. The CD 
signature of peptide 164 has also been compared with the CD signature of the NPY segment (25-36) 
(Figure 59). 
 
 
 
 
 
 
Figure 59. CD spectra of peptide 164 in comparison with NPY (25-36). 
It is interesting to note that the CD spectra of the native sequence and of the peptide 164 in 
buffer/TFE are almost superimposable in the range 205-225 nm, suggesting a similar helical 
conformation. Peptide 163 and 164 were obtained in very less amount < 0.8 mg, thus not enough 
for NMR analysis. 
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2. 4. 3. Results on NPY analogues 165 and 166 
 
2. 4. 3. 1. CD studies 
NPY analogues 165 and 166 contain two substitutions, trans-pentacin 33 in position 34, and               
a trans--amino acids in position 30. Peptide 165 contains the -amino acid 31, while its enantiomer                  
-amino acid 32 has been  introduced in peptide 166. Therefore, these analogues can be considered 
as --foldamers. Accordingly, their CD spectra in water and water/organic solvent are 
reminiscent of those of the --foldamer 161, as shown in figure 60.  
 
 
 
 
 
 
 
 
                                            a)                                                                      b) 
 
Figure 60. CD spectra of compound 165. a) CD spectrum in water and in 20% of methanol and TFE in water;                
b) CD spectrum in phosphate buffer and in 20% of methanol and TFE in buffer. 
 
Interestingly, in the case of the peptide 165 there are no significant changes in the CD shape, going 
from acidic to slightly basic conditions in presence of methanol or TFE. This suggests that the 
combination of the two building blocks 33 and 31 induce a conformation that is pH-independent. 
Further, the CD spectra of compound 166 are given in figure 61. 
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                                       a)                                                                          b)  
Figure 61. CD spectra of compound 166. a) CD spectrum in water and in 20% of methanol and TFE in water; b) CD 
spectrum in phosphate buffer and in 20% of methanol and TFE in buffer. 
 
In water and water/organic solvent they are comparable to those of peptide 165, suggesting that the 
presence of the enantiomer of the -amino acid does not induce a different conformation. However, 
it should be noted that in buffer and buffer/methanol the band at 197 nm is less intense than for 
peptide 165, and that the CD curve in buffer/TFE has a more positive contribution below 200 nm 
than that of the peptide 165, suggesting a more ordered structure for the peptide 165 in slightly 
basic conditions. It is also interesting to compare the curves of peptide 165 and 166, with the curves 
of the peptide 161, which has the cis--amino acid 30 in position 30, and therefore we can see the 
effect of the configuration. Figure 62 and 63 show the curves of peptide 165, 166 and 161 in 
different solvents. 
 
 
 
 
 
 
 
 
 
                                          a)                                                                               b) 
Figure 62. CD spectra of peptide 165 and 166 in comparison with peptide 161 in water and water/20% methanol. 
190 200 210 220 230 240 250
-8000
-7000
-6000
-5000
-4000
-3000
-2000
-1000
0
1000
 Water
 Water-Methanol (80:20)
 Water-TFE (80:20)
 [

] R
 (
d
e
g
 c
m
2
 d
m
o
l-1
)
wavelenght (nm)
190 200 210 220 230 240 250
-7000
-6000
-5000
-4000
-3000
-2000
-1000
0
1000
 Buffer 50 mM pH 7.4
 Buffer 50 mM pH 7.4 - Methanol (80:20) 
 Buffer 50 mM pH 7.4 - TFE (80:20) 
 [

] R
 (
d
e
g
 c
m
2
 d
m
o
l-1
)
wavelenght (nm)
190 200 210 220 230 240 250
-8000
-7000
-6000
-5000
-4000
-3000
-2000
-1000
0
1000
 [
Q
] R
 (
d
e
g
 c
m
2
 d
m
o
l-
1
)
wavelenght (nm)
 Peptide 161 in water
 Peptide 165 in water
 Peptide 166 in water
190 200 210 220 230 240 250
-7000
-6500
-6000
-5500
-5000
-4500
-4000
-3500
-3000
-2500
-2000
-1500
-1000
-500
0
500
1000
 [

] R
 (
d
e
g
 c
m
2
 d
m
o
l-1
)
wavelenght (nm)
 Peptide 161 in Water-Methanol (80:20)
 Peptide 165 in Water-Methanol (80:20)
 Peptide 166 in Water-Methanol (80:20)
 88 
 
It appears clear that all three peptides are similar in water or water/methanol (Figure 62). In 
contrast, the peptides 165 and 166 seem to possess the highest helix propensity when dissolved in 
water/TFE or buffer/TFE (Figure 63, panels a and d). However, in the absence of any organic 
solvent the peptide 166 is probably more ordered than the peptide 165 at physiologic pH, as 
suggested by the relative intensity of the minima at 197 nm and 205 nm, which is about 1:1 for 166 
and >1 at the expenses of the minimum at 205 nm for 165 (Figure 63, panel b).   
 
 
 
 
 
 
 
  
 
        a)                                                                                b) 
 
 
 
 
 
 
 
 
                                         c)                                                                               d) 
Figure 63. CD spectra of peptide 165 and 166 in comparison with peptide 161 in water/TFE, in phosphate buffer, and 
in 20% of methanol and TFE in buffer. 
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2. 4. 3. 2.  NMR studies 
Peptide 165 and 166 have also been investigated by NMR spectroscopy. In comparison with the 
peptides 161 and 162, the NMR spectrum of peptide 165 showed better signals dispersion. The 
analysis at different temperatures showed the best dispersion at 313 K, which is a quite high 
temperature for a small peptide. This might indicate that the peptide aggregates at low temperatures 
or that an ensemble of differently stable conformations exists in equilibrium.  
Due to the high temperature used to study the conformation, the peptide was not subjected to further 
heating for the determination of the temperature coefficients. Nevertheless, the 1D NMR spectra 
recorded from 283 K to 313 K were used to look at the correlation between the  and the CSD-
NH values (Table 16), which in this case is expected to be small, due to the fact that the peptide in 
the cooled state (283 K) is less ordered than after warming (313 K). Indeed, the correlation was 
found to be only 17%, as shown in Figure 64, which confirms the presence of unordered structure 
and/or different conformers in the cooled state. 
 
Temperature 
 
NH-
His
27
 
NH- 
Tyr
28
 
NH-
Ile
29
 
NH-
Asn
30
 
NH-
31
31
 
NH- 
  Arg
33
 
NH-
33
34
 
NH-
Arg
35
 
NH-
Tyr
36
 
 
283.0   K 
 
  8.3143 n.d. 7.9724 n.d. 7.7306 8.1326 7.7839 8.0997 8.0997 
 
288.0   K 
 
8.3345 8.2162 7.9924 8.2162 7.7621 8.1551 7.8011 n.d. n.d. 
 
293.0   K 
 
8.3529 n.d. 8.0098 n.d. 7.7913 8.1754 7.8163 n.d. n.d. 
298.0  K 8.3722 n.d. 8.0281 n.d. n.d. 8.1963 n.d. n.d. n.d. 
 
303.0   K 
 
8.3894 8.2506 8.0442 8.2756 7.8501 8.2156 7.8501 8.1572 8.1828 
 
313.0   K 
 
8.4204 8.2726 8.0711 8.3085 7.8752 8.2487 7.9007 8.1803 8.2151 
/T (ppb/K) 3.53 2.25 3.29 3.69 4.82 3.87 3.89 2.68 3.84 
 
CSD-NH (ppm)
 
-0.4757 
 
- 
 
-0.5476 
 
- 
 
- 
 
-0.5574 
 
- 
 
-0.5903 
 
-0.4903 
 
Table 16. Temperature coefficients (/T) and chemical shift deviations (based on the  values at 283 K) for the 
NPY analogue 165. 
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Figure 64. Correlation between temperature coefficients (/T)  and the NH shift deviation from the random coil 
expectation value (CSD-NH). 
 
The deuterium/proton exchange experiment showed the presence of a broad signal at 8.14 ppm, 
similarly to the peptides 161 and 162. But, contrary to the latter peptides, the 1D NMR spectrum of 
the re-lyophilized peptide 165 was comparable to that recorded before freeze-drying, the broad 
signal at 8.14 ppm in D2O could belong to the amide proton of Thr
32
 (Figure 65). 
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                                              Thr32 
                                                    Ile29                                                                             Tyr36 
 
a)                                            
 
 
 
 
b) 
 
 
 
 
                                                
c) 
 
 
Figure 65. Deuterium proton exchange studies. a) NMR sample in H2O/D2O 9:1 prepared with the peptide obtained 
after HPLC purification and lyophilization; b) NMR sample in 100% D2O, obtained after lyophilization from the first 
NMR sample; c) NMR sample in H2O/D2O 8:2, obtained after lyophilization from the NMR sample in 100% D2O. 
(Vertical lines show the shifted signals). 
 
 
The coupling constants showed values higher than 6 Hz, thus excluding a typical -helix structure 
(Table 17). The values of 8.0 Hz for Tyr
36
 and 8.2 Hz for 33
34
 suggest possible -strand- or turn-
like conformations for these two residues. 
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Protons 3JHN(Hz) 
 
HN-His26 
 
7.8 
 
HN-Tyr28 
 
7.4 
 
HN-Ile29 
 
7.7 
 
HN-Asn30 
 
7.2 
 
HN-3131 
 
7.2 
 
HN-Arg33 
 
7.3 
 
HN-3334 
 
8.2 
 
HN-Arg35 
 
6.1 
 
HN-Tyr36 
 
8.0 
 
Table 17. Vicinal coupling constants for HN, H of peptide 165 in H2O/D2O (90:10). 
 
ROESY studies on peptide 165 showed contacts (i,i+1) of medium and weak intensity. Additionally 
two contacts d (i, i+2) involving the pairs 29-31 and 32-34 were observed, as for peptide 161. 
(Table 18). 
 
Contacts 
Distances 
(Å) 
dN 
(i,i+1) 
dN 
(i,i+1) 
dN 
(i,i+1) 
dNN 
(i,i+1) 
day 
(i,i+2) 
dN 
(i,i+1) 
dN 
(i,i+1) 
H 3131-HN Thr32 3.6 Weak       
H Asn30-HN 3131 3.5 Weak       
HIle29-HN Asn30 2.9 Medium       
H Tyr28-HN Ile29 3.8 Weak       
H Thr32-HN Arg33 4.3 Weak       
H Arg33-HN 3334 4.2 Weak       
H 3334-HN Arg35 2.9 Medium       
H Arg26-HN His27 3.2 Medium       
HAsn30-HN 3131 4.3  Weak      
HArg33-HN 3334 4.7  Weak      
HIle29-HN Asn30 4.2  Weak      
HTyr28-HN Ile29 4.1  Weak      
HHis27-HN Tyr28 4.4  Weak      
H Ile29-HN Asn30 4.1   Weak     
HN Asn
30
-HN 31
31
 4.4    Weak    
HN Arg
33
-HN 33
34
 4.2    Weak    
H Thr32-H 3334 4.4     Weak   
H Ile29-H 3131 4.4     Weak   
H 3131-HN Thr32 4.2      Weak  
H Tyr28-HN Ile29 4.2       Weak 
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Table 18. All sequential and medium range proton-proton NOEs in peptide 165 (the different line thickness reflects 
the weak and medium NOE intensity). 
 
 
ROESY analysis showed that most contacts dN (i,i+1) are of weak intensity within the segment 
28-34, which suggests that the backbone structure is more flexible than in peptides 161 and 162, 
where the contacts dN (i,i+1) are mainly of medium intensity.  
Moreover, fewer contacts between amide protons dNN (i, i+1), but more contacts dN (i,i+1) of weak 
intensity within the segment 27-31 were detected, suggesting a different conformation in this 
region. This is supported by the presence of one contacts (i,i+2) between Ile
29
 and 31
31
, which was 
absent in peptide 161. Also NOEs such as dN and dN (i,i+1) were found for peptide 165, which 
were not detected in the ROESY spectra of peptides 161 and 162.                                                           
 
1D NMR analysis of peptide 166 at different temperatures showed good dispersion of signals at 313 
K, thus this temperature was used to record 2D experiments. As already discussed for peptide 165, 
also peptide 166 was not subjected to warming for the calculation of the temperature coefficients. 
However, a correlation between the CSD-NHs for the cooled state at 283 K and the corresponding 
 values obtained upon heating up to 313 K (Table 19) was determined. Likely to peptide 165, 
also in this case the correlation was very poor (about 37%), as shown in Figure 66.   
 
 
Distances Ac-Arg
26
-His
27
-Tyr
28
-Ile
29
-Asn
30
-31
31
-Thr
32
-Arg
33
-33
34
-Arg
35
-Tyr
36
-NH2 
dN (i, i+1) 
 
dN (i, i+1) 
 
dN (i, i+1) 
 
dNN (i, i+1) 
 
d (i, i+2) 
 
dN (i, i+1) 
 
dN (i, i+1) 
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Temperature 
 
NH- 
  Ile
29
 
NH-
Asn
30
 
NH-
32
31
 
NH- 
Thr
32
 
NH-
Arg
33
 
NH-
33
34
 
 
283.0   K 
 
7.9023 8.2125 7.7378 n.d. 8.1812 7.7836 
 
288.0   K 
 
7.9194 8.2287 7.7468 n.d. 8.1939 7.8046 
 
293.0   K 
 
7.9367 8.2445 7.7582 n.d. 8.2073 7.8267 
298.0  K 7.9567 8.2619 7.7699 8.1096 8.2216 7.8506 
 
303.0   K 
 
7.9717 8.2744 7.7801 8.1214 8.2333 7.8711 
 
313.0   K 
 
8.0022 8.3034 7.8033 8.1492 8.2586 7.9121 
/T ppb 3.33 3.03 2.18 2.64 4.07 4.28 
CSD-NH (ppm) -0.6177 -0.5475 - - -0.5088 - 
 
Table 19. Temperature coefficients (/T) and chemical shift deviation for the NPY analogue 166. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 66. Correlation between temperature coefficients (/T)  and the NH shift deviation from the random coil 
expectation value (CSD-NH). 
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Adj. R-Square -0,36665
Value Standard Error
B Intercept 6,52146 4,48721
B Slope 5,45662 8,01549
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In deuterium/proton exchange experiment performed in pure deuterium oxide the peptide 166 
showed a very broad peak over the region 8.1-8.4 ppm and centered at 8.2 (Figure 67). The 1D 
NMR spectrum recorded after lyophilization of the sample in pure D2O was not identical to that of 
the sample in water: in particular, the signals dispersion was still very good and with sharp signals,  
but some signals were shifted and/or new ones appeared. Therefore, the peptide 166 clearly changed 
its conformation upon lyophilization, as already observed for peptides 161 and 162. However 
contrarily to the latter, peptide 166 did not show any tendency to aggregate, similarly to peptide 
165. 
 
 
 
 
                                                            
                                                                 Ile
29                                                                     
            Tyr
36
 
a) 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
c) 
 
Figure 67. Deuterium proton exchange studies. a) NMR sample in H2O/D2O 9:1 prepared with the peptide obtained 
after HPLC purification and lyophilization; b) NMR sample in 100% D2O, obtained after lyophilization from the first 
NMR sample; c) NMR sample in H2O/D2O 8:2, obtained after lyophilization from the NMR sample in 100% D2O. 
(Vertical lines show the shifted signals; the arrows indicate new signals). 
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The coupling constants of this peptide are higher than 6 Hz, and, as for the peptides 161 and 162, 
furthermore the coupling constant for trans--amino acid 32 at the position 31 was again >8 Hz, 
suggesting a -strand- or turn-like conformation (Table 20).  
 
Protons 3JHN(Hz) 
HN-Ile28 7.6 
 
HN-Asn30 
 
7.5 
 
HN-3331 
 
8.4 
 
HN-Thr32 
 
6.8 
 
HN-Arg33 
 
6.9 
 
HN-3334 
 
7.2 
 
Table 20. Vicinal coupling constants for HN, H of peptide 166 in H2O/D2O (90:10). 
 
ROESY analysis showed contacts (i,i+1) of medium and weak intensity, and one contact (i,i+2) of 
weak intensity, involving positions 29 and 31 (Table 21).  
      
Contacts 
Distances 
(Å) 
dN 
(i,i+1) 
dN 
(i,i+1) 
dN 
(i,i+1) 
dN 
(i,i+1) 
dN 
(i,i+2) 
d 
(i,i+1) 
H Ile29-HN Asn30 3.4 Medium      
H 3334-HN Arg35 3.0 Medium      
H 3231-HN Thr32 3.8 Medium      
HArg33-HN 3334 4.0 Weak      
H Asn30-HN 3231 3.9 Medium      
HTyr28-HN Ile29 4.2 Weak      
H Ile29-HN Asn30 4.5 
 
Weak     
H Tyr28-HN Ile29 4.3 
 
Weak     
H Asn30-HN 3231 4.3 
 
Weak     
HArg33-HN 3334 4.6  Weak     
HN Asn
30
-HN3231 4.5  
 
Weak    
HN Arg
33
-HN 33
34
 4.2   Weak    
H Ile29-HN Asn30 4.7    Weak   
H3230-HN Thr31 4.8    Weak   
H Ile29-HN 3231 4.8     Weak  
H 3231-HN Thr32 4.6      Weak 
H Tyr28-HN Ile29 4.8      Weak 
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Table 21. All sequential and medium range proton-proton NOEs in peptide 166 (the different line thickness reflects 
the weak and medium NOE intensity). 
 
 
The presence of contacts dN (i,i+1) of medium intensity suggests a more ordered structure than 
peptide 165. However, the same contacts dN (i,i+1) were found within the segment 28-31, 
suggesting structural similarities between the two peptides. Therefore, the presence of the different 
enantiomer of the trans--amino acid at position 31 does not induce a different conformation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Distances Ac-Arg
26
-His
27
-Tyr
28
-Ile
29
-Asn
30
-32
31
-Thr
32
-Arg
33
-33
34
-Arg
35
-Tyr
36
-NH2 
dN (i, i+1) 
 
dN (i, i+1) 
 
dNN (i, i+1) 
 
dN (i, i+1) 
 
dN (i, i+2) 
 
dN (i, i+1) 
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2. 4. 4. Results on NPY analogues 167 and 168 
 
2. 4. 4. 1. CD studies 
In the NPY analogues 167 and 168, only one unnatural amino acid has been introduced in position 
34, the (1R,2S)-configured trans--amino acid 32 in peptide 167, while its enantiomer trans--
amino acid 31 in peptide 168. CD spectra of crude peptides were measured in water and in 20% 
methanol or TFE in water. As for the monosubstituted NPY analogues 163 and 164, the CD spectra 
of the NPY segment (25-36) in different solvents can be used as reference for these peptides. The 
CD spectra of compounds 167 and 168 are shown in figure 68. 
 
 
 
 
 
 
 
 
 
 
                                             a)                                                                              b) 
Figure 68. CD spectra of compounds 167 (a) and 168 (b) in water and in 20% methanol or TFE in water. (These 
spectra were recorded at the Ruhr-University of Bochum). 
 
Both peptides show a low-intensity spectrum in water, which is characterized by a negative band at 
210 nm for peptide 168, and a blue-shifted one for peptide 167 (205 nm). One negative contribution 
around 210-215 nm has been previously found for the monosubstituted NPY analogue 164 that 
contains the (1S,2S)-configured cis--amino acid 30 at position 34. However, the latter displayed an 
additional predominant minimum at 195 nm, which would suggest that peptide 164 was more 
disordered than peptide 168 in water. In contrast, a negative CD contribution at 205 nm was found, 
other than for peptide 167, also for peptides 161, 162, 163, 165 and 166: however, the latter 
analogues showed an additional minimum around 195 nm, which would suggest that they were 
more disordered than peptide 167 in water. In fact, the water CD spectrum of peptide 167 reminds 
that of a 310-helix, whereas only the TFE CD spectra of the other peptides do it, confirming the 
superior folding propensity of peptide 167 versus the others.  
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In 20% MeOH, the curves of both peptides assume a shape similar to that of -turn type II, 
displaying a maximum at 195 nm and a minimum close to at 220 nm (the additional shoulder at 230 
nm for peptide 168 might be due to the aromatic residues).
124
 
 In presence of TFE, the CD signature of peptide 167 is similar to that in methanol, but the 
minimum is red-shifted to 225 nm and becomes more intense, suggesting a superior structure-
stabilizing effect of TFE over MeOH. In contrast, the curve of the peptide 168 in TFE shows a 
reduced intensity of the minimum at 220 nm. Moreover, an exciton splitting at 235 nm (neg.) and 
250 nm (pos.) is detected, which should be attributed to the two tyrosine side chains. The CD 
spectra of peptides 167 and 168 have been compared with the CD signature of the NPY segment 
(25-36), as shown in figure 69. 
 
 
 
 
 
 
 
 
 
 
 
Figure 69. CD spectra of peptides 167 and 168 in comparison with NPY (25-36). 
The presence of the trans-isomer in position 34 induces a different conformation to the NPY 
sequence: indeed, in TFE the native sequence is -helical, whereas the peptides 167 and 168 are 
likely to build a turn. However, peptide 167 and the NPY segment have similar spectra in water, 
both reminiscent of a 310-helix, although the band at 205 nm of peptide 167 is more negative, 
probably because of higher content of disordered structure. As mentioned above, peptides 164 and 
168 present both a CD contribution around 210-215 nm, but peptide 164 is apparently less ordered 
than peptide 168, as indicated by the band at 195 nm (Figure 70, panel a). Instead, peptide 167 
displays a minimum at 205 nm.  
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This suggests that the -amino acid at position 34 can induce different conformations, depending on 
the configuration of the cyclopentane ring. This is true not only in water, but also in the presence of 
MeOH or TFE (Figure 70, panels b and c). NMR studies are currently ongoing in the Reiser group. 
 
 
 
 
 
 
 
 
 
 
                                        a)                                                                            b) 
 
 
 
 
 
 
 
 
 
c) 
Figure 70. CD spectra of peptides 167 and 168 in comparison to peptide 164. 
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Summary 
In this work conformationally constrained -amino acids in which the backbone is constrained by a 
five-membered ring have been prepared and utilized as building blocks in the design of NPY 
analogues. Stereoisomers 130, 143 and 153 of 2-(2-Fmoc-amino cyclopentyl) acetic acid were 
synthesized in enantiomerically pure form (Figure 71). 
 
 
 
 
 
Figure 71. Isomers of the 2-(2-amino cyclopentyl) acetic acid 
 
-Amino acid 130 has been prepared by an Arndt-Eistert homologation of enantiomerically pure 
trans-Fmoc-pentacin 132 as described by Gellman et al. (Scheme 30).
43 
 
 
 
Scheme 30. Synthesis of 2-((1R,2S)-2-Fmoc-aminocyclopentyl) acetic acid 132.                                                                           
Reagents and conditions: a) 1. IBCF/N-methylmorpholine, THF, -15 °C; 2. CH2N2, 0 °C, 4 h, 72%; b) cat. PhCO2Ag, 
ultrasounds, dioxane/H2O, 1 h, 35%. 
 
Trans-(153) and cis-(143) isomers have been synthesized by modifications of the hydrochloride 
salts of trans- and cis-ethyl 2-((R)-1-phenylethylamino)cyclopentyl)acetate (150 and 151), obtained 
by selective reduction of imine mixture 140 (Scheme 31). 
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Schema 32. Synthesis of Fmoc-protected cis-(143) and trans-(153)  2-(2-amino cyclopentyl) acetic acid. Reagents 
and conditions: a) Benzene (abs.), reflux, 6 h, 78%; b) 1. NaBH4, EtOH, 0 °C, 1 h; 2. HCl, recrystallization, 55%;                
c) LiOH, THF/MEOH/H2O, 9 h, 0 °C, quant.; d) H2 (50 bar), 10 % Pd/C, 50 °C, EtOH, 48 h, 85%; e) Fmoc-OSu, 
NaHCO3, Acetone/H2O 1:1, 18 h, 70%; f)  Li/NH3, -78 °C, THF/tBuOH, overnight, 73% ; g) 1 N HCl, 80 °C, 8 h, 52%;              
h) Fmoc-OSu, NaHCO3, Acetone/H2O 1:1, 18 h, 72%. 
 
 
 
 
 
 
 103 
 
NPY analogues containing isomers of the 2-(2-amino cyclopentyl) acetic acid and in combination 
with trans-pentacin 33 have been prepared by solid phase synthesis and investigated by CD- and 
NMR spectroscopy (Figure 72). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 72. Structure of NPY analogues containing trans-pentacin 33 in position 34, in combination with isomers of 
the 2-(2-amino cyclopentyl) acetic acid in position 31 and 28. 
 
 
Conformational analysis of peptides 161, 162, 165 and 166 suggests the presence of a flexible 
conformation in water. However the detection of one/two (i,i+2) contacts or of one (i,i+5) contact, 
like in peptide 162, indicates the presence of turn-like or loop motifs. 
Further, CD studies showed that in buffer and in organic solvents peptide 165 and 166 seem to 
possess the highest helix propensity, suggesting that the trans-isomers of the 2-(2-amino 
cyclopentyl) acetic acid are more able to induce an ordered conformation (Figure 69). 
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Figure 69. CD spectra of peptide 165 and 166 in comparison with peptide 161 in water/TFE and in 20% of TFE in 
buffer. 
 
Different results were obtained with NPY analogues containing only one unnatural amino acid in 
position 34 (Figure 70). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 70. Structure of NPY analogues containing trans-pentacin 33 and isomers of the 2-(2-amino cyclopentyl) 
acetic acid in position 34. 
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CD studies on peptide 163, which contain trans-pentacin 33 in position 34, suggested a 
conformation highly flexible in water or buffer, while a 310 helical conformation is likely in organic 
solvents (Figure 71).  
The introduction of the -amino acids at position 34 induces different conformations, depending on 
the configuration of the cyclopentane ring. The presence of cis-isomer (peptide 164) induces a 
flexible structure in water, while a helical conformation similar to that of NPY native sequence was 
observed in buffer/TFE. (Figure 71) 
 
  
 
 
 
 
 
 
Figure 71. CD spectra of peptide 163 and 164 in comparison with NPY (25-36), in buffer and in 20% of TFE in 
buffer. 
 
Peptides containing the trans-isomers in position 34 showed to adopt a more ordered structure. CD 
studies on NPY 167 and 168 suggest the presence of a stable -turn type II in methanol or TFE. 
However, when the trans--amino acids were present at position 31, together with the                    
(1S,2S)-configured trans-pentacin 33 at position 34, there were no significant changes in the 
conformational preferences, as shown for the peptides 165 and 166. 
Concluding, the 2-(2-amino cyclopentyl) acetic acid is able to induce different conformational 
properties on the structure of NPY, depending on the position of the substitution and the absolute 
configuration. The biological activity of all NPY analogues will be tested against the own receptors, 
in collaboration with University of Leipzig. 
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Experimental part 
 
Instruments and general techniques 
1
H-NMR spectra were recorded on Bruker Avance 300 (300 MHz) and Bruker Avance 600               
(600 MHz). The chemical shifts are reporter in  (ppm) relative to chloroform (CDCl3, 7.26 ppm), 
dimethylsulfoxide (DMSO-d6, 2.49 ppm), methanol-d3 or methanol-d4 (CD3OH, 3.34 ppm), 
deuterium oxide (D2O, 4.79 ppm). The spectra were analysed by first order, the coupling constant 
(J) are reported in Hertz (Hz). Characterisation of signals: s = singlet, bs = broad singlet,                           
d = doublet, t = triplet, q = quartet, m = multiplet, bm = broad multiplet, dd = double doublet,                   
dt = double triplet, ddd = double double doublet. Integration is determined as the relative number of 
atoms. Diastereomeric ratios were determined by comparing the integrals of corresponding protons 
in the 
1
H-NMR spectra. 
 
13
C-NMR spectra were recorded on Bruker Avance 300 (75.5 MHz) and Bruker Avance 600                   
(150.9 MHz). The chemical shifts are reported in  (ppm) relative to chloroform (CDCl3, 77 ppm), 
dimethylsulfoxide (DMSO-d6, 39.52 ppm), methanol-d3 or methanol-d4 (CD3OH, 49 ppm).                   
13
C NMR resonance assignment were aided by the use of the DEPT 135 (DEPT = distortionless 
enhancement by polarisation transfer) or HSQC (Heteronuclear Single Quantum Correlation) 
techniques to determine the number of hydrogens attached to each carbon atom and is declared as: 
+ = primary or tertiary (positive DEPT signal intensity or straight line in HSQC), - = secondary 
(negative DEPT signal or dot line in HSQC) and quat = quaternary (no DEPT signal intensity) 
carbon atoms. In some cases DEPT 90 spectra were recorded to distinguish between primary and 
tertiary carbon atoms and HMBC (Heteronuclear Multiple Bond Correlation) to distinguish between 
quaternary carbon and aromatic CH. 
 
2D-NMR spectra (COSY, NOESY, ROESY, TOCSY, HMBC, HSQC) were recorded on Bruker 
Avance 600 (600 MHz). 
 
IR spectra were recorded with a Bio-Rad Excalibur series FT-IR. 
 
MS spectra were recorded in the mass spectroscopy department of the University of Regensburg. 
 
Optical rotations were measured on a Perkin-Elmer-polarimeter 241 with sodium lamp at 589 nm 
in the specified solvent. Concentration is indicated as [g/100ml]. 
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CD spectra were measured on a JASCO model J-710/720 at the Institute of Analytical Chemistry of 
the University of Regensburg (research group of Prof. Dr. O. Wolfbeis) at 21°C between 260 and 
190 nm in the specified solvent, with 8 scans. The length of the rectangular cuvette was 0.1 mm, the 
resolution was 0.2 nm, the band width 1.0 nm, the sensitivity 10-20 mdeg, the response 0.25 s, the 
speed 20 nm/min. The background was substracted for each spectrum. The absorption value is 
measured as molar ellipticity per residue (deg cm
2
 dmol
-1
). The spectra were smoothed by adjacent 
averaging algorithm or FFT filter with the Origin 8.0 program. 
 
Thin layer chromatography (TLC) was performed on alumina plates coated with silica gel 
(Merck silica gel 60 F 254, layer thickness 0.2 mm) or glass plates coated with flash 
chromatography silica gel (Merck silica gel 60 F 254, layer thickness 0.25 mm). Visualisation was 
accomplished by UV light (wavelength l= 254 nm), permanganate solution, ninhydrin/acetic acid 
solution, vanillin/H2SO4 solution, anisaldehyde solution or Draggendorf-Munier reagent. 
 
Column chromatography was performed on silica gel Geduran SI 60 (70-230 mesh) purchased 
from Merck and flash chromatography on flash-silica gel 60 (230-400 mesh ASTM) purchased 
from Merck. All solvents were distilled before use. Other chemicals were purchased from 
commercial suppliers and used as received. All reactions with oxygen or moisture sensitive 
reactants were performed under nitrogen atmosphere. 
 
HPLC-chromatography analytical and preparative reverse Phase HPLC was performed on Agilent 
equipment 1100/1 (Böblingen, Germany) by using the column: Phenomenex Luna C18(2), 3 μm, 
2.00 x 150 mm and a Nucleodur 100-5 C18, 5 m, 21 x 250 mm, (Macherey–Nagel; Dueren, 
Germany). The flow rate was 0,3 mL/min for the analytical HPLC runs and 16 mL/min for 
preparative applications. The binary solvent system (A/B) was: (A) ACN, (B) 0.0059% TFA in 
water. The absorbance was detected at 220 nm. 
 
Melting point were measured by Automated Melting Point System of the SRS (Stanford Research 
System).  All samples were analyzed in a range between 25 °C and 400 °C.  
 
Elemental analysis: microanalytical department of the University of Regensburg. 
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Solid phase peptide synthesis  
(General procedure for the preparation of peptides) 
The syntheses of peptides was carried out using 50 mg Fmoc-Rink-amide MBHA resin (loading: 
0.45 mmol/g) in a 5-ml syringe with teflon-frit for each peptide. Swelling of the resin in DMF/NMP 
8:2 for 30 min. 
Double coupling with Fmoc-AA-OH/HOBt/HBTU/DIPEA 5:5:4.8:10 eq. in DMF/NMP 8:2 (2x40 
min.) for all natural amino acids (protecting groups: trityl for Asn and His, tBu for Thr and Tyr, Pbf 
for Arg). Double coupling with Fmoc-trans-pentacin 132 /HOBt/HBTU/DIPEA 3:3:2.8:6 eq. 
DMF/NMP 8:2 (2x60 min.) Single coupling with Fmoc-ACPA-OH /HOBt/HBTU/DIPEA 3:3:2.8:6 
eq. DMF/NMP 8:2 (60 min.) Fmoc cleavage with 40% piperidine in DMF/NMP 8:2 for 3 min, 
followed by 20% piperidine in DMF/NMP 8:2 for 10 min. Acetylation of the N-terminus with 
Ac2O/DIPEA 10:10 eq. in DMF/NMP 8:2 (2X20 min.) After each coupling/Fmoc-cleavage step 
washings with DMF (5x). After completion of the peptide-chain assembly washings with DMF 
(5x), DCM (5x), Et2O (5x). Peptide cleavage from the resin and simultaneous side-chain 
deprotection: treatment of the peptide-resin with the mixture TFA/water/TIS/thioanisole 90:3:4:3 
for 3 h, then filtering-off of the resin and precipitation of the peptide from ice-cold Et2O. Recovery 
of the peptide by centrifugation at 3 °C for 8 min, then repeated ether-washing/centrifugation cycles 
(3-4 times). Peptide drying under nitrogen flow.  
 
 
NMR analysis 
NOE peaks intensities were converted into distances. Calibration of the unknown interproton 
distances was done using the peak intensity and distance of a proton pair with a fixed distance rref as 
reference by:  
r (1-2) = rref 
. 
(Vref/V1-2)
1/6
 
 
where r (1-2)  is the unknown distance between protons 1 and 2, rref is the reference distance (aromatic 
vicinal proton-proton distances H,H of tyrosine: 2.48 Å), Vref is the integral of NOE peak of the 
reference protons and V1-2 is the integral of NOE peak between proton 1 and 2 calculated in 
NOESY or ROESY spectrum.  
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Preparation of compounds  
 
 
 
(1S,2S)-2-(ethoxycarbonyl)-N-((S)-1-phenylethyl)cyclopentanaminium chloride (136)
40
 
 
To a stirred solution of -ketoester 133 (40 mL, 270 mmol, 1 equiv) in absolute ethanol (320 mL) 
under N2 was added (S)-(-)--methylbenzylamine 134 (69.6 mL, 540 mmol, 2 equiv) and glacial 
acetic acid (30.8 mL, 540 mmol, 2 equiv). The reaction mixture was stirred at room temperature 
until the formation of the enamine was complete (2 h; monitored by TLC, 7:3 hexane/EtOAc, Rf = 
0.22). The reaction mixture was diluted with 640 mL of absolute ethanol and heated to 72 °C, and 
sodiumcyanoborohydride (42.4 g, 675 mmol, 2.5 equiv) was then added to the reaction mixture in 
five portions over a 5 h period. The disappearance of enamine was monitored by TLC. Through the 
course of the reaction a solid formed on the surface that hindered efficient mixing of additional 
sodium cyanoborohydride. This solid could be broken up with a spatula or by use of a mechanical 
stirrer. When the reaction was complete (6-8 h), 200 mL of H2O was added, and the ethanol was 
removed via rotary evaporation. The resulting mixture was extracted with diethyl ether (700 mL). 
The ethereal solution was passed through a plug of silica, eluting with an additional 1.5 L of ether. 
The filtrate was concentrated, the resulting oil was dissolved in EtOAc (1.2 L), and 4 N HCl in 
dioxane (65 mL) was added dropwise at room temperature with stirring. The resulting solution was 
stored at 0 °C for 1 h. A white precipitate formed during this time. The solid was isolated by 
filtration and washed with EtOAc (200 mL). This solid could be purified by recrystallization from 
ethanol (75 g of solid in 450 mL ethanol). The resulting solid was filtered and washed with 
acetonitrile and then recrystallized from acetonitrile (27 g in 400 mL).  
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After filtration and drying, compound 136 (23 g, 73.7 mmol) was obtained as a white crystalline 
solid (29% yield ). 
1
H NMR indicated the diastereomeric excess to be > 99%.  
 
 
mp: 240-241 °C; []20 (measured) = 42.3 (c  0.19 , MeOH); ([]20 not reported in literature). 
1
H NMR (CD3OD, 300MHz)  7.53-7.40 (m, 5H), 4.44 (q, J = 6.6 Hz, 1H), 4.14 (m, 2H), 3.80 (dt, 
J = 8.1 Hz, 6.4 Hz, 1H), 3.11 (m, 1H), 2.27-2.00 (m, 2H), 1.89-1.59 (m, 7H), 1.24 (t, J = 7.2 Hz, 
3H); 
13
C NMR (CD3OD, 300MHz)  137.8, 130.6, 130.5, 128.7,62.4, 60.4, 59.1, 48.6, 31.8, 31.1, 
25.1, 20.2, 14.4;  IR (neat): 2748, 2673, 2476, 1719, 1598, 1465, 1369, 1189, 1155, 1035, 856, 767, 
707. MS (ES-MS): m/z (%) = 261.9 (100) [M+H
+
], 303.1 (20) [MH
+
 + MeCN], 637.3 (5) 
[2MH
+
+TFA]. HR-MS (ES-MS): 262.1802 (C16H24NO2 [M+H]
+ 
: calcd. 262.1802). 
 
 
 
 
 
 
 
 
 
 
 
 
 
(1S,2S)-2-((S)-1-phenylethylamino)cyclopentanecarboxylic acid (137)
40
 
 
 
Compound 136 (6.27 g, 21.0 mmol, 1 equiv) was dissolved in THF/MeOH/H2O (6:3:1, 100 mL), 
and the solution was cooled to 0 °C. LiOH (2.51 g, 105 mmol, 5 equiv) was added. The mixture 
was stirred at 0 °C for 9 h. Aqueous HCl (1 N, 110 mL) was added at 0 °C. The solvent was then 
removed on a vacuum rotary evaporator to give the product as a white solid, which was used for the 
next step without further purification. 
 
Rf  = 0.38 (DCM/MeOH 90:10). 
1
H NMR (DMSO-d6, 300 MHz)  10.12 (br s, 2H), 7.68-7.57 (m, 2H), 7.38-7.25 (m, 3H), 4.21 (m, 
1H), 3.37-3.20 (m, 2H), 2.15-1.99 (m, 1H), 1.94-1.68 (m, 3H), 1.58 (d, J = 6.6 Hz, 3H), 1.64-1.47 
(m, 1H), 1.45-1.28 (m, 1H);  
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13
C NMR (DMSO-d6, 300 MHz)  175.21, 137.40, 128.89, 128.77, 128.29, 58.57, 56.76, 46.22, 
31.13, 30.86, 24.44, 20.95. MS (ES-MS): m/z (%) = 234 (100) [M+H
+
], 275 (57) [MH
+
 + MeCN], 
467.1 (53) [2M+H
+
].  
 
 
 
 
 
 
 
 
 
 
 
 
(1S,2S)-2-aminocyclopentanecarboxylic acid (33)
40
 
 
 
The white solid compound mixture 136 was dissolved in 300 mL of 95% ethanol in a 
hydrogenation flask; 10% Pd-C (2.0 g) was added. The resulting mixture was shaken under H2 (50 
psi) for 48 h. After the reaction was complete (the disappearance of starting material was monitored 
by TLC), the mixture was filtered through Celite, and the filtrate was concentrated to obtain the HCl 
salt of (1S,2S)-aminocyclopentanecarboxylic acid 33 as a white solid, which was used for the next 
step without further purification. 
 
1
H NMR (D2O, 300 MHz)  3.84-3.73 (q, J = 7.5 Hz, 1H), 2.940-2.76 (m, 1H), 2.19-1.97 (m, 2H), 
1.85-1.57 (m, 4H).  
13
C NMR (D2O, 300 MHz)   177.38, 53.93, 48.40, 30.43, 28.59, 22.86;  
MS (ES-MS): m/z (%) = 130 (100) [M+H
+
], 171 (22) [MH
+
 + MeCN]. 
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(1S,2S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)cyclopentanecarboxylic acid (132)
40
 
 
 
The crude 33 was dissolved in acetone/H2O (2:1, 300 mL) and cooled to 0 °C, and Fmoc-OSu            
(9.2 g, 27.3 mmol, 1.1 equiv) and NaHCO3 (17 g, 202 mmol, 9.6 equiv) were added. The reaction 
mixture was stirred at 0 °C for 1 h and was then allowed to stir at room temperature overnight. 
Water (100 mL) was added. The acetone was removed under reduced pressure. The aqueous residue 
was diluted with water (300 mL) and stirred for 1 h with diethyl ether (300 mL).The layers were 
separated, and the aqueous layer was acidified with 1 N aqueous HCl and extracted with ethyl 
acetate.  
The organic layer was dried over MgSO4 and concentrated to give a white solid. The crude product 
was purified by crystallization from n-hexane/CH2Cl2 to afford compound 132 (6.31 g, 20 mmol, 
85%) as a white solid. 
 
 
Rf  = 0.41 (DCM/MeOH 90:10). mp: 164-165 °C; []
20
(measured) = 36.5 (c 0.128, MeOH); 
(Literature  []20 = 36.3, c 1.21, MeOH); 
1
H NMR (CD3OD, 300 MHz)  7.81-7.73 (d, J = 7.5 Hz, 2H), 7.67-7.59 (d, J = 7.5 Hz, 2H),            
7.41-7.34 (t, J = 7.5 Hz, 2H), 7.33-7.26 (t, J = 7.5 Hz, 2H), 4.49-4.10 (m, 4H), 2.71-2.56 (q, J = 7.6 
Hz,  1H), 2.09-1.91 (m, 2H), 1.89-1.62 (m, 3H), 1.60-1.46 (m, 1H); 
13
C NMR (CD3OD, 300 MHz) 
 178.69, 158.41, 145.43, 142.64, 128.69, 128.18, 126.27, 126.21, 120.94, 67.69, 57.31, 51.53, 
33.82, 29.90, 24.24;  
IR (neat): 2878, 2360, 1682, 1540, 1472, 1443, 1342, 1293, 1186, 1152, 1104, 1087, 1037, 934, 
774, 757, 733; MS (ES-MS): m/z (%) = 352 (100) [M+H
+
], 369.1 (33) [M+NH4
+
], 392.9 (17) 
[MH
+
 + MeCN], 703.3 (45) [2M+H
+
], 720.3 (42) [2M+NH4
+
]. Elemental analysis calcd. (%) for 
C21H21NO4 (351.15): C 71.78, H 6.02, N 3.99, found C 71.55, H 6.05, H 3.80. 
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(9H-fluoren-9-yl)methyl (1S,2S)-2-(2-diazoacetyl)cyclopentylcarbamate (131)
39
 
 
 
Compound 132 (0.56 g, 1.59 mmol, 1 equiv) was placed in a oven-dried flask containing a over-
dried stir bar and dissolved in dry THF (8 ml) under a N2 atmosphere. The solution was cooled to –
15° C with ice/brine bath. N-methyl-morpholine (183 L, 1.67 mmol, 1.1 equiv) and 
isobutylchloroformate (216 L, 1.67 mmol, 1.1 equiv) were added via syringe. The mixture was 
stirred for 1 h and allowed to warm at 0° C. A white precipitate forming during this time. In 
parallel, 8 ml of a ethereal solution of diazomethane was prepared from nitrosomethylurea ( 0.82 g, 
7.95 mmol, 5 equiv) in 2.4 ml of KOH 50 % at 0° C. After stirring for 1 h, the organic layer was 
separated from aqueous layer, and it was dropped slowly  to the  reaction mixture until the yellow 
color was persistent.  
The flask was stoppered, placed under N2, and stirred for 4 h, being allowed to warm from 0° C to 
room temperature. Glacial acetic acid (1 ml) was then added to decompose any excess 
diazomethane. An off-white precipitate formed at this time. The reaction mixture was diluted with 
CH2Cl2 (200 ml), washed with saturated aqueous NaHCO3 (2x100 ml), aqueous HCl (1N, 100 ml) 
and saturated aqueous NaCl solution (100 ml). The organic layer was dried over NaSO4, filtered, 
and concentrated. The crude product was purified by column chromatography (5% ethyl acetate in 
CH2Cl2, loaded by adsorption onto silica gel) to give compound 131 (0.42 g, 1.2 mmol, 70 %) as 
white solid.  
 
Rf  = 0.38 ( dichloromethane/ethyl acetate  9:1). mp:139-140 °C;
 
[]20 (measured) = 155.8                     
(c 0.102,  MeOH); ([]20 not reported in literature). 
1
H NMR (DMSO-d6, 300 MHz) 7.89 (d, J = 7.1 Hz, 2H), 7.68 (d, J = 7.1 Hz, 2H), 7.41                
(t, J = 7.4 Hz, 2H), 7.32 (t, J = 7.4 Hz, 2H), 6.01 (s, 1H), 4.35-4.26 (d, J = 6.8 Hz 2H), 4.24-4.16              
(t, J = 6.8 Hz, 1H), 4.01-3.87 (m, 1H), 2.78-2.63 (m, 1H), 1.93-1.74 (m, 2H), 1.71-1.35 (m, 4H). 
13
C NMR (DMSO-d6, 300 MHz) 196.20, 155.40, 143.79, 140.64, 127.49, 126.93, 125.01, 
120.01, 65.04, 55.10, 46.66, 32.60, 27.99, 22.94. IR (neat): 3327, 3082, 2874, 2116, 1690, 1616, 
1539, 1447, 1396, 1355, 1297, 1273, 1242, 1149, 1104, 1085, 1034, 760, 736. 
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MS (ES-MS): m/z (%) = 376 (100) [M+H
+
], 348 (22) [MH
+
-N2], 393 (75) [M+NH4
+
], 723.3 (3) 
[2MH
+
-N2], 768.3 (32) [2M+NH4
+
]. HR-MS (ES-MS): 398.147 (C22H21N3NaO3 [M+Na]
+ 
: calcd. 
398.1475). 
 
 
 
 
 
 
 
2-((1R,2S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)cyclopentyl)acetic acid (130)
39
 
 
 
Compound 131 (0.145 g, 0.387 mmol, 1 equiv) was dissolved in water/dioxane (1/5, 20 ml), and the 
flask was covered in aluminum foil to exclude light. Silver benzoate was (9 mg, 10 mol %) was 
added as a catalyst, and the mixture was sonicated at room temperature under N2 for 1 h. At 0° C 
the solution was acidified to pH 2 with aqueous HCl (1 N).  
The solution was extracted with diethyl ether (4x25 ml). The organic layer was dried over Na2SO4, 
filtered and concentrated to give a white solid. The crude was purified by column chromatography 
on silica gel (30% ethyl acetate in hexane). The residue was recrystallized from CH2Cl2/hexane to 
obtain a white solid (0.041 g, 0.12 mmol, 29%). 
 
Rf  = 0.43 ( dichloromethane/methanol  96:4). mp:130-131 °C;
 
[]20 = +13.6 (c 0.124 , MeOH); 
([]20 not reported in literature). 1H NMR (CD3OD, 300 MHz) 7.82-7.71 (d, J = 7.4 Hz, 2H), 
7.67-7.57 (d, J = 7.4 Hz, 2H), 7.41-7.33 (t, J = 7.4 Hz, 2H), 7.32-7.24 (t, J = 7.4 Hz, 2H), 4.43-4.26 
(m, 2H), 4.22-4.13 (t, J = 6.8 Hz, 1H), 3.59-3.46 (q, J = 8.1 Hz, 1H), 2.56-2.43 (dd, J = 3.5 Hz, 1H), 
2.20-2.08 (m, 1H), 2.07-190 (m, 4H), 1.75-1.54 (m, 2H), 1.52-1.37 (m, 1H), 1.34-1.15 (m, 1H); 
13
C NMR (CD3OD, 300 MHz) 176.90, 158.78, 145.44, 142.66, 128.79, 128.17, 126.25, 120.95, 
67.53, 58.66, 48.61, 43.74, 38.91. IR (neat): 3308, 1680, 1539, 1445, 1349, 1286, 1254, 1151, 
1031, 938, 758, 736. MS (ES-MS): m/z (%) = 365.9 (92) [M+H
+
], 382.9 (50) [M+NH4
+
], 406.9 
(26) [MH
+
 + MeCN], 731.3 (98) [2M+H
+
], 748.3 (30) [2M+NH4
+
]. HR (ES-MS): 388.1516 
(C22H23NNaO4 [M+Na]
+ 
: calcd. 388.1519). 
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2-(2-ethoxy-2-oxoethyl)-N-((R)-1-phenylethyl)cyclopentanaminium chloride (150) and (151)
 
 
In a round-bottom flask fitted with a Dean-Stark-trap, ethyl 2-(2-oxocyclopentyl)acetate 138 ( 5.87 
g, 34 mmol, 1 equiv) and R(+)--methylabenzylamine 139 (4.6 g , 38 mmol, 1.1 equiv) were 
dissolved in 34.5 ml dry benzene and refluxed for 6 h. Benzene was removed in vacuo, and the 
crude imine mixture 140 was used for the next step without further purification. The crude imine 
mixture 140 was dissolved in 34 ml of dry ethanol and cooled at 5 °C. NaBH4 ( 385 mg, 10.2 mmol, 
0.3 equiv) was added within 2 h. After that, 10 ml of water were added and the ethanol was 
removed in vacuo. The aqueous layer was extracted with ethyl acetate, dried over Na2SO4 and 
concentrated. The two isomers 148 and 149 were separated by column chromatography on silica gel 
(hexanes/ethyl acetate, 90:10), giving two yellow oils.  
The resulting oils were dissolved separately in diethyl ether (110 ml for compound 148; 63 ml for 
compound 149, and 4.4 N HCl in ethyl acetate (5.5 ml for compound 148; 3.8 ml for compound 
149) was added dropwise at room temperature with stirring. The resulting solution were stored at            
0 °C for 1 h. A white precipitate formed during this time. The solid was isolated by filtration and 
washed with diethyl ether. The salts were recrystallized  from ethanol/diethyl ether, giving 
compound 150, 3.71 g, 11.9 mmol, 35 %; compound 151, 2.1 g, 6.8 mmol, 20%. (dr (87/88) = 
63:37). (below are shown also NMR information about the intermediate compound 140, 148, 149) 
 
 
Ethyl 2-((E,Z)-2-((R)-1-phenylethylimino)cyclopentyl)acetate (140)
49 
1
H NMR (CDCl3, 300 MHz) 7.39-7.25 (m, 5H), 7.24-7.16 (m, 1H), 4.48-4.39 (m, 1H), 4.20-4.07 
(m, 2H), 2.98-2.87 (m, 1H), 2.84-2.67 (m, 1H), 2.55-1.97 (m, 5H), 1.96-1.82 (m, 1H), 1.77-1.56      
(m, 1H), 1.48-1.36 (m, 4H), 1.29-1.19 (t, J = 7.4 Hz, 3H). 
13
C NMR (CDCl3, 300MHz) 177.85, 
177.56, 173.24, 146.15, 145.95, 128.65, 128.34, 128.29, 128.23, 127.35, 126.61, 126.51, 126.46, 
126.42, 61.62, 61.47, 60.18, 60.15, 43.37, 43.16, 37.04, 30.79, 30.69, 28.70, 28.56, 24.97, 24.66, 
24.50, 22.74, 22.65, 14.30, 12.26. 
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Ethyl 2-((1S,2R)-2-((R)-1-phenylethylamino)cyclopentyl)acetate (148) 
 
Rf  = 0.21 (hexanes/ethyl acetate, 90:10). 
1
H NMR (CDCl3, 300 MHz) 7.33-7.15 (m, 5H), 4.14-4.05 (q, J = 7.1 Hz, 2H), 3.85-3.76                 
(q, J = 6.5 Hz, 1H), 2.66-2.58 (q, J = 7.1 Hz, 1H), 2.51-2.44 (dd, J = 5.8 Hz, 1H), 2.22-2.10               
(dd, J = 5.8 Hz, 1H), 2.08-1.96 (m, 1H), 1.95-1.83 (m, 1H), 1.78-1.39 (m, 4H), 1.32-1.27 (d, J = 6.5 
Hz, 3H), 1.26-1.19 (t, J = 7.1 Hz, 3H), 1.22-1.10 (m, 1H). 
13
C NMR (CDCl3, 600 MHz) 173.38, 
146.66, 128.29, 126.73, 126.58, 63.02, 60.149, 56.871, 42.91, 39.20, 33.34, 30.46, 24.06, 22.40, 
14.23. 
 
 
 
 
Ethyl 2-((1S,2S)-2-((R)-1-phenylethylamino)cyclopentyl)acetate (149) 
 
Rf  = 0.40 (hexanes/ethyl acetate, 90:10). 
1
H NMR (CDCl3, 300 MHz) 7.35-7.18 (m, 5H), 4.20-4.11 (q, J = 7.4 Hz, 2H), 3.77-3.69               
(q, J = 6.9 Hz, 1H), 2.99-2.90 (m, 1H), 2.59.2.51 (dd, J = 6.1 Hz, 1H), 2.46-2.35 (m, 1H), 2.17-2.07 
(dd, J = 6.1 Hz, 1H), 1.72-1.33 (m, 7 H), 1.32-1.24 (m, 7H). 
13
C NMR (CDCl3, 300 MHz) 
174.21, 146.56, 128.36, 126.77, 126.67, 126.49, 60.19, 58.80, 56.43, 55.08, 38.29, 34.14, 30.86, 
29.48, 24.47, 20.69, 14.33. 
 
 
 
 
(1R,2S)-2-(2-ethoxy-2-oxoethyl)-N-((R)-1-phenylethyl)cyclopentanaminium chloride (150)  
 
mp: 148-149 °C;  []20 = - 6.8 (c 0.176, EtOH);  
1
H NMR (DMSO-d6, 300 MHz) br s, 2H), 7.69-7.58 (d, J = 7.2 Hz, 2H), 7.49-7.35             
(q, J = 7.2 Hz, 3H), 4.46-4.33 (q, J = 6.8 Hz, 1H), 4.09-3.99 (q, J = 6.8 Hz, 2H), 3.20-3.08 (m, 1H), 
2.82-2.71 (dd, J = 4.1 Hz, 1H), 2.47-2.41 (m, 1H), 2.32-2.19 (m, 1H),1.97-164 (m, 4H), 1.63-1.57 
(d, J = 6.7 Hz, 3H), 1.28-1.18 (m, 1H), 1.20-1.13 (t, J = 6.9 Hz, 3H).  
13
C NMR (DMSO-d6,300MHz) 171.73, 137.77, 128.75, 128.70, 127.77, 60.78, 59.79, 37.44, 
30.63, 29.58, 22.80, 19.30, 14.01. IR (neat): 2943, 2755, 2596, 2537, 1720, 1582, 1457, 1373, 
1344, 1189, 1089, 1025, 777, 713, 546. MS (ES-MS): m/z (%) = 275.9 (100) [M+H
+
], 317.0 (4) 
[MH
+ 
+ MeCN], 587.2 (6) [2MH
+ 
+ HCl], 665.3 (8) [2MH
+
 + TFA]. HR (ES-MS): 276.1955 
(C17H26NNO2 [M+H]
+ 
: calcd.  276.1958). 
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(1S,2S)-2-(2-ethoxy-2-oxoethyl)-N-((R)-1-phenylethyl)cyclopentanaminium chloride (151) 
 
mp: 150-151 °C; []20 (measured) = 31.8 (c 0.132 , EtOH); (Literature []20 = 34.1, c 1.5, EtOH). 
1
H NMR (DMSO-d6, 300 MHz) br s, 2H), 7.71-7.62 (d, J = 7.5 Hz, 2H), 7.48-7.36 (m, 3H), 
4.42-4.29 (q, J = 6.1 Hz, 1H), 4.14-4.04 (q, J = 7.2 Hz, 2H), 3.31-3.21 (m, 1H), 2.81-2.70                    
(dd, J = 3.6 Hz, 1H), 2.60-2.52 (m, 1H), 2.34-2.21 (m, 1H), 1.71-1.56 (m, 7H), 1.51-1.35(m, 2H),  
1.23-1.16 (t, J = 7.2 Hz, 3H). 
13
C NMR (DMSO-d6,300MHz) 171.71, 137.65, 128.76, 127.87, 
59.93, 58.24, 36.09, 32.70, 28.33, 26.40, 19.70, 14.02. IR (neat): 2985, 2361, 2008, 1726, 1582, 
1462, 1314, 1258, 1221, 1144, 1035, 765. MS (ES-MS): m/z (%) = 275.9 (100) [M+H
+
], 551.2 (2) 
[2M+H
+
], 587.2 (1) [2MH
+ 
+ HCl], 665.3 (4) [2MH
+
 + TFA].  
HR (ES-MS): 276.1955 (C17H26NNO2 [M+H]
+ 
: calcd.  276.1958). 
 

 
 
 
 
 
 
 
2-((1S,2R)-2-((R)-1-phenylethylamino)cyclopentyl)acetic acid (152) 
 
Compound 150 (6.27 g, 20 mmol, 1 equiv) was dissolved in THF/MeOH/H2O (6:3:1, 100 mL), and 
the solution was cooled to 0 °C. LiOH (2.4 g, 100 mmol, 5 equiv) was added. The mixture was 
stirred at 0 °C for 9 h. Aqueous HCl (1 N, 100 mL) was added at 0 °C. The solvent was then 
removed on a vacuum rotary evaporator to give the product as a white solid, which was used for the 
next step without further purification. 
 
Rf  = 0.35 ( DCM/MeOH  9:1),  
1
H NMR (DMSO-d6, 300 MHz) br s7.72-7.63 (d, J = 7.3 Hz, 2H), 7.43-7.34 (m, 3H), 
4.45-4.30 (q, J = 6.4 Hz, 1H), 3.12-3.01 (m, 1H), 2.73-2.61(dd, J = 4.3 Hz, 1H), 2.47-2.40 (m, 1H), 
2.24-2.10 (m, 1H), 2.01-1.86 (m, 1H), 1.79-1.65 (m, 3H), 1.64-1.57 (d, J = 6.8 Hz, 3H), 1.53-1.41 
(m, 1H), 1.36-1.13 (m, 1H);  
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13
C NMR (DMSO-d6,300MHz) 173.46, 137.88, 128.70, 128.61, 127.87, 60.89, 56.41, 48.44, 
38.84, 29.71, 22.92, 19.62. MS (ES-MS): m/z (%) = 248.2 (100) [M+H
+
], 293.3 (62) [MH
+
 + 
MeCN], 495.3.1 (33) [2MH
+
].  
 
 
 
 
 



2-((1S,2R)-2-aminocyclopentyl)acetic acid (31) 
 
The white solid compound 152 mixture was dissolved in 250 mL of 95% ethanol in a 
hydrogenation flask; 10% Pd-C (3.0 g) was added. The resulting mixture was shaken under H2               
(50 psi) at 50° C for 36 h. After the reaction was complete (the disappearance of starting material 
was monitored by TLC), the mixture was filtered through Celite, and the filtrate was concentrated 
to obtain the HCl salt of 2-((1S,2S)-2-aminocyclopentyl)acetic acid 31 as a white solid, which was 
used for the next step without further purification. 
 
 
1
H NMR (D2O, 300 MHz) 3.34-3.23 (q, J = 5.8 Hz 1H), 2.58-2.40 (m, 2H), 2.27-1.84 (m, 3H), 
1.71-1.52 (m, 3H), 1.36-1.21 (m, 1H). 
13
C NMR (D2O,300MHz)   
MS (ES-MS): m/z (%) = 144.0 (22) [M+H
+
], 185.0 (100) [MH
+
 + MeCN], 287 (10) [2M+H
+
]. 







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2-((1S,2R)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)cyclopentyl)acetic acid (153) 
 
 
The crude mixture 31 was dissolved in acetone/H2O (2:1, 300 mL) and cooled to 0 °C, and                
Fmoc-OSu (8.77 g, 26 mmol, 1.1 equiv) and NaHCO3 (16.2 g, 19.2 mmol, 9.6 equiv) were added. 
The reaction mixture was stirred at 0 °C for 1 h and was then allowed to stir at room temperature 
overnight. Water (100 mL) was added. Acetone was removed under reduced pressure.  
The aqueous residue was diluted with water (300 mL) and stirred for 1 h with diethyl ether                  
(300 mL).  
The layers were separated, and the aqueous layer was acidified with 1 N aqueous HCl and extracted 
with ethyl acetate. The organic layer was dried over Na2SO4 and concentrated to give a white solid. 
The crude product was purified  by crystallization from n-hexane/CH2Cl2 to afford compound 153 
(6.21g, 17 mmol, 85%) as a white solid. 
 
 
Rf  = 0.31 (DCM/MeOH  96:4). mp:130-131 °C; []
20
 = -13.6  (c 0.16 , MeOH);  
1
H NMR (CD3OD, 300 MHz) ) 7.82-7.71 (d, J = 7.4 Hz, 2H), 7.67-7.57 (d, J = 7.4 Hz, 2H), 
7.41-7.33 (t, J = 7.4 Hz, 2H), 7.32-7.24 (t, J = 7.4 Hz, 2H), 4.43-4.26 (m, 2H), 4.22-4.13 (t, J = 6.8 
Hz, 1H), 3.59-3.46 (q, J = 8.1 Hz, 1H), 2.56-2.43 (dd, J = 3.5 Hz, 1H), 2.20-2.08 (m, 1H), 2.07-190 
(m, 4H), 1.75-1.54 (m, 2H), 1.52-1.37 (m, 1H), 1.34-1.15 (m, 1H); 
13
C NMR (CD3OD, 300 MHz) 176.90, 158.78, 145.44, 142.66, 128.79, 128.17, 126.27, 120.95, 
67.53, 58.66, 48.61, 43.74, 38.91, 32.82, 31.11, 22.58. IR (neat):  2959, 2363, 2008, 1938, 1680, 
1560, 1440, 1360, 1280, 1149, 1105, 1080, 1038, 989, 760. MS (ES-MS): m/z (%) = 365.9 (93) 
[M+H
+
], 383.1 (48) [M+NH4
+
], 407 (27) [MH
+ 
+ MeCN], 731.3 (100) [2MH
+
], 748.4 (30) 
[2M+NH4
+
]. Elemental analysis calcd. (%) for C22H23NO4 (365.16): C 72.31, H 6.34, N 3.83, 
found  C 71.95, H 6.35, H 3.60. 
 





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(3aS,6aS)-1-((R)-1-phenylethyl)hexahydrocyclopenta[b]pyrrol-2(1H)-one (141) 
 
 
Compound 151 (2.6 g, 8.3 mmol, 1 equiv) was dissolved in THF/MeOH/H2O (6:3:1, 40 mL), and 
the solution was cooled to 0 °C. LiOH (1 g, 41.6 mmol, 5 equiv) was added. The mixture was 
stirred at 0 °C for 9 h. Aqueous HCl (1 N, 43 mL) was added at 0 °C.  
The solvent was then removed on a vacuum rotary evaporator to give the product 141 (1.9 g) as a 
colorless oil in quantitative yield. 
Rf  = 0.51 (Ethyl acetate), []
20
 = 31.4  (c 0.188, MeOH); 
1
H NMR (DMSO-d6, 300 MHz)  7.37-7.19 (m, 5H), 5.15-5.04 (q, J = 7.3 Hz, 1H), 3.64-3.52              
(q, 1H), 2.49-2.40 (m, 1H), 2.08-1.93 (m, 1H), 1.75-1.51 (m, 4H), 1.51-1.44 (d, J = 7.2 Hz, 3H), 
1.44-1.25 (m, 2H). 
13
C NMR (DMSO-d6,300MHz) 173.68, 140.50, 128.29, 127.05, 126.90, 
61.76, 54.95, 50.31, 34.06, 33.59, 32.80, 24.18, 18.13. IR (neat): 3392, 2955, 2865, 1650, 1439, 
1418, 1364, 1334, 1268, 1213, 1030, 768. MS (ES-MS): m/z (%) = 230 (24) [M+H
+
], 247 (6) 
[M+NH4
+
], 271 (48) [MH
+ 
+ MeCN], 459.1 (100) [2M+H
+
]. HR-MS (ES-MS): 230.1537 
(C15H20NO [M+H]
+ 
: calcd.  230.1539). 





 
 
 
(3aS,6aS)-hexahydrocyclopenta[b]pyrrol-2(1H)-one (142)  
 
 
In a flask under argon atmosphere NH3 (55 ml) was condensed at -78° C and Li (0.266 g, 38 mmol, 
4.6 equiv) was added. When the metal dissolved in NH3, a solution containing the compound 141             
(1.9 g, 8.3 mmol, 1 equiv), in dry THF- t-BuOH (17 ml of 90 : 10 mixture) was quickly added.  
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After 20 min powdered NH4Cl (3.5 g) was added and the reaction mixture was stirred overnight and 
allowed to warm to room temperature. After that, the mixture was extracted with ethyl acetate           
(3 x 50 ml). The organic layer was dried over Na2SO4 and concentrated under reduced pressure. The 
residue was purified by silica gel chromatography in pure ethyl acetate giving compound 142       
(0.8 g, 6.4 mmol, 77%). 
 
Rf  = 0.21 ( Ethyl acetate ). mp:187-188 °C;  []
20
 = - 16.9  (c 0.136, MeOH); 
1
H NMR (CDCl3, 300 MHz) 6.46 (br s, 1H), 4.12-4.04 (m, 1H), 2.87-2.73 (m, 1H), 2.66-2.55 (m, 
1H), 2.08-1.97 (dd, J = 3.4 Hz, 1H), 1.85-1.55 (m, 5H), 1.53-1.43 (m, 1H).                                   
13
C NMR (CDCl3,300MHz) IR (neat): 3288, 
2952, 2864, 1649, 1420, 1321, 1301, 1270, 1179, 1148, 1108, 1043, 853. 
 
MS (ES-MS): m/z (%) = 126 (4) [M+H
+
], 167 (52) [MH
+ 
+ MeCN], 251.1 (100) [2M+H
+
].
HR-MS (ES-MS): 126.0911 (C7H12NO [M+H]
+ 
: calcd. 126.0913).



 
 
 
 
 
 
 
2-((1S,2S)-2-aminocyclopentyl)acetic acid (30) 
 
A solution of compound 142 (0.8 g, 6.4 mmol, 1 equiv) in 1N HCl (22 ml) was stirred at 80° C for 
36 h. After that, the reaction mixture was washed with DCM to remove impurities. The aqueous 
layer was concentrated under pressure giving compound 30 (0.5 g, 3.5 mmol, 55%) as a white solid.  
 
mp:124-125 °C; 
1
H NMR (D2O, 300 MHz) 7.08 (br s, 3H), 3.71-3.62 (m, 1H), 2.47-2.30 (m, 
2H),  2.28-2.16 (m, 1H), 2.15-2.01 (m, 1H), 1.91-1.80 (m, 1H), 1.79-1.54 (m, 3H), 1.43-1.28 (m, 
1H). 
13
C NMR (D2O, 300MHz) 180.72, 54.72, 39.17, 37.06, 30.25, 29.34, 21.81. 
MS (ES-MS): m/z (%) = 144 (28) [M+H
+
], 185 (100) [MH
+ 
+ MeCN], 287 (10) [2M+H
+
]. 
HR-MS (ES-MS): 144.1021 (C7H14NO2 [M+H]
+ 
: calcd. 144.1019).
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2-((1S,2S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)cyclopentyl)acetic acid (143) 
 
 
Crude mixture 30 was dissolved in acetone/H2O (2:1, 92 mL) and cooled to 0 °C, and               
Fmoc-OSu (2.8 g, 8.32 mmol, 1.3 equiv) and NaHCO3 (5.16 g, 61.4 mmol, 9.6 equiv) were added.  
The reaction mixture was stirred at 0 °C for 1 h and was then allowed to stir at room temperature 
overnight. Water (20 mL) was added. The acetone was removed under reduced pressure.                     
The aqueous residue was diluted with water (10 mL) and stirred for 1 h with diethyl ether (20 mL).            
The layers were separated, and the aqueous layer was acidified with 1 N aqueous HCl and extracted 
with ethyl acetate. The organic layer was dried over Na2SO4 and concentrated to give a white solid.  
The crude product was purified  by crystallization from n-hexane/CH2Cl2 to afford compound 143 
(1.9 g, 5.2 mmol, 85%) as a white solid. 
 
Rf  = 0.28 ( DCM/MeOH 96:4 ). mp:119-120 °C;  []
20
 = +10.4  (c 0.15 , MeOH);
 
1
H NMR (CD3OD, 300 MHz) 7.80-7.73 (d, J = 7.2 Hz, 2H), 7.68-7.60 (d, J = 7.2 Hz, 2H),             
7.41-7.33 (t, J = 7.4 Hz, 2H), 7.32-7.25 (t, J = 7.4 Hz, 2H), 4.47-4.38 (m, 1H), 4.34-4.25 (m, 1H), 
4.22-4.15 (t, J = 6.4 Hz, 1H), 4.08-4.01 (q, J = 5.4 Hz, 1H), 2.42-2.25 (m, 2H), 2.18-2.03 (m, 1H), 
2.01-1.65 (m, 3H), 1.61-1.46 (m, 2H), 1.44-1.24 (m, 1H); 
13
C NMR (CD3OD, 300 MHz)  177.11, 158.60, 145.44, 142.67, 128.79, 128.19, 126.29, 120.94, 
67.49, 55.56, 48.64, 40.96, 35.51, 32.67, 30.53, 22.81. IR (neat): 3327, 2914, 2362, 1686, 1527, 
1450, 1308, 1279, 1245, 1218, 1083, 1033, 757, 735. MS (ES-MS):  m/z (%) =  365.9 (100) 
[M+H
+
], 383.0 (60) [M+NH4
+
], 407 (18) [MH
+
 + MeCN], 731.3 (92) [2MH
+
], 748.4 (45) 
[2M+NH4
+
]. HR-MS (ES-MS): 388.1516 (C22H23NNaO4 [M+Na]
+ 
: calcd. 388.1519).
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2-((1S,2R,3R,5R)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-((tert 
butyldimethylsilyloxy)methyl)-5-methoxycyclopentyl)acetic acid (109) 
Compound 99 (50 mg, 0.12 mmol, 1 equiv) was dissolved in DMF (5.00 ml) under inert 
atmosphere. After adding imidazole (50 mg, 0.7 mmol, 6 equiv), TBSCl (53 mg, 0.35 mmol,                    
3 equiv) and a catalytic amount of DMAP, the reaction mixture was stirred for 5 h at room 
temperature. Imidazole (50 mg, 0.7 mmol, 6 equiv) and TBSCl (53 mg, 0.35 mmol, 3 equiv) were 
then added again and the reaction was stirred for 24 h. Methanol (9.70 ml/1.1 mmol) was added and 
the mixture stirred for another hour. This mixture was diluted with 25% citric acid (10 ml) and 
extracted with ethyl acetate (3×20 ml). The combined extracts were washed with water and brine 
and finally dried over sodium sulfate. Evaporation of the solvent gave a viscous oil, which was 
purified on silica gel using a mixture of DCM/MeOH (98 : 2) as the eluent giving the final product 
109 (50 mg, 0.092 mmol, 78.8%) as a white solid 
 
mp: 74-75 °C; []20 = -18.4  (c 0.21 , DCM). 
1
H NMR (CDCl3, 300MHz) 7.78-7.71 (d, J = 7.6 Hz, 2H), 7.61-7.55 (d, J = 7.6 Hz, 2H),                
7.42-7.26 (m, 4H), 5.67-5.59 (d, J = 9.5 Hz, 1H), 4.42-4.35 (d, 2H), 4.24-4.04 (m, 2H), 3.78-3.71 
(m, 2H), 3.57-3.50 (m, 1H), 3.24 (s, 3H), 2.75-2.64 (dd, J = 6.9 Hz, 1H), 2.55-2.45 (dd, J = 6.9 Hz, 
1H), 2.42-2.27 (m, 1H), 2.19-2.07 (m, 1H), 2.01-1.90 (m, 1H), 1.82-1.70 (m, 1H), 0.90 (s, 9H),      
0.06 (s, 6H). 
13
C NMR (CD3Cl3, 300MHz) 178.58, 156.85, 144.04, 141.33, 127.62, 127.01, 
125.06, 119.97, 80.13, 66.51, 62.87, 56.58, 56.29, 48.20, 47.35, 38.04, 31.65, 30.78, 25.83, 18.05, -
5.62. IR (neat): 3333, 2930, 1690, 1535, 1450, 1407, 1346, 1251, 1086, 1023, 945, 836, 775, 746. 
MS (ES-MS): m/z (%) = 540.2 (100) [M+H
+
], 557.2 (30) [Mà+NH4
+
], 1079.6 (45) [2MH
+
]. 
HR-MS (ES-MS): 540.278 (C30H42NO6Si [M+H]
+ 
: calcd. 540.2776). 
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(S)-benzyl-2-(2-((1S,2R,3R,5R)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-((tert-
butyldimethylsilyloxy)methyl)-5-methoxycyclopentyl)acetamido)propanoate (112) 
 
Compound 109 (100 mg, 0.186 mmol, 1 equiv) was dissolved in DCM(1ml) at 0° C. After that, 
EDC (40 mg, 0.2 mmol, 1.1 equiv) and HOBt (31 mg, 0.2 mmol, 1.1 equiv)  were added and the 
mixture were strirred for 20 min at 0° C. Then, (S)-1-(benzyloxy)-1-oxopropan-2-aminium chloride 
113 (65 mg, 0.22 mmol, 1.2 equiv) and DIPEA(0.13 ml, 0.74 mmol, 4 equiv) were added and the 
reaction mixture was allowed to warm at r.t. and stirred in overnight.  Water (10 ml) was added and 
the layers were separated and the aquous layer extracted once with DCM. The combined organic 
layers were washed with water and brine and finally dried over Na2SO4 and concentrated. The crude 
product was purified by column chromatography (10% of ethyl acetate in DCM) giving the product 
as brown oil (88 mg, 0.125 mmol, 68 %). 
 
 
1
H NMR (CDCl3, 300MHz) 7.75-7.67 (d, J = 7.3 Hz, 2H), 7.59-7.52 (d, J = 7.2 Hz, 2H), 7.39-
7.18 (m, 9H), 6.37-6.39 (d, J = 7.5 Hz, 1H), 5.72-5.66 (d, J = 9.6 Hz, 1H), 5.14-5.10 (d, J = 5.3 Hz, 
2H), 4.65-4.54 (m, 1H), 4.40-4.25 (m, 2H), 4.19-4.02 (m, 2H), 3.75-3.64 (m, 2H), 3.56-3.47 (dd, 
1H), 3.23-3.19 (s, 3H), 2.53-2.41 (m, 1H), 2.38-2.27 (m, 2H), 2.20-2.08 (m, 1H), 1.97-1.86 (m, 
1H), 1.75-1.64 (m, 1H), 1.37-1.32 (d, J = 6.9 Hz, 3H), 0.08 (s, 9H), 0.03 (s, 6H). 
13
C NMR 
(CD3Cl3, 300MHz) 172.99, 172.34,156.88, 144.10, 141.31, 135.46, 129.06, 128.62, 128.25, 
128.15, 127.64, 127.04, 127.02, 125.35, 125.14, 125.11, 119.97, 80.26, 66.99, 66.62, 62.82, 56.76, 
56.23, 48.93, 48.04, 47.31, 38.24, 34.56, 30.41, 29.73, 25.91, 18.38, 5.54. MS (ES-MS): m/z (%) = 
701.5 (100) [M+H
+
], 724.4 (40) [M+NH4
+
]. HR-MS (ES-MS): 701.3515 (C40H53N2O7Si [M+H]
+ 
: 
calcd. 701.3527). 
 

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


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(S)-benzyl-2-(2-((1S,2R,3R,5R)-2-((S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-5-Pbf-
guanidinopentanamido)-3-((tert-butyldimethylsilyloxy)methyl)-                                                       
5-methoxycyclopentyl)acetamido)propanoate (115) 
 
Compound 112, after cleavage of Fmoc group, (50 mg, 0.025 mmol, 1 equiv) was dissolved in 
DCM(1ml) at 0° C. After that, EDC (15 mg, 0.073 mmol, 1.1 equiv) and HOBt (12 mg, 0.073 
mmol, 1.1 equiv) were added and the mixture were strirred for 20 min at 0° C. Then, Fmoc-D-
Arg(Pbf) (39 mg, 0.088 mmol, 1.2 equiv) and DIPEA(0.046 ml, 0.27 mmol, 4 equiv) were added 
and the reaction mixture was allowed to warm at r.t. and stirred in overnight.  Water (10 ml) was 
added and the layers were separated and the aqueous layer extracted once with DCM. The 
combined organic layers were washed with water and brine and finally dried over Na2SO4  and 
concentrated. The crude product was purified by column chromatography (1% of MeOH in DCM) 
giving the product as brown oil (29 mg, 0.026 mmol, 40 %). 
 
 
1
H NMR (CDCl3, 300MHz) 7.76-7.70 (d, J = 7.4 Hz, 2H), 7.60-7.52 (m, 2H), 7.38-7.23 (m, 9H), 
7.01-6.90 (d, 1H), 6.71-6.62 (br s, 2H), 6.28-6.17 (br s, 2H), 6.03-5.95 (br s, 1H), 5.15-5.05 (q, 2H), 
4.54-4.07 (m, 6H), 3.72-3.48 (m, 3H), 3.33-3.26 (m, 1H), 3.24 (s, 3H), 3.20-3.10(m, 1H), 2.90 (s, 
2H), 2.58 (s, 3H), 2.51 (s, 3H), 2.40-2.16 (m, 3H), 2.06 (s, 3H), 2.01-1.49 (m, 6 H), 1.42 (s, 6H), 
1.35-1.32 (d, J =  6.9 Hz, 3H), 0.86 (s, 9H), 0.02 (s, 6H).  
13
C NMR (CD3Cl3, 300MHz) 172.81, 
171.85, 158.67, 156.51, 143.77, 141.24, 138.39, 135.33, 132.32, 128.37, 128.08, 127.70, 127.08, 
125.13, 124.52, 119.92, 117.40, 86.28, 80.11, 67.14, 66.98, 62.98, 60.37, 56.03, 54.87, 53.40, 
48.51, 47.05, 43.19, 38.45, 34.35, 31.90, 25.25, 23.81, 22.66, 21.02, 19.28, 18.08, 17.97, 17.92. 
HR-MS (ES-MS): 1109.5425 (C59H81N6O11SSi [M+H]
+ 
: calcd.1109.5448). 



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




 
(S)-benzyl-2-((S)-2-(2-((1S,2R,3R,5R)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-((tert-
butyldimethylsilyloxy)methyl)-5-methoxycyclopentyl)acetamido)-5-
(Pbf)guanidinopentanamido)propanoate (116) 
 
Compound 109 (20 mg, 0.034 mmol, 1 equiv) was dissolved in DCM (1ml) at 0° C. After that, 
EDC (9.2 mg, 0.047 mmol, 1.3 equiv) and HOBt (7 mg, 0.047 mmol, 1.3 equiv) were added and the 
mixture were stirred for 20 min at 0° C. Then, dipeptide Arginine(Pbf)-Alanine-OBn (24 mg, 0.045 
mmol, 1.2 equiv) and DIPEA(0.025 ml, 0.14 mmol, 4 equiv) were added and the reaction mixture 
was allowed to warm at r.t. and stirred in overnight.  Water (5 ml) was added and the layers were 
separated and the aqueous layer extracted once with DCM. The combined organic layers were 
washed with water and brine and finally dried over Na2SO4  and concentrated. The crude product 
was purified by column chromatography (2% of MeOH in DCM) giving the product as colorless oil 
(15 mg, 0.0135 mmol, 45 %). 
 
1
H NMR (CDCl3, 300MHz) 7.77-7.70 (d, J = 7.2 Hz, 2H), 7.59-7.52 (d, J = 7.2 Hz, 2H), 7.40-
7.24 (m, 9H), 6.87-6.78 (m, 1H), 6.27-6.08 (br s, 2H), 5.90-5.82 (m, 1H), 5.15-5.01 (m, 2H), 4.56-
3.96 (m, 6H), 3.79-3.50 (m, 3H), 3.21 (s, 3H), 2.92 (s, 2H), 2.57 (s, 3H), 2.50 (s, 3H9), 2.40-2.14 
(m, 3H), 2.07 (s, 3H), 1.97-1.53 (m, 5H), 1.47 (s, 6H), 1.22-1.18 (d, J = 6.01 Hz, 3H), 0.90 (s, 9H), 
0.06 (s, 6H). ).  
13
C NMR (CD3Cl3, 300MHz) 173.38, 172.49, 158.73, 156.94, 156.25, 143.97, 
141.29, 135.38, 132.37, 128.58, 128.36, 127.65, 127.02, 125.06, 124.58, 119.97, 117.45, 86.35, 
67.07, 66.66, 64.46, 56.58, 56.26, 48.49, 47.25, 43.22, 30.48, 28.60, 25.86, 25.37, 19.30, 18.08, 
17.94, 17.50, 12.48, 5.57.  
HR-MS (ES-MS): 1109.5425 (C59H81N6O11SSi [M+H]
+ 
: calcd.1109.5448).



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(S)-benzyl-2-((S)-2-(2-((1S,2R,3R,5R)-2-((S)-2-(2-((1S,2R,3R,5R)-2-((S)-2-(((9H-fluoren-9-
yl)methoxy)carbonylamino)-5-guanidinopentanamido)-3-((tert-
butyldimethylsilyloxy)methyl)-5-methoxycyclopentyl)acetamido)propanamido)-3-((tert-
butyldimethylsilyloxy)methyl)-5-methoxycyclopentyl)acetamido)-5-
guanidinopentanamido)propanoate (117) 
 
Compound 115, after cleavage of benzyl ester group (5.4 mg, 0.005 mmol, 1 equiv) was dissolved 
in DCM (1ml) at 0° C. After that, EDC (1.4 mg, 0.007 mmol, 1.3 equiv) and HOBt (1 mg, 0.007 
mmol, 1.3 equiv) were added and the mixture were stirred for 20 min at 0° C. Then, compound 116, 
after cleavage of Fmoc group (7 mg, 0.008 mmol, 1.2 equiv) and DIPEA(3.8 l, 0.024 mmol, 4 
equiv) were added and the reaction mixture was allowed to warm at r.t. and stirred in overnight.  
Water (5 ml) was added and the layers were separated and the aqueous layer extracted once with 
DCM. The combined organic layers were washed with water and brine and finally dried over 
Na2SO4 and concentrated. The crude product was purified by preparative HPLC giving the product 
as a white solid (4.9 mg, 0.003 mmol, 60 %). 
 
HR-MS (ES-MS): 1659.7846 (C84H115N12O19S2 [M+H]
+ 
: calcd. 1659.7837). 

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Ac-Arg
26
-His
27
-Thr
28
-Ile
29
-Asn
30
-(1S,2S-ACPA)
31
-Thr
32
-Arg
33
-(1S,2S-ACPC)
34
-Arg
35
-Tyr
36
-
NH2 (161)            
(3.21 mg, 0.00215 mmol) HR-MS (ES-MS): 1492.8426 (C66H108N24O16 [M+4H]
+4 
: calcd. 
374.2167). 
 
 
Ac-Arg
26
-His
27
-(1S,2S-ACPC)
28
-Ile
29
-Asn
30
-(1S,2S-ACPA)
31
-Thr
32
-Arg
33
-(1S,2S-ACPC)
34
-
Arg
35
-Tyr
36
-NH2     (162)                                                                                                                                          
(3.9 mg, 0.0026 mmol) HR-MS (ES-MS): 1502.8646 (C68H110N24O15 [M+4H]
+4 
: calcd. 376.7218). 
 
 
 
Ac-Arg
25
-His26-Tyr
27
-Ile
28
-Asn
29
-Leu
30
-Ile
31
-Thr
32
-Arg
33
-(1S,2S-ACPC)
34
-Arg
35
-Tyr
36
-NH2   
(163)   
(0.67 mg, 0.0004 mmol) HR-MS (ES-MS): 1655.9419 (C76H121N25O17 [M+4H]
+4 
: calcd. 
414.9916). 
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Ac-Arg
25
-His
26
-Tyr
27
-Ile
28
-Asn
29
-Leu
30
-Ile
31
-Thr
32
-Arg
33
-(1S,2S-ACPA)
34
-Arg
35
-Tyr
36
-NH2     
(164) 
(0.72 mg, 0.00043 mmol) HR-MS (ES-MS): 1669.9586 (C77H123N25O17 [M+4H]
+4 
: calcd. 
418.4955). 
 
 
Ac-Arg
26
-His
27
-Tyr
28
-Ile
29
-Asn
30
-(1S,2R-ACPA)
31
-Thr
32
-Arg
33
-(1S,2S-ACPC)
34
-Arg
35
-Tyr
36
-
NH2   (165) 
(4.37 mg, 0.0028 mmol) HR-MS (ES-MS): 1554.8557 (C71H110N24O16 [M+4H]
+4 
: calcd. 
389.7206). 
 
 
 
Ac-Arg
26
-His
27
-Tyr
28
-Ile
29
-Asn
30
-(1R,2S-ACPA)
31
-Thr
32
-Arg
33
-(1S,2S-ACPC)
34
-Arg
35
-Tyr
36
-
NH2     (166) 
(4.15 mg, 0.0026 mmol) HR-MS (ES-MS): 1554.8557 (C71H110N24O16 [M+4H]
+4 
: calcd. 
389.7206) 
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Ac-Arg
25
-His
26
-Tyr
27
-Ile
28
-Asn
29
-Leu
30
-Ile
31
-Thr
32
-Arg
33
-(1S,2R-ACPA)
34
-Arg
35
-Tyr
36
-NH2 
(167) 
HR-MS (ES-MS): 1669.9586 (C77H123N25O17 [M+4H]
+4 
: calcd. 418.4955). 
 
 
 
 
Ac-Arg
25
-His
26
-Tyr
27
-Ile
28
-Asn
29
-Leu
30
-Ile
31
-Thr
32
-Arg
33
-(1R,2S-ACPA)
34
-Arg
35
-Tyr
36
-NH2 
(168) 
HR-MS (ES-MS): 1669.9586 (C77H123N25O17 [M+4H]
+4 
: calcd. 418.4955). 
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Appendix of NMR and X-Ray Data 
 
NMR spectorscopic data 
 
1
H-Spectra                (Top of the page) 
13
C-Spectra               (Bottom of the page)   
 
 
 
For the NPY analogues 161, 162, 163, 164, 165 and 166, the HPLC chromatograms after 
purification are given. 
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(1S,2S)-2-(ethoxycarbonyl)-N-((S)-1-phenylethyl)cyclopentanaminium chloride (136) 
1
H NMR (CD3OD, 300MHz) 
 
13
C NMR (CD3OD, 300MHz) 
 
 139 
 
(1S,2S)-2-((S)-1-phenylethylamino)cyclopentanecarboxylic acid (137) 
 
1
H NMR (DMSO-d6, 300 MHz) 
 
 
13
C NMR (DMSO- d6, 300MHz) 
 
 140 
 
(1S,2S)-2-aminocyclopentanecarboxylic acid (33) 
1
H NMR (D2O, 300 MHz)  
 
13
C NMR (D2O, 300MHz) 
 
 141 
 
(1S,2S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)cyclopentanecarboxylic acid (132) 
1
H NMR (CD3OD, 300 MHz)  
 
13
C NMR (CD3OD, 300MHz) 
 
 142 
 
(1S,2S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)cyclopentanecarboxylic acid (131) 
1
H NMR (DMSO-d6, 300 MHz)  
 
13
C NMR (DMSO-d6, 300 MHz)  
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2-((1R,2S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)cyclopentyl)acetic acid (130) 
1
H NMR (CD3OD, 300 MHz)  
                    
13
C NMR (CD3OD, 300 MHz)  
 
 144 
 
ethyl 2-((E,Z)-2-((R)-1-phenylethylimino)cyclopentyl)acetate (140) 
1
H NMR (CDCl3, 300 MHz)  
 
13
C NMR (CDCl3, 300 MHz)  
 
 145 
 
ethyl 2-((1S,2R)-2-((R)-1-phenylethylamino)cyclopentyl)acetate (148) 
1
H NMR (CDCl3, 300 MHz)  
 
13
C NMR (CDCl3, 300 MHz) 
  
 146 
 
ethyl 2-((1S,2S)-2-((R)-1-phenylethylamino)cyclopentyl)acetate (149) 
1
H NMR (CDCl3, 300 MHz)  
 
13
C NMR (CDCl3, 300 MHz) 
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(1R,2S)-2-(2-ethoxy-2-oxoethyl)-N-((R)-1-phenylethyl)cyclopentanaminium chloride (150) 
1
H NMR (DMSO-d6, 300 MHz)  
 
13
C NMR (DMSO-d6,300MHz) 
 
 148 
 
(1S,2S)-2-(2-ethoxy-2-oxoethyl)-N-((R)-1-phenylethyl)cyclopentanaminium chloride (151) 
1
H NMR (DMSO-d6, 300 MHz)  
 
13
C NMR (DMSO-d6,300MHz) 
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2-((1S,2R)-2-((R)-1-phenylethylamino)cyclopentyl)acetic acid (152) 
1
H NMR (DMSO-d6, 300 MHz)  
 
13
C NMR (DMSO-d6,300MHz) 
 
 
 150 
 
2-((1S,2R)-2-aminocyclopentyl)acetic acid (31) 
1
H NMR (D2O, 300 MHz)  
 
13
C NMR (D2O,300MHz) 
 
 151 
 
2-((1S,2R)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)cyclopentyl)acetic acid (153) 
1
H NMR (CD3OD, 300MHz)  
 
13
C NMR (CD3OD, 300 MHz) 
 
 152 
 
(3aS,6aS)-1-((R)-1-phenylethyl)hexahydrocyclopenta[b]pyrrol-2(1H)-one (141) 
 
1
H NMR (DMSO-d6, 300 MHz)  
 
13
C NMR (DMSO-d6,300MHz) 
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(3aS,6aS)-hexahydrocyclopenta[b]pyrrol-2(1H)-one (142)  
 
1
H NMR (CDCl3, 300 MHz)  
 
13
C NMR (CDCl3,300MHz) 
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2-((1S,2S)-2-aminocyclopentyl)acetic acid (30) 
1
H NMR (D2O, 300 MHz)  
 
13
C NMR (D2O, 300MHz) 
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2-((1S,2S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)cyclopentyl)acetic acid (143) 
1
H NMR (CD3OD, 300 MHz)  
 
13
C NMR (CD3OD, 300 MHz) 
 
 156 
 
2-((1S,2R,3R,5R)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-((tert 
butyldimethylsilyloxy)methyl)-5-methoxycyclopentyl)acetic acid (109) 
1
H NMR (CDCl3, 300 MHz)  
 
13
C NMR (CDCl3, 300 MHz) 
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(S)-benzyl-2-(2-((1S,2R,3R,5R)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-((tert-
butyldimethylsilyloxy)methyl)-5-methoxycyclopentyl)acetamido)propanoate (112) 
 
1
H NMR (CDCl3, 300 MHz)  
 
13
C NMR (CDCl3, 300 MHz) 
 
 158 
 
(S)-benzyl-2-(2-((1S,2R,3R,5R)-2-((S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-5-Pbf-
guanidinopentanamido)-3-((tert-butyldimethylsilyloxy)methyl)- 
5-methoxycyclopentyl)acetamido)propanoate (115) 
 
1
H NMR (CDCl3, 300MHz) 
 
13
C NMR (CD3Cl3, 300MHz) 
 
 159 
 
(S)-benzyl-2-((S)-2-(2-((1S,2R,3R,5R)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-((tert-
butyldimethylsilyloxy)methyl)-5-methoxycyclopentyl)acetamido)-5-
(Pbf)guanidinopentanamido)propanoate (116) 
 
1
H NMR (CDCl3, 300MHz) 
 
 
13
C NMR (CD3Cl3, 300MHz) 
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Ac-Arg
26
-His
27
-Thr
28
-Ile
29
-Asn
30
-(1S,2S-ACPA)
31
-Thr
32
-Arg
33
-(1S,2S-ACPC)
34
-Arg
35
-Tyr
36
-
NH2 (161) 
 
Injection 30 l; Gradient 5-98% in 20 min, 98% for 5 min; Wavelenght = 220 nm;                                 
Retention time = 6.793 min; yield = 86,7%. 
 
 
Ac-Arg
26
-His
27
-(1S,2S-ACPC)
28
-Ile
29
-Asn
30
-(1S,2S-ACPA)
31
-Thr
32
-Arg
33
-(1S,2S-ACPC)
34
-
Arg
35
-Tyr
36
-NH2     (162)         
 
Injection 30 l; Gradient 5-98% in 20 min, 98% for 5 min; Wavelenght = 220 nm;                                 
Retention time = 7.345 min; yield = 98%. 
min0 5 10 15 20 25 30 35
mAU
0
20
40
60
80
min0 5 10 15 20 25 30 35 40
mAU
0
50
100
150
200
250
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Ac-Arg
25
-His26-Tyr
27
-Ile
28
-Asn
29
-Leu
30
-Ile
31
-Thr
32
-Arg
33
-(1S,2S-ACPC)
34
-Arg
35
-Tyr
36
-NH2   
(163)  

Injection 30 l; Gradient 5-98% in 20 min, 98% for 5 min; Wavelenght = 220 nm;                                 
Retention time = 8.546 min; yield = 96.7% 
 
Ac-Arg
25
-His
26
-Tyr
27
-Ile
28
-Asn
29
-Leu
30
-Ile
31
-Thr
32
-Arg
33
-(1S,2S-ACPA)
34
-Arg
35
-Tyr
36
-NH2     
(164) 
 
Injection 30 l; Gradient 5-98% in 20 min, 98% for 5 min; Wavelenght = 220 nm;                                 
Retention time = 8.360 min; yield = 96.2%. 
min
0 5 10 15 20 25 30 35
mAU
0
50
100
150
200
250
300
350
min0 5 10 15 20 25 30 35
mAU
0
50
100
150
200
250
300
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Ac-Arg
26
-His
27
-Tyr
28
-Ile
29
-Asn
30
-(1S,2R-ACPA)
31
-Thr
32
-Arg
33
-(1S,2S-ACPC)
34
-Arg
35
-Tyr
36
-
NH2   (165) 
 
Injection 30 l; Gradient 5-98% in 20 min, 98% for 5 min; Wavelenght = 220 nm;                                 
Retention time = 7.271 min; yield = 87.4% 
 
 
Ac-Arg
26
-His
27
-Tyr
28
-Ile
29
-Asn
30
-(1R,2S-ACPA)
31
-Thr
32
-Arg
33
-(1S,2S-ACPC)
34
-Arg
35
-Tyr
36
-
NH2     (166) 
 
Injection 30 l; Gradient 5-98% in 20 min, 98% for 5 min; Wavelenght = 220 nm;                                 
Retention time = 7.271 min; yield = 94,6% 
 
min0 5 10 15 20 25 30 35 40
mAU
0
100
200
300
400
500
min0 5 10 15 20 25 30 35 40
mAU
0
100
200
300
400
500
600
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Crystal data of compound 150:                                                                                                                             
Empirical formula                                            C17 H26 N O2, Cl  
Formula weight                                              311.84  
Crystal size                                                    0.1545 x 0.0825 x 0.0586 mm  
Crystal description                                         prism  
Crystal colour                                                translucent colourless  
Crystal system                                               Orthorhombic  
Space group                                                   C 2 2 21  
Unit cell dimensions                                      a = 7.75993(17) Å   alpha = 90 °.  
                                                                        b = 16.3395(4) Å    beta = 90 °.  
                                                                        c = 26.7466(7) Å   gamma = 90 °.  
 Volume                                                          3391.29(14) Å
3
  
 Z, Calculated density                                     8,  1.222 Mg/m
3 
 
 Absorption coefficient                                   2.021 mm
-1
  
 F(000)                                                            1344  
   
Data Collection:                                                                                                                            
Measurement device type                              SuperNova, Single source at offset), Atlas  
 Measuremnet method                                   \w scans  
Temperature                                                   123 K  
Wavelength                                                    1.54184 Å  
Monochromator                                             graphite  
Theta range for data collection                      3.30 to 73.62 °.  
Index ranges                                                  -6<=h<=9, -20<=k<=13, -27<=l<=33  
Reflections collected / unique                        5942 / 3300 [R(int) = 0.0331]  
Reflections greater I>2\s(I)                            3168  
Absorption correction                                    Analytical  
Max. and min. transmission                           0.971 and 0.943  
Refinement   
Refinement method                                        Full-matrix least-squares on F
2
  
Hydrogen treatment                                        :  
Data / restraints / parameters                          3300 / 0 / 196  
Goodness-of-fit on F
2
                                     1.052  
Final R indices [I>2sigma(I)]                         R1 = 0.0423, wR2 = 0.1117  
R indices (all data)                                          R1 = 0.0436, wR2 = 0.1137  
 164 
 
Absolute structure parameter                          -0.020(15)  
Largest diff. peak and hole                              0.289 and -0.229 e.Å
-3
  
 
 
 
 
x 
 
y 
 
z 
 
U(eq) 
 
O(1) 
O(2) 
N(1) 
C(1) 
C(2) 
C(3) 
C(4) 
C(5) 
C(6) 
C(7) 
C(8) 
C(9) 
C(10) 
C(11) 
C(12) 
C(13) 
C(14) 
C(15) 
C(16) 
C(17) 
Cl(1) 
7289(3) 
8246(2) 
5796(2) 
6041(3) 
7758(3) 
7224(3) 
5370(3) 
4622(3) 
6977(3) 
6393(3) 
7007(3) 
8588(3) 
8655(4) 
7142(4) 
5569(4) 
5492(3) 
8966(3) 
8071(3) 
7515(3) 
7596(5) 
1894(1) 
5779(1) 
7016(1) 
7568(1) 
6935(1) 
6467(1) 
5578(1) 
5644(1) 
6290(1) 
8301(1) 
8886(1) 
8722(1) 
8898(1) 
9343(2) 
9591(1) 
9413(2) 
8983(1) 
6545(1) 
6388(1) 
6909(2) 
7731(2) 
8060(1) 
3048(1) 
2839(1) 
4426(1) 
4021(1) 
4094(1) 
4227(1) 
4406(1) 
4057(1) 
4411(1) 
4823(1) 
3907(1) 
3688(1) 
3240(1) 
3014(1) 
3228(1) 
3679(1) 
3644(1) 
3152(1) 
2341(1) 
2089(1) 
4512(1) 
  56(1) 
42(1) 
23(1) 
25(1) 
27(1) 
35(1) 
36(1) 
33(1) 
25(1) 
31(1) 
25(1) 
32(1) 
39(1) 
44(1) 
42(1) 
32(1) 
33(1) 
35(1) 
47(1) 
63(1) 
30(1) 
 
Table 2.  Atomic coordinates ( x 104) and equivalent isotropic 
displacement parameters (Å
2
 x 10
3
). 
U(eq) is defined as one third of the trace of the orthogonalized 
Uij tensor. 
 
O(1)-C(15) 
O(2)-C(15) 
O(2)-C(16) 
N(1)-C(1) 
N(1)-C(6) 
N(1)-H(1M) 
N(1)-H(1N) 
C(1)-C(2) 
C(1)-C(5) 
C(2)-C(3) 
C(2)-C(14) 
C(3)-C(4) 
C(4)-C(5) 
C(6)-C(7) 
C(6)-C(8) 
C(8)-C(9) 
C(8)-C(13) 
C(9)-C(10) 
C(10)-C(11) 
1.199(3) 
1.329(3) 
1.458(3) 
1.509(3) 
1.509(3) 
0.93(3) 
0.91(3) 
1.549(3) 
1.528(3) 
1.553(3) 
1.532(3) 
1.521(3) 
1.523(3) 
1.528(3) 
1.512(3) 
1.390(3) 
1.392(3) 
1.401(3) 
1.381(4) 
 
C(14)-H(14A) 
C(14)-H(14B) 
C(16)-H(16A) 
C(16)-H(16B) 
C(17)-H(17A) 
C(17)-H(17B) 
C(17)-H(17C) 
C(15)-O(2)-C(16) 
C(1)-N(1)-C(6) 
H(1M)-N(1)-H(1N) 
C(1)-N(1)-H(1N) 
C(6)-N(1)-H(1M) 
C(1)-N(1)-H(1M) 
C(6)-N(1)-H(1N) 
N(1)-C(1)-C(5) 
C(2)-C(1)-C(5) 
N(1)-C(1)-C(2) 
C(1)-C(2)-C(14) 
C(3)-C(2)-C(14) 
0.9900 
0.9900 
0.9900 
0.9900 
0.9800 
0.9800 
0.9800 
116.2(2) 
116.66(15) 
104(3) 
109.3(17) 
105.0(18) 
110.5(17) 
110.9(17) 
109.69(17) 
105.74(17) 
110.86(16) 
112.71(16) 
114.84(17) 
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C(1)-C(2)-C(3) 
C(2)-C(3)-C(4) 
C(3)-C(4)-C(5) 
C(1)-C(5)-C(4) 
N(1)-C(6)-C(7) 
N(1)-C(6)-C(8) 
C(7)-C(6)-C(8) 
C(6)-C(8)-C(9) 
C(9)-C(8)-C(13) 
C(6)-C(8)-C(13) 
C(8)-C(9)-C(10) 
C(9)-C(10)-C(11) 
C(10)-C(11)-C(12) 
C(11)-C(12)-C(13) 
C(8)-C(13)-C(12) 
C(2)-C(14)-C(15) 
O(2)-C(15)-C(14) 
O(1)-C(15)-O(2) 
O(1)-C(15)-C(14) 
O(2)-C(16)-C(17) 
N(1)-C(1)-H(1) 
C(2)-C(1)-H(1) 
C(5)-C(1)-H(1) 
C(1)-C(2)-H(2) 
C(3)-C(2)-H(2) 
C(14)-C(2)-H(2) 
C(2)-C(3)-H(3A) 
C(2)-C(3)-H(3B) 
C(4)-C(3)-H(3A) 
C(4)-C(3)-H(3B) 
H(3A)-C(3)-H(3B) 
C(3)-C(4)-H(4A) 
C(3)-C(4)-H(4B) 
C(5)-C(4)-H(4A) 
C(5)-C(4)-H(4B) 
H(4A)-C(4)-H(4B) 
C(1)-C(5)-H(5A) 
C(1)-C(5)-H(5B) 
 
105.16(18) 
104.90(17) 
102.54(18) 
104.01(18)                      
1 07.28(17) 
113.19(16) 
111.33(16) 
118.9(2) 
119.80(19) 
121.1(2) 
120.1(2) 
119.6(3) 
120.6(2) 
120.1(3) 
119.8(2) 
112.97(19) 
111.75(19) 
123.1(2) 
125.1(2) 
106.6(2) 
110.00 
110.00 
110.00 
108.00 
108.00 
108.00 
111.00 
111.00 
111.00 
111.00 
109.00 
111.00 
111.00 
111.00 
111.00 
109.00 
111.00 
111.00 
 
 C(4)-C(5)-H(5A) 
C(4)-C(5)-H(5B) 
H(5A)-C(5)-H(5B) 
N(1)-C(6)-H(6) 
C(7)-C(6)-H(6) 
C(8)-C(6)-H(6) 
C(6)-C(7)-H(7A) 
C(6)-C(7)-H(7B) 
C(6)-C(7)-H(7C) 
H(7A)-C(7)-H(7B) 
H(7A)-C(7)-H(7C) 
H(7B)-C(7)-H(7C) 
C(8)-C(9)-H(9) 
C(10)-C(9)-H(9) 
C(9)-C(10)-H(10) 
C(11)-C(10)-H(10) 
C(10)-C(11)-H(11) 
C(12)-C(11)-H(11) 
C(11)-C(12)-H(12) 
C(13)-C(12)-H(12) 
C(8)-C(13)-H(13) 
C(12)-C(13)-H(13) 
C(2)-C(14)-H(14A) 
C(2)-C(14)-H(14B) 
C(15)-C(14)-H(14A) 
C(15)-C(14)-H(14B) 
H(14A)-C(14)-H(14B) 
O(2)-C(16)-H(16A) 
O(2)-C(16)-H(16B) 
C(17)-C(16)-H(16A) 
C(17)-C(16)-H(16B) 
H(16A)-C(16)-H(16B) 
C(16)-C(17)-H(17A) 
C(16)-C(17)-H(17B) 
C(16)-C(17)-H(17C) 
H(17A)-C(17)-H(17B) 
H(17A)-C(17)-H(17C) 
H(17B)-C(17)-H(17C) 
 
111.00 
111.00 
109.00  
108.00  
108.00  
108.00  
109.00  
109.00  
109.00  
109.00  
110.00  
109.00  
120.00  
120.00  
120.00  
120.00  
120.00  
120.00  
120.00  
120.00  
120.00  
120.00  
109.00  
109.00  
109.00  
109.00  
108.00  
110.00  
110.00  
110.00  
110.00  
109.00  
110.00  
110.00  
109.00  
109.00  
109.00  
109.00 
 
                                               
 
Table 3.  Bond lengths [Å] and angles [°]. 
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U11 
 
U22 
 
U33 
 
U23 
 
U13 
 
U12 
 
  O(1) 
O(2) 
N(1) 
C(1) 
C(2) 
C(3) 
C(4) 
C(5) 
C(6) 
C(7) 
C(8) 
C(9) 
C(10) 
C(11) 
C(12) 
C(13) 
C(14) 
C(15) 
C(16) 
C(17) 
Cl(1) 
 
74(1) 
45(1) 
25(1) 
29(1) 
30(1) 
45(1) 
48(1) 
30(1) 
27(1) 
40(1) 
33(1) 
36(1) 
54(1) 
77(2) 
56(2) 
36(1) 
30(1) 
32(1) 
39(1) 
77(2) 
26(1) 
 
59(1) 
47(1) 
21(1) 
24(1) 
22(1) 
24(1) 
26(1) 
31(1) 
21(1) 
25(1) 
17(1) 
27(1) 
32(1) 
26(1) 
31(1) 
28(1) 
36(1) 
41(1) 
65(2) 
63(2) 
36(1) 
 
35(1) 
35(1) 
23(1) 
23(1) 
29(1) 
38(1) 
34(1) 
39(1) 
25(1) 
29(1) 
25(1) 
33(1) 
31(1) 
29(1) 
39(1) 
33(1) 
34(1) 
2(1) 
37(1) 
50(2) 
28(1) 
 
-12(1) 
-2(1) 
-2(1) 
-4(1) 
-3(1) 
2(1) 
-4(1) 
-12(1) 
-2(1) 
-6(1) 
-2(1) 
-1(1) 
2(1) 
5(1) 
5(1) 
0(1) 
-7(1) 
-11(1) 
-5(1) 
-1(1) 
4(1) 
 
4(1) 
-3(1) 
1(1) 
1(1) 
1(1) 
0(1) 
9(1) 
4(1) 
-3(1) 
-5(1) 
-3(1) 
1(1) 
4(1) 
-6(1) 
-18(1) 
-6(1) 
5(1) 
11(1) 
-4(1) 
-10(2) 
2(1) 
 
-29(1) 
-4(1) 
3(1) 
2(1) 
5(1) 
4(1) 
-11(1) 
-4(1) 
1(1) 
-1(1) 
1(1) 
-5(1) 
-13(1) 
-10(1) 
4(1) 
2(1) 
-1(1) 
-1(1) 
4(1) 
30(2) 
4(1) 
 
 
Table 4.  Anisotropic displacement parameters (Å2 x 103). 
The anisotropic displacement factor exponent takes the form: 
-2 pi
2
 [ h
2
 a*
2
 U11 + ... + 2 h k a* b* U12 ] 
 
   
 
 
x 
 
y 
 
z 
 
U(eq) 
 
H(1) 
H(1M) 
H(1N) 
H(2) 
H(3A) 
H(3B) 
H(4A) 
H(4B) 
H(5A) 
H(5B) 
H(6) 
H(7A) 
H(7B) 
H(7C) 
H(9) 
H(10) 
H(11) 
H(12) 
H(13) 
H(14A) 
H(14B) 
H(16A) 
6017 
5970(40) 
4670(40) 
8357 
7303 
7972 
5315 
4756 
3553 
4364 
8173 
5234 
7194 
6378 
9624 
9734 
7185 
4535 
4409 
9466 
9926 
6307 
7202 
7337(16) 
7727(16) 
6706 
5219 
5353 
5824 
5116 
6527 
6054 
8113 
9088 
9349 
8596 
8716 
9474 
9887 
9582 
8868 
7102 
6151 
6719 
3684 
4739(11) 
4432(10) 
4392 
3929 
4493 
4759 
4371 
4198 
3725 
4490 
4747 
4843 
5144 
3841 
3093 
2709 
3068 
3829 
3640 
3682 
2364 
30 
28 
28 
33 
43 
43 
43 
43 
40 
40 
29 
38 
38 
38 
38 
47 
53 
50 
38 
40 
40 
57 
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H(16B) 
H(17A) 
H(17B) 
H(17C) 
    8187 
    8798 
    6924 
    7119 
    6500 
    7913 
    8129 
    7688 
  2150 
  2070 
  2282 
  1751 
    57  
    76  
    76  
    76 
 
Table 5.  Hydrogen coordinates ( x 104) and isotropic 
displacement parameters ( 2 x 103). 
 
 
 
C(16)-O(2)-C(15)-C(14) 
C(15)-O(2)-C(16)-C(17) 
C(16)-O(2)-C(15)-O(1) 
C(6)-N(1)-C(1)-C(2) 
C(1)-N(1)-C(6)-C(7) 
C(6)-N(1)-C(1)-C(5) 
C(1)-N(1)-C(6)-C(8) 
N(1)-C(1)-C(2)-C(14) 
C(5)-C(1)-C(2)-C(14) 
N(1)-C(1)-C(5)-C(4) 
C(5)-C(1)-C(2)-C(3) 
C(2)-C(1)-C(5)-C(4) 
N(1)-C(1)-C(2)-C(3) 
C(1)-C(2)-C(3)-C(4) 
C(3)-C(2)-C(14)-C(15) 
C(1)-C(2)-C(14)-C(15) 
C(14)-C(2)-C(3)-C(4) 
C(2)-C(3)-C(4)-C(5) 
C(3)-C(4)-C(5)-C(1) 
C(7)-C(6)-C(8)-C(9) 
C(7)-C(6)-C(8)-C(13) 
N(1)-C(6)-C(8)-C(9) 
N(1)-C(6)-C(8)-C(13) 
C(6)-C(8)-C(9)-C(10) 
C(13)-C(8)-C(9)-C(10) 
C(6)-C(8)-C(13)-C(12) 
C(9)-C(8)-C(13)-C(12) 
C(8)-C(9)-C(10)-C(11) 
C(9)-C(10)-C(11)-C(12) 
C(10)-C(11)-C(12)-C(13) 
C(11)-C(12)-C(13)-C(8) 
C(2)-C(14)-C(15)-O(1) 
C(2)-C(14)-C(15)-O(2) 
176.54(18) 
170.6(2) 
-3.6(3) 
69.9(2) 
175.19(16) 
-173.69(17) 
52.0(2) 
-121.23(18) 
119.96(18) 
-90.1(2) 
-5.9(2) 
29.5(2) 
112.95(18) 
-19.9(2) 
72.8(2) 
-47.6(2) 
-144.43(19) 
38.1(2) 
-41.9(2) 
108.7(2) 
-66.9(2) 
-130.35(19) 
54.1(2) 
-175.03(19) 
0.6(3) 
176.17(19) 
0.6(3) 
-1.3(3) 
0.8(4) 
0.5(4) 
-1.2(3) 
-56.0(3) 
123.8(2) 
 
Table 6.  Torsion angles [°].  
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D-H...A 
 
d(D-H) d(H...A) d(D...A) <(DHA) 
N(1)-H(1M)...Cl(1)#1 
N(1)-H(1N)...Cl(1) 
C(3)-H(3A)...O(1) 
C(9)-H(9)...Cl(1)#2 
C(11)-H(11)...O(1)#3 
0.93(3) 
0.91(3) 
0.9900 
0.9500 
0.9500 
2.23(3) 
2.23(3) 
2.5300 
2.7300 
2.5300 
3.1399(17) 
3.1413(16) 
3.171(3) 
3.649(2) 
3.468(3) 
168(2)  
175(2)  
122.00  
162.00  
171.00 
        
Table 7.  Hydrogen-bonds [Å and °]. 
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Crystal Data of compound 151: 
Empirical formula                                       C17 H25 N O2, Cl  
Formula weight                                           310.83  
Crystal size                                                  0.2722 x 0.0343 x 0.0199 mm  
Crystal description                                      needle  
Crystal colour                                              translucent colourless  
Crystal system                                             Monoclinic  
Space group                                                 P 21  
Unit cell dimensions                                    a = 10.5439(7) Å   alpha = 90 °.  
                                                                     b = 6.8764(4) Å    beta = 93.685(7) °.  
                                                                     c = 11.9424(9) Å   gamma = 90 °.  
Volume                                                        864.08(10) Å
3
  
Z, Calculated density                                   2,  1.195 Mg/m
3
  
Absorption coefficient                                 1.983 mm
-1
    
F(000)                                                          334  
   
  
Data Collection:  
Measurement device type                            SuperNova, Single source at offset), Atlas  
Measuremnet method                                  \w scans  
Temperature                                                 123 K  
Wavelength                                                  1.54184 Å  
Monochromator                                           graphite  
Theta range for data collection                    3.71 to 70.92 °.  
Index ranges                                                -12<=h<=10, -7<=k<=8, -14<=l<=13  
Reflections collected / unique                      6453 / 3163 [R(int) = 0.0582]  
Reflections greater I>2\s(I)                          2998  
Absorption correction                                  Analytical  
Max. and min. transmission                         0.990 and 0.930  
Refinement  
Refinement method                                      Full-matrix least-squares on F
2
  
Hydrogen treatment                                      :  
Data / restraints / parameters                       3163 / 1 / 193  
Goodness-of-fit on F
2 
                                  1.051  
Final R indices [I>2sigma(I)]                      R1 = 0.0679, wR2 = 0.1791  
R indices (all data)                                       R1 = 0.0704, wR2 = 0.1840  
Absolute structure parameter                       -0.06(2)  
Largest diff. peak and hole                          0.359 and -0.569 e.Å
-3
  
   
 
 
 170 
 
 
   
x 
 
y 
 
z 
 
U(eq) 
 
O(1) 
O(2) 
N(1) 
C(1) 
C(2) 
C(3) 
C(4) 
C(5) 
C(6) 
C(7) 
C(8) 
C(9) 
C(10) 
C(11) 
C(12) 
C(13) 
C(14) 
C(15) 
C(16) 
C(17) 
Cl(1) 
-7694(3) 
-8482(3) 
-8522(3) 
-7404(3) 
-6579(4) 
-5433(4) 
-5121(5) 
-5938(4) 
-7079(4) 
-8615(3) 
-9795(4) 
-7392(3) 
-6199(3) 
-5497(4) 
-6214(4) 
-7602(3) 
-8249(4) 
-8121(4) 
-8197(5) 
-8759(6) 
-8705(1) 
-1118(5) 
-4152(4) 
-3220(4) 
-3589(6) 
-5114(7) 
-4815(8) 
-2965(9) 
-1433(7) 
-1716(6) 
-3944(6) 
-3040(6) 
-3975(5) 
-2691(6) 
-2862(7) 
-4385(6) 
-4172(5) 
-2392(5) 
-2436(6) 
-4461(7) 
-6365(8) 
1291(1) 
-8578(3) 
-8488(2) 
-4363(2) 
-2452(3) 
-2206(3) 
-1580(4) 
-1196(4) 
-1424(4) 
-2055(3) 
-3169(3) 
-2698(3) 
-4932(3) 
-4739(3) 
-5822(3) 
-6524(3) 
-6221(3) 
-6790(3) 
-8044(3) 
-9656(4) 
-9999(4) 
-4416(1) 
51(1) 
44(1) 
31(1) 
34(1) 
41(1) 
48(1) 
56(2) 
48(1) 
40(1) 
32(1) 
37(1) 
31(1) 
34(1) 
39(1) 
37(1) 
33(1) 
34(1) 
38(1) 
47(1) 
61(2) 
35(1) 
 
Table 2.  Atomic coordinates ( x 104) and equivalent isotropic 
displacement parameters (Å
2
 x 10
3
). 
U(eq) is defined as one third of the trace of the orthogonalized 
Uij tensor. 
 
 
O(1)-C(15) 
O(2)-C(15) 
O(2)-C(16) 
N(1)-C(7) 
N(1)-C(9) 
N(1)-H(1N) 
C(1)-C(2) 
C(1)-C(7) 
C(1)-C(6) 
C(2)-C(3) 
C(3)-C(4) 
C(4)-C(5) 
C(5)-C(6) 
C(7)-C(8) 
C(9)-C(10) 
C(9)-C(13) 
C(10)-C(11) 
C(11)-C(12) 
C(12)-C(13) 
C(13)-C(14) 
C(14)-C(15) 
 
1.212(5) 
1.339(5) 
1.461(5) 
1.519(4) 
1.502(4) 
0.84(5) 
1.382(6) 
1.511(5) 
1.407(6) 
1.395(6) 
1.385(8) 
1.377(7) 
1.392(6) 
1.530(5) 
1.542(5) 
1.547(5) 
1.535(5) 
1.513(6) 
1.537(5) 
1.538(5) 
1.513(5) 
 
 
C(16)-C(17) 
C(2)-H(2) 
C(3)-H(3) 
C(4)-H(4) 
C(5)-H(5) 
C(6)-H(6) 
C(7)-H(7) 
C(8)-H(8A) 
C(8)-H(8B) 
C(8)-H(8C) 
C(9)-H(9) 
C(10)-H(10A) 
C(10)-H(10B) 
C(11)-H(11A) 
C(11)-H(11B) 
C(12)-H(12A) 
C(12)-H(12B) 
C(13)-H(13) 
C(14)-H(14A) 
C(14)-H(14B) 
C(16)-H(16A) 
 
1.484(7) 
0.9500 
0.9500 
0.9500 
0.9500 
0.9500 
1.0000 
0.9800 
0.9800 
0.9800 
1.0000 
0.9900 
0.9900 
0.9900 
0.9900 
0.9900 
0.9900 
1.0000 
0.9900 
0.9900 
0.9900 
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C(16)-H(16B) 
C(17)-H(17A) 
C(17)-H(17B) 
C(17)-H(17C) 
C(15)-O(2)-C(16) 
C(7)-N(1)-C(9) 
C(7)-N(1)-H(1N) 
C(9)-N(1)-H(1N) 
C(6)-C(1)-C(7) 
C(2)-C(1)-C(6) 
C(2)-C(1)-C(7) 
C(1)-C(2)-C(3) 
C(2)-C(3)-C(4) 
C(3)-C(4)-C(5) 
C(4)-C(5)-C(6) 
C(1)-C(6)-C(5) 
N(1)-C(7)-C(8) 
N(1)-C(7)-C(1) 
C(1)-C(7)-C(8) 
C(10)-C(9)-C(13) 
N(1)-C(9)-C(13) 
N(1)-C(9)-C(10) 
C(9)-C(10)-C(11) 
C(10)-C(11)-C(12) 
C(11)-C(12)-C(13) 
C(9)-C(13)-C(12) 
C(12)-C(13)-C(14) 
C(9)-C(13)-C(14) 
C(13)-C(14)-C(15) 
O(1)-C(15)-O(2) 
O(1)-C(15)-C(14) 
O(2)-C(15)-C(14) 
O(2)-C(16)-C(17) 
C(1)-C(2)-H(2) 
C(3)-C(2)-H(2) 
C(2)-C(3)-H(3) 
C(4)-C(3)-H(3) 
C(3)-C(4)-H(4) 
C(5)-C(4)-H(4) 
C(4)-C(5)-H(5) 
C(6)-C(5)-H(5) 
C(1)-C(6)-H(6) 
C(5)-C(6)-H(6) 
N(1)-C(7)-H(7) 
0.9900 
0.9800 
0.9800 
0.9800 
115.8(3) 
114.4(3) 
105(4) 
110(4) 
121.2(3) 
119.1(3) 
119.7(4) 
120.9(4) 
119.5(5) 
120.3(5) 
120.5(4) 
119.6(4) 
108.4(3) 
112.1(3) 
113.8(3) 
105.2(3) 
114.4(3) 
113.4(3) 
105.3(3) 
105.6(3) 
104.7(3) 
99.5(3) 
112.0(3) 
113.6(3) 
110.9(3) 
123.8(3) 
124.5(4) 
111.6(3) 
106.8(4) 
120.00 
120.00 
120.00 
120.00 
120.00 
120.00 
120.00 
120.00 
120.00 
120.00 
107.00 
 
C(1)-C(7)-H(7) 
C(8)-C(7)-H(7) 
C(7)-C(8)-H(8A) 
C(7)-C(8)-H(8B) 
C(7)-C(8)-H(8C) 
H(8A)-C(8)-H(8B) 
H(8A)-C(8)-H(8C) 
H(8B)-C(8)-H(8C) 
N(1)-C(9)-H(9) 
C(10)-C(9)-H(9) 
C(13)-C(9)-H(9) 
C(9)-C(10)-H(10A) 
C(9)-C(10)-H(10B) 
C(11)-C(10)-H(10A) 
C(11)-C(10)-H(10B) 
H(10A)-C(10)-H(10B) 
C(10)-C(11)-H(11A) 
C(10)-C(11)-H(11B) 
C(12)-C(11)-H(11A) 
C(12)-C(11)-H(11B) 
H(11A)-C(11)-H(11B) 
C(11)-C(12)-H(12A) 
C(11)-C(12)-H(12B) 
C(13)-C(12)-H(12A) 
C(13)-C(12)-H(12B) 
H(12A)-C(12)-H(12B) 
C(9)-C(13)-H(13) 
C(12)-C(13)-H(13) 
C(14)-C(13)-H(13) 
C(13)-C(14)-H(14A) 
C(13)-C(14)-H(14B) 
C(15)-C(14)-H(14A) 
C(15)-C(14)-H(14B) 
H(14A)-C(14)-H(14B) 
O(2)-C(16)-H(16A) 
O(2)-C(16)-H(16B) 
C(17)-C(16)-H(16A) 
C(17)-C(16)-H(16B) 
H(16A)-C(16)-H(16B) 
C(16)-C(17)-H(17A) 
C(16)-C(17)-H(17B) 
C(16)-C(17)-H(17C) 
H(17A)-C(17)-H(17B) 
H(17A)-C(17)-H(17C) 
H(17B)-C(17)-H(17C) 
107.00 
107.00 
109.00 
109.00 
109.00 
109.00 
109.00 
109.00 
108.00 
108.00 
108.00 
111.00 
111.00 
111.00 
111.00 
109.00 
111.00 
111.00 
111.00 
111.00 
109.00 
111.00 
111.00 
111.00 
111.00 
109.00 
110.00 
110.00 
110.00 
110.00 
109.00 
109.00 
109.00 
108.00 
110.00 
110.00 
110.00 
110.00 
109.00 
109.00 
109.00 
109.00 
109.00 
109.00 
110.00 
 
Table 3.  Bond lengths [Å] and angles [°]. 
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U11 U22 U33 U23 U13 U12 
O(1) 
O(2) 
N(1) 
C(1) 
C(2) 
C(3) 
C(4) 
C(5) 
C(6) 
C(7) 
C(8) 
C(9) 
C(10) 
C(11) 
C(12) 
C(13) 
C(14) 
C(15) 
C(16) 
C(17) 
Cl(1) 
67(2) 
58(2) 
30(1) 
40(2) 
44(2) 
41(2) 
45(2) 
52(2) 
48(2) 
41(2) 
39(2) 
32(2) 
36(2) 
36(2) 
44(2) 
36(2) 
38(2) 
40(2) 
55(2) 
82(3) 
38(1) 
44(2) 
46(2) 
35(2) 
39(2) 
48(2) 
65(3) 
88(4) 
55(3) 
40(2) 
28(2) 
36(2) 
31(2) 
32(2) 
44(2) 
34(2) 
33(2) 
33(2) 
39(2) 
54(3) 
63(3) 
26(1) 
44(2) 
28(1) 
27(1) 
24(1) 
32(2) 
38(2) 
33(2) 
35(2) 
32(2) 
27(2) 
35(2) 
27(2) 
32(2) 
38(2) 
32(2) 
29(2) 
32(2) 
34(2) 
34(2) 
40(2) 
39(1) 
8(1) 
-1(1) 
-2(1) 
1(2) 
6(2) 
12(2) 
7(2) 
-3(2) 
-3(2) 
3(1) 
1(1) 
1(1) 
-3(1) 
3(2) 
2(1) 
-1(1) 
1(1) 
7(2) 
-2(2) 
-7(2) 
-1(1) 
6(1) 
1(1) 
-3(1) 
1(1) 
2(2) 
-1(2) 
-9(2) 
-4(2) 
-3(2) 
-2(1) 
1(2) 
-2(1) 
-3(1) 
3(2) 
2(1) 
-1(1) 
0(1) 
1(1) 
7(2) 
11(2) 
-5(1) 
-6(2) 
-7(1) 
-1(1) 
-3(2) 
5(2) 
10(2) 
-11(2) 
-18(2) 
-8(2) 
-1(2) 
-1(2) 
-1(1) 
-5(2) 
-1(2) 
9(2) 
0(1) 
6(1) 
5(2) 
-1(2) 
-21(3) 
-1(1) 
 
Table 4.  Anisotropic displacement parameters (Å2 x 103). 
The anisotropic displacement factor exponent takes the form: 
-2 pi
2
 [ h
2
 a*
2
 U11 + ... + 2 h k a* b* U12 ]. 
 
 
 
 
x 
 
y 
 
z 
 
U(eq) 
 
 
H(1N) 
H(2) 
H(3) 
H(4) 
H(5) 
H(6) 
H(7) 
H(8A) 
H(8B) 
H(8C) 
H(9) 
H(10A) 
H(10B) 
H(11A) 
H(11B) 
H(12A) 
H(12B) 
H(13) 
H(14A) 
H(14B) 
H(16A) 
 
-9190(50) 
-6796 
-4870 
-4339 
-5721 
-7635 
-8752 
-9678 
-9923 
-10540 
-7183 
-6439 
-5658 
-5501 
-4604 
-5889 
-6136 
-8092 
-9161 
-7856 
-7266 
-3600(80) 
-6384 
-5872 
-2752 
-173 
-652 
-5382 
-1631 
-3600 
-3310 
-5294 
-1324 
-3163 
-1601 
-3269 
-5704 
-4145 
-5382 
-2379 
-1188 
-4476 
-4710(40) 
-2466 
-1419 
-773 
-1148 
-2217 
-3206 
-2626 
-1959 
-3207 
-4620 
-4603 
-4087 
-6222 
-5652 
-6337 
-7334 
-6420 
-6637 
-6473 
-9726 
37 
49 
58 
67 
57 
48 
39 
44 
44 
44 
37 
40 
40 
47 
47 
44 
44 
39 
41 
41 
57 
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     H(16B) 
H(17A) 
H(17B) 
H(17C) 
      -8571 
-9678 
-8373 
-8599 
       -3408 
-6334 
-7394 
-6623 
    -10136 
-9916 
-9523 
-10784 
     57 
74 
74 
74 
 
Table 5.  Hydrogen coordinates ( x 104) and isotropic 
displacement parameters (Å
2
 x 10
3
). 
 
 
 
 
C(16)-O(2)-C(15)-C(14) 
C(15)-O(2)-C(16)-C(17) 
C(16)-O(2)-C(15)-O(1) 
C(9)-N(1)-C(7)-C(8) 
C(7)-N(1)-C(9)-C(10) 
C(7)-N(1)-C(9)-C(13) 
C(9)-N(1)-C(7)-C(1) 
C(7)-C(1)-C(6)-C(5) 
C(2)-C(1)-C(7)-N(1) 
C(2)-C(1)-C(6)-C(5) 
C(7)-C(1)-C(2)-C(3) 
C(6)-C(1)-C(7)-C(8) 
C(2)-C(1)-C(7)-C(8) 
C(6)-C(1)-C(7)-N(1) 
C(6)-C(1)-C(2)-C(3) 
C(1)-C(2)-C(3)-C(4) 
C(2)-C(3)-C(4)-C(5) 
C(3)-C(4)-C(5)-C(6) 
C(4)-C(5)-C(6)-C(1) 
N(1)-C(9)-C(13)-C(12) 
N(1)-C(9)-C(13)-C(14) 
C(10)-C(9)-C(13)-C(14) 
C(13)-C(9)-C(10)-C(11) 
C(10)-C(9)-C(13)-C(12) 
N(1)-C(9)-C(10)-C(11) 
C(9)-C(10)-C(11)-C(12) 
C(10)-C(11)-C(12)-C(13) 
C(11)-C(12)-C(13)-C(14) 
C(11)-C(12)-C(13)-C(9) 
C(9)-C(13)-C(14)-C(15) 
C(12)-C(13)-C(14)-C(15) 
C(13)-C(14)-C(15)-O(1) 
C(13)-C(14)-C(15)-O(2) 
-170.2(4) 
-175.8(4) 
6.9(6) 
179.3(3) 
-88.9(3) 
150.4(3) 
52.9(4) 
-178.1(4) 
-103.2(4) 
0.0(6) 
177.7(4) 
-48.5(5) 
133.4(4) 
74.9(4) 
-0.5(6) 
0.3(6) 
0.4(7) 
-0.9(7) 
0.7(6) 
164.8(3) 
45.6(4) 
-79.6(3) 
-21.2(4) 
39.6(3) 
-147.0(3) 
-6.3(4) 
31.9(4) 
76.5(4) 
-43.9(3) 
165.3(3) 
53.5(4) 
-126.4(4) 
50.6(4) 
 
Table 6.  Torsion angles [°]. 
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D-H...A 
 
d(D-H) 
 
d(H...A) 
 
d(D...A) 
 
<(DHA) 
 
N(1)-H(1N)...Cl(1)#1 
C(7)-H(7)...Cl(1)#2 
C(14)-H(14A)...Cl(1)#1 
0.84(5) 
1.0000 
0.9900 
2.39(5) 
2.7100 
2.8000 
3.200(3) 
3.598(4) 
3.715(4) 
163(5) 
148.00 
154.00 
 
Table 7.  Hydrogen-bonds [Å and °]. 
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